var title_f7_3_7216="Lung cancer extension MRI I";
var content_f7_3_7216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic extension of lung carcinoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T2-weighted section at the same level as the previous CT scan shows high T2-signal intensity in the right hepatic lobe (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7216=[""].join("\n");
var outline_f7_3_7216=null;
var title_f7_3_7217="Normal versus emphysema chest radiograph in AAT";
var content_f7_3_7217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Normal versus emphysema chest radiograph in alpha-1 antitrypsin deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 292px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEkAfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDifEGtW+hWaXN2krxvIIwIgCckE9yPQ1gf8LE0n/n3v/8AvhP/AIqk+Kv/ACL1v/19L/6A9eveBbfwr4f/AGXbLxVqXhbQdU1cJOkLXmnxzPPM11IkYYkbmA44znavGKAPIf8AhYmk/wDPvf8A/fCf/FUf8LE0n/n3v/8AvhP/AIqvctItfD3ib4KeOLvVPBHhjSvFOjW2oWt3HaabFH5E0cTlWQ4JHGOdx5UkGvjmgD1X/hYmk/8APvf/APfCf/FUf8LE0n/n3vv++E/+KryqigD1X/hYmk/8+99/3wn/AMVR/wALD0n/AJ977/vhP/iq8rFFAHqv/Cw9J/5977/vhP8A4qj/AIWFpP8Az733/fCf/FV5YBXSeDtGOo3ayOu6MHCj1NAHp+h6qmsgG2trmMHkeaqjP5E13dl4H1K8tUnjnswrfws7ZH1+Wp/AvhGXykfyTzgjjrXqunaYbK32yHk849KAPJW8CaopwZrP/vtv/iaVfAeqN0ms/wDvtv8A4mvXJLdc8CkSADtQB5Qvw91Y4/f2P/fb/wDxNOHw71Y/8vFj/wB9v/8AE160sWO2akWL2oA8jHw41c/8vFh/32//AMTTh8NdYP8Ay8WH/fx//ia9fWGrCQ+ooA8aHwz1n/n50/8A7+P/APEU4fDDWv8An50//v4//wARXtKw9OKkWL0FAHin/Crtb/5+dO/7+P8A/EUH4Xa2P+XnTv8Av4//AMRXt4hp3k+ooA8NPww1of8ALzp//fx//iKYfhnrQ/5eNP8A+/j/APxFe6NBntUTQZ7c0AeIf8Kz1n/n40//AL+P/wDEVXu/h7q1tGzyTWRC9drv/wDE17n5WD071U1a0823faOox+NAHz1c6LdW0uyUx59if8KZc6RcQWP2otG8ecEITlfrxXo2uacZrLzkUF4jhh7Vj2SqY5IXGY3Ugg0AeV69rtvotuk1zDcSRsdpMSg7T75IrC/4WJpP/Pvf/wDfCf8AxVdL4z0cRS3NnOC1tOpCH09K8NvbZ7O6kglHzIcfUetAHpn/AAsTSf8An3v/APvhP/iqP+FiaT/z73//AHwn/wAVXldJQB7toOsW+t2LXVokqRhzHiUAHIAPYn1rDPj/AEsMR9nvuDj7if8AxVJ8Lv8AkW5P+vhv/QVrd/ZN0PS9d+Jmp22uaZZalarpU0ixXkCTIHE0I3AMCM4JGfc0AYZ8f6X/AM+97/3wn/xVOHjzTDGXFvelQcH5E/8Aiq9N8C67pWtan4ZGpeBvA4tNW1CaxlVfDZtlh2khClzITHK7EfcUZ7V5R+0RpljpXxk8R2OlWVtY2URt/Lt7aJYo0zbRE4VQAMkk/U0AT/8ACwNK/wCfe+/74T/4qnL480xv+Xe9/wC+F/8Aiq8w2d8cVZt0zQB6zpXiSz1OVYreOcOxwA6gf1r0LR/BWpaqoa3mtEz/AM9HYfyU15B8PNMe51NLgAgRng19T+BVIiXcMYFAHIr8J9dIz9q0z/v5J/8AEU8fCTXj/wAvel/9/JP/AIivao+gqePoKAPEB8INfP8Ay+aX/wB/ZP8A4ilHwf1//n80r/v7J/8AEV7qtPHtQB4T/wAKd8Qf8/mlf9/ZP/iKP+FO+IP+fzSv+/sn/wARXvIpaAPBf+FO+IP+fzSv+/sn/wARR/wp3xB/z+aV/wB/ZP8A4ive6BQB4J/wpzxB/wA/mlf9/ZP/AIij/hTniD/n80r/AL+yf/EV73S0AeB/8Kc8Qf8AP5pX/f2T/wCIo/4U74g/5/NK/wC/sn/xFe+YpCOaAPAz8HvEA/5fNK/7+yf/ABFNPwg18dbvS/8Av7J/8RXvjDNRuKAPBT8JNeHW70z/AL+Sf/EVGfhTrg/5etN/7+Sf/EV7vIKrSDrQB4RN8NNZiHzXOnn6SP8A/EVk3vhHULTPmSWxx/dZv8K98vItymuQ1y13K3FAHgPiTU4/D6hryGeRfWEA/wAyK53/AIWFpX/Pvff98J/8VXf/ABG0ZbqwlBUcc187X8Bt7p4iMYNAHpX/AAsLSv8An3vv++E/+Kqey8caZd3kFtHBeCSZ1jUsi4BJwM/N715PWl4d/wCQ/pn/AF9Rf+higD3CiiigDjPir/yL1v8A9fS/+gPXoXw/8V/DC8+Evg3QfHev3ME2jXct7Lp6WsrxTP58rIsuImDrtfoCPvEGvPfir/yL1v8A9fS/+gPXldAH1jq/jL4P6Vonj2Xwfr0lvd+INJltRpkNhLFa+aIWRCi+SAhJbklsfMTxXydRS0AAoHSiloAKAKUCtLQdGu9b1GKzsoyWc8tjhR6mgBuiaVcaveLBbxuwzglRn8PrX1n8HvhCukwR6hrShGIBFv1x9a1Pgz8MLPw/YQ3t1ENw5UsOWPrXqN5dhV2pgAUAI5gt4/Lt0WNBwMDmqLsGOc5qGSRnOc0sXJFAEm3NLs74qaNPUVIF6cdKAIkjPFSrGBTgOKkAxQAgUDoKmRfamj86ep5xQBIqjvUyJTUWpkFAAEpdlPWpAvNAEITimmPmrJWk25oApvGOTUbRgrtPQ1dZaiZPagDiby0+z3dxE65RjkZ9DXJalp5t7gsoO0nivUtas/PtvMUfvI/1FcpfQrPbMpGG7GgDy/xTp631lIrD94OVPvXz/wCMtMZi8oGJ4uGHqK+ldVjKO4PSvJPHem4maaMYLdfegDxE0lXNRg+z3boBhSciqhFAHrHwu/5FuT/r4b/0Fa0/2bPF+ieCviDf6j4mvDZWMmmy26SCCSXMhlhYDCKT0RucY4rM+F3/ACLcn/Xw3/oK158kZctt5bdigD6d0TW/gzpaaTbv441y903Sr46la2FzZSeUlxkkOSlsrtgk4BYj2rxT45a9pvin4ra7rOhXButNuTB5UxjePdtt40PysAw+ZSOR2rkLuHyZNnXiol4ByOtAEajOB2rRsoDIyogyzEAVUiXLDNdz8P8ARze3wmYZjjPH1oA9I+Huh/Z4IUVeeCfrXvHh+08iJBjtzXHeDtMEaKxXmvRrGPYg+lAGhHVpBVSLrVlD0oAnWpVqIcVID+dAD+9LTc5pM80APFKKZmlDYNAD+1LxgUzdTg1ADsUhFANLQA1gKjdamIqNhQBXYVWlXGausKrSjrQBnzrlTXPatBuVq6SUdayb+PKmgDy7xPZCW3kBWvmbx9pv2TUnYetfW+uQbg1fPPxX0/bIzgcUAeQ9q0fDv/If0zP/AD9Rf+his85BI9DV/wAO/wDIwaZ/19Rf+higD3KiiigDjPir/wAi9b/9fS/+gPXldeq/FX/kXrf/AK+l/wDQHryqgBaKKKACloq1YWrXU6oB8v8AEaALGkaZJqE6qoPlkgcdWPoK+tvgh8M4NKso7/U4QHIDbCPyFcv8B/h0LsxaxqEX+jIcW6EffI/i+gr6ImZIYRDFwB6d6AH3l0AnAwo4UDtWLLI0jHNWJ23nGTjFJFACcigCONTjpUyIetTpBnpUwh4oASIZUHFSbaWJQoOTTHcZ60AONND/ADdjUEkwA4PWqzXIQHHU96ANRJARTt2McYrGFyWzjNSRMdxO49OmaAN+3cHg1YGMVj2chD8kmteM7gMDmgCQVKnJ4piAZGeamCY5oAcAKQgUqntTiOKAImUEVE6c1Pj0pGXOaAKxHb1rktctfs1ywX7jfMK7Blwaztfszc6czoMyRfMPcd6APIfEUWyUsPutXnviW086F1K9en1r1LXot8HTkVwuowb85oA+evFdiyNvA+6cVzBr1bxhYAtKpHWvLZ4/LldPQ4oA9S+F3/IuSf8AXw3/AKCtefQzukjkYBya9B+F/wDyLkn/AF8N/wCgrXnCnEj49aALE0jTOXbrTRyeaaTzUsS7jQBPaxF3VQMknivfPhzoYtrKEMvzH5m+teWeBdIa/wBVjJXMcZyeK+mPCOlbI0ZlwBQB1Og2XlQgkYroYgBwKqWyhVAUVdjGOtAE8QqwDgcdarK2OlPD8UAW1fj3pwaqqvT1fmgC1uppaojJgVVnuQp5PPpQBeMgAOTUAuMyYHSqBnZs84FRrLz6UAbgbinB6oxTbohzTllAPrQBoKfSpBVWGTPtU6mgCSmsM0oINBoAiYVXkXrVk1DJzQBQlWs66j+U1qyCqVwODQBx2sQ8HivFPilp4a3ZyOMV7xqsfytXlfxFtRJp0hxyM0AfLF7GEkcAYwam8Oj/AIqDTP8Ar6i/9DFSa4m29lXHQ1H4d/5GDS/+vqL/ANDFAHuVFFFAHG/FX/kXrf8A6+l/9AevK69U+Kn/ACL1v/19L/6A9eV0AFFFLQA5FLEADJr1r4LeBJvFGuRwMrC0iw9zIB27KPc15todnJe38UMCF5XYIigfeYnAFfeHwt8JQ+C/CFvbbVN9KokuJO5Yj+nSgDooLeDSbGO1tUVFRQoC9FA7CqMshYk55p91JuY/pUMMbuenWgCaGMueTV2ONUXLkKvvUU8kVjbmSQjiuI1nXLieVsHaoPAoA7mfULWAABg7HsDWdNrIc7Uworh472Vxlm49atxTM67xQB1sd5mNySemearve4BzVGwlMsbg84FMYEggtwPXtQBP9oeVhyR70rvnA5PPaqSsEG9j+Bp5uN8YC8k96ANFTwGyMEdKkSUKoK9c9zWaZduCeoqRJS2MD35oA3rdzt3DoT+VbFvOPKBB4FczaSORsLcHnGa2bZsKqDjigDWSUk4FWVkOBzkVmIctwP8A61XI5AvAOTQBc544qQdOtV4Wzn0qQNggUAPYU3vT+1RtQA1x9KanUgjg04nsaYvBoA8+8X6d9knlVV/dsN6fT0rzLUoyHc17z4ss/tWlM6jMkXzD6d68Q1SPEzr7kUAea+LbXLFiPvDrXjniODyb5uOGr37xNbh7UNjGK8Y8aw4YPjkH9KAOp+F3/IuSf9fDf+grXm6gmR8c8mvSPhf/AMi5J/18N/6Ctebp99/940ASqKv2kRJGB1qpAmWrsvBejtqWqQpjKKct9KAPUfhZoBjs43dMO/zE4r2/TIRHGiIMAVzfhrTltLaNQOcCuxs0CqCaAL8QCpk1IHyBjpVUvuIA6VJmgCcOKcHqsXC9DzTQxPJNAFwSU8PgcnAqi06oOTzVS4vCTjdhaANK5vBtKofxqj5u45z+NZz3ignB5rOe+bcctgUAdI1wFGAQc1Wludz4zz7Vz0mpKrrls0iagZJGC0AdnZT5hU5wKm835uM/WsTS5S1qhY5NajHDKR0NAGnBKARzV4PkViwygdOTWlC+5R2oAto1PLVVVsd6mB96AH1FJUlMfvQBTl61Vm5Bq3IOtVJO9AGDqiZVq858Yw+bp9wMZO04r0zUkyrVwHiJN0cq+oIoA+QfFP7vVpAOuTmq/h4/8VDpn/X1F/6GKueNkMXiG6jbqrmqXh3/AJGHTP8Ar6i/9DFAHudFFFAHG/FX/kXrf/r6X/0B68rr1P4q/wDIvW//AF9L/wCgPXllABTlpKcASQB1PSgD2/8AZg8LDV/Ff9p3Me6CyOI89DIe/wCAr641GTnaOnSvKP2etFXRPD1nCVxIVMkh9WPNem3b7nPNAECrvbBrStokjXc3Qd6oQsI/mOT6Cub8ca+1tb/ZoHIkYYbB6UAS+JdXgklZBICF6Vxt1cq7EbgPQmsyAzSksWIB7mnTzxQqAOXPPFAGpb79hwvynua0bNQImJbOD61yqaz5asvBDdj1qzBqJc7UO3uRnNAHbaddRhmwevpUFzeCPcsfJ9TWNpMkkjoV/Nq0L+MZDMCHPXHQ0AVnuy0gCjJ7+1XbFnkUKTgg85qCCFRtIwMjjnrTI7hYLsxFhvY4Kjk0AbXl4DEr8wPJq0WjjQMf4hj6VQZ5ZZRtGF45PWpFRpnIY8dfwoAv2kgku1CglfWtaOZhcDcPlrJ05SLtEQEgcn3xWjNGVXJOMHrQBsLNlAePQcVNE2T1rNtACgOSQOeauiQDABx7UAadsSSfYVMSBtJNU7Jid5PAxVlzlFPYH0oAtqcqKYwpIXBGM9KeelAEDe3akPqKe/0poxjjGaAHyp5kDKw4Iwa8N8T2vkX0qYxhjXui8xnNeV+O7PF3KwHIIbNAHl2uQhrKYY7ZFeN+OLYG0kYDkc17drIAt3B9DXkXjSMfZZQenNAC/C7/AJFyT/r4b/0Fa85XJlce/SvRvhd/yLkn/Xw3/oK155AN8jD/AGqAL1nHnAxya9++FHh/7JYJdTJ+8k5Ga8p8CaM2q6zBEFzGp3MfavpzRLNYoo40HyqMCgDd02Hge1ah4GBVeIrBFzwaTzSeexoAnSXB/rTmuMDGearM277vaqVzOsKNJKcAetAGg1yqgsxqnNqyrkZ/CuP1PxFuYrGcD1rFGrksfMbAPqaAPQH1LcP8KqXd6QfmOBXLW2rKflXn3NPmuWmcEkmgDWmv8sClZ9xcyO7bckUsDDI3DIpZxuc+WvBoAryMcqxOfar1rKTjtVUxoEBJyParNqrmFsDC0AdPptwRDGD2raaYOqc81yMTtGqc7QB61t2chkjUk8UAb1u5wMACtO3J2A54rEtpBuATP1NakD4j5YGgC4rYNWI2yKzg43EDpViOXHFAF4NTWPWo1bPWnA0AQS96qS96uS1Tk70AZOoZwa4PxCAN3rXe6iPlNcD4lOFY0AfKHxUt/s/jK544cBhWF4c48Q6Z/wBfUX/oYrtPjXb7dbtbgDh02n8K4vw7/wAjDpn/AF9Rf+higD3OiiigDjfip/yL9t/19L/6A9eWV6n8VP8AkXrf/r6X/wBAevLKAAVv+CNMOq+J7G3IygfzH+grAHWvWPgRpRn1G4vmXgERJ/M0AfUfgSEW8C8Ywtb7Hc7GqGgxCG26fw1eQEjgHk0AIRlzjPyjNeaeIGE2pO8hBwcYr1hoNkMj4/hrxXW7ry7q4YkffKjNAEN/drEjBmwe3tXMz3/mylVY8npnmo726kuZgQOPu57VDHb7eWGTn73WgC1buWbLghTxnNdFpVoP3bxsWzxWRbxF0CIAJByD6it3RJtl2gB3AfKR2xQB0kBSCFSAPSrkkrSwKVH3Rx71WW0ZlJBBQngjmtC1QKihlJGMYNAGY6ySYJOFHOB/KqVvGTcmYZDF8k46V0b2oP7o8ZO4Y7VLaWsYlLBRwDuJoAsRRgwiQDGVGN1SRqsSMc54x9TV+zEDWzB14HOKy9SEuPk4VjnAHSgC9pzohLsQAePrVu7uEMYCkKM45rIt45IYYzJkDGeaGl3qOMgGgDVtp+zHA7CtCKUEAc1z1uWdhtyQeeO1bsUTEY6D9TQBo2co2ueMcDNWmnyoGe9V7WBVt+eTuqztURjHHPWgB9o5DjP41oe2azoAPNAPStE8Z6YoAilqvuwallbIPNVmyRQBbRuMVxXi2ISXEiEfNs49/auxQcCuS8XgrqAHQlARQB45r6FI5AeMA15H40GLeSvafFkfyysOAc/hXi/jo7YX+lAEfwv48Oyj/p5f+S1wVsB5rfX0rvfhf/yLkn/Xy38lrl/CmnnUtcgtl5DSfN9KAPbPhFoX2PS1upExLPyM9hXsmmQiOPc31rnPD1msMMMSgBI1AAFdLM2yEIvU9aAIri4MkvBwO1WUchRkgVTjjwwJ5pJ5hnr0oAtyyqikqcGvPfHHiWK2Bi80cds9TS+O/Fa6NYOUbMrfKo968F1DVJ768a4uJCzse54FAHYPr0txPuj4z3PardpdMWwzbmPPPWuS0uVXIDnCHvXR2cZ81Vi5x3oA6uwkJILY4rbhLOQOi1z9gUhwHbLnnFXxdlzgkAe1AG/uWIDPzN6Cia4YkL0B9qz4phgbnzjtUk06b0zwPY0AXYmwuxjx3rW01fMUqFAUetc6JgpZ93U8VuaTcIkBfIz70AXpEBbJJFWYpTCoycL6msgXW+YknpUyu85xyfagDoIdQIPByAK19OuDNCx7g1yCRuCAxC102kbRbjGTzQBrs2CtTxseCKiTBUGpBmgC9EciparwsAtS7qACSqcvWrDHNQSgd6AMzUBlDXn/AIn+6/HSvQr0fITXA+JwMNQB88fGSDzbGKYD5o3rzTw5/wAh/S/+vqL/ANDFeufEqMSafcJjJAJFeReG/wDkYNM/6+ov/QxQB7pRRRQBxvxU/wCRet/+vpf/AEB68sr1P4qf8i9b/wDX0v8A6A9eWUAL0Wvpz4KaL9g0S0DL87jzG+p5r528M2B1PXrK1xlXkBb6Dk19h+DLMQ20YAwAKAO/swFtR05NaFvFlkX0qlCuII1/Gre8q2FOMDk0AL4o1K30nRJriZvlUcD1NfL2raw+qXcxPyxMxKgfXvXpXxu11lgtNLt2PmyfM/P3VryDakIwxGfftQBrK3yoBhiOKkhnSJyPvEfw/wCNY8Vy8ny7dkTD7+auRQhSqtnzD0I7igDY895ZFKHaB0AGBXQ6QhnZTtHmKMlRxmsfSraKVowXZQgHOK6eG0Fs2+NtwB++KAN60j8sKxOARmtklAsLZBQrXNTXalPNL4AGGXv9cVp6TO9/bmNFKlM9+cUAT3VwFnRs4LH9Kc8rl1CfKueT3NNi04xB2m3KeqqarwySz3iRxH5mPAXmgDf03MkmCCFIxirohXcS44HQetU9Ptp0vyZ942nofStl1CykEZxzQAl1aq4CuMDFZc1osRycsnato7nI4OPU1BcgBcZz65oAo2xVSAQo9h2ratmTG5s/jXMTTJBMR8zMDyatW17544bCg9KAOtjmUW4I29T71HK+6PO/Az2qjbKfsaDnkk/hUpXMYznk+tAE8MgB+UEn1NaeSyA1jQpg9c+3StmFcwp9KAGyYIHGDVY8HpVh0wDk/Sqcrk8jqKALkZ3IPaub8YpumiYdduK3bdiVNY3icbmjPX5aAPJ/FkPyNnowrwf4hgpFKD1r6J8UR7oSfQV83/E+QoZBnBOaAJ/hf/yLkn/Xw3/oK1p/BPSPN1Ce9dMhThcisz4Xf8i3J/18N/6CtepfCTTBa6NGNuGYZPHegD0vSodsYOKuONxpY18uAD1qCWcLx3oAkkGxMmsDU7goGYHArUuZswcnlv0rmNcnCRkE/KBmgDxX4j6m9/rrQgny4eMe9cqgJbpk1d1tzPq91Lk4ZyBVUSCAjcw3elAGnYgDaZDgDpXQ2eoGNlWJPlbqa5FHWQ75ZcIenPStTTXkkmAjcBMfeJ5oA7qGRECOWyD+dWRMXf5flWsnTpIbaP7zOc8lhmrxkVnJRhzQBs277QBzg1JOzqis+VUfrWT9oZWUQhifWteWOWaFfO6Ed6AMyXVkE6pCTnpg810ujSSSxvnIXHSuQFmY9SwowCeM9a6nRGdbgwplnIxgUAbdpGNpOcn3rXs1x04wK51pxbymNj8ynkVpR3wWEEjlvegDchhVvnc5rds3jSJVAAxXF299ubC5C96v296xfHNAHXm6G0c1LFchhjNc2spI68DtV61lPFAHQQyZNWlPHWseNnbAGa0oVKp3NAE2aZJ0pwHGaY/FAGde9DXC+JlyrV3d7jaa4nxEuY2oA8H+ISfunB6MDXj2hLs8Taevpdx/+hivaPiIv7lvY15BYps8Xad/tXUR/wDHxQB7RRRRQBxvxU/5F63/AOvpf/QHrywV6n8VP+Ret/8Ar6X/ANAevLBQB6L8F9PFzrs9yy5EahF+pr6u8O2+2FBj0r57+BFj/oXm45kkJr6Y0WHCoccKM0AbEa5kRRyelW/s7N5jY4602xTDl26AZqbUrpbXRru4J+6hwT0oA+Yvidf+d4ou3Lbtp2Z9AOwrjTOXYtjI2kKvf8al8Y3E0niK4LnJJJx7ZqokWQkmdpb9BQBbsYXlmzIST/dHSutt4wq/cHlDGDnmsLTnWNwET5fetNrnLhUUsvQEdMUAdFbtFboGibce5P8ADV6PVt4jwOMdcdawbG3kkfBbcCQc46V01ppEVyF2ysrpyQB1oAvWVolwS+SN3GOuM+tdN4c042zSoDkt1PpVPTtPjt1V2LgA59jXYWLrIQ7qoJGPqKAIngA+WTDEcVXt7VIpd8ZRHHIxWrMIGKFdwcdV61z2qz+XKvlHZGThs9c0Abl5qan7Olw6iU8jA60y9vVjkBUg71BznjFclfhp3jcBw0GSpPpVSz1CW4itDIGLuD9AM8UAdkl68igA8UySVi+FJIwCT6VWsYXO0MTtIzV/9yg2Zw2etAGbdRPIMqeB3qzpMRjbL4JPY1ZuAIoBuxlugHeqNpK/n46KTyTQB10ZUQoN2eOwpHPCgA9appMdo5Jx3NOaYnByScetAF+P/d/Wr8Mw8rHpWELnGMmrdjKZG2+ooAvSyZBI6VnSPlunJqeeRo24Pb86oMd/zqcc8j0oA0rUEbvpVTXohLAkgHzKcN9PWpbOTY+M5B4NLfsBbyD2oA8v8VqFgkH+cV8x/FRsyvjpnFfTfjFillO/cA18yfEwZU5780AXPhh/yLkn/Xw3/oK17/4CsxHp0fy8ACvAPhh/yLkn/Xw3/oK19O+ErcJYIAPSgDQvv3cAJ9KwkYySEtzW9racKvYDmsiOEjoABQBVuMuwUHgVw3je/W2tp8MBhSM+9dvdP5Ucj9Bg14P8S9ZAuGt1Y7upoA4jULn96xB5JrMeUsxI6nvUE7tIc8ilXC49aALVucgB8tXU6ZOiRAFR9a5GOTyyCDiui0hpLmEhYsg/xmgDpYrplKsfmRugHWtazt5JXDtkDqtR+HdLEsZWNcv6t2rrbHSpVBWQAHtigBdGi86YRqmTjrXS3lmtrbIxG4+9SaDpkdr88jruz90da0tahN5bbFYRqnYUAc/F5F1NGTCMjgkDGKh0rc+qO0R2EMQCKmtIEBdWc/LRYXFrDK6I3Gcbh3NAEN+j29wfNI3E5+tOF0HARuvbHarGuRIIUkjYMWGR65rFsEld+uMnnNAHSWy52gHNa1jGxc8cDtWZp8YBBbL1v2myPnAoAv2lozjLECta1t4ouWy5qhBcqoAwcmnHUEjbBbJoA3oyOCBVtJARiudGogplf1NS2upLvAZutAHQjgUx8GoYpgy5FS7s89KAKd6nyGuM8QKNjV212QVNcXr33G4oA8S8ew7oJsDpXjsMe3xNpTY/5eohn/gYr3Dxkm6OYeorxoRgeItP4PF3F/6GKAPVKKKKAON+Kn/IvW//AF9L/wCgPXlnY16n8VP+Ret/+vpf/QHry+FDLLHGBkswWgD6U+BtkU0azyOSufzNfQ1pCIrXgYzXk/wq07yLG1jCkFVVa9jkHlxbeyjH40ARiZhbsPfGaw/HWrJa6ILYuoZ/nf2HpWjdCQQxqhPzHivE/jLq7wtcJHJhlyoOelAHmGt3S32s3cqfMN2KpS3nSJQFAOAcdayVuSCTu5Pp/E3rWxpFtPcvGkQzkfMzDIHrQBqaTb3MzAlTs7mu00nRJrkr8y9eM1L4e0V1QNLtK46E/wA67Oxs1X7qnJFAEVloixbWOyR8YODwK3re28i027NszfMNp4A9KrZWNVOQMf3aRdQCoxc8DoT/ACoAvrPKp5ZVTH3e1aNpIFG+WXC9sf0rkP7RknYmNQqA4yeSPwrWtpGZkWWQueCNo7elAHUpe/N5agKWPJxyap3tr5+44DHORU0EXnK06Jt2jhTzz61Hah45DliS3XNADUhBITAwo596juYYo9LEyoqrHwMDH4VeEXk2sjueSdoxWJ4kvI5dNSxjcKSeeeaAL1pqcQTyypZ8cEfw08yszfXngVi6TCUiHm9urdM1sxKZiAikIOdxoAld1KHjnpk1DYAG4BCgrnvTpyFGByo9KTT5EDkkA9xzQBu4cxoACaDG+FDdMYqNboeWud49qbLMpxljn0FAFjG3aMZHrV3TWQXGMgZ4rLZuRhuP50scu2QFTz70AbkyEqQ2Bt5FUHwm4AcGr2Q6/wA6y536juDQA+OQrIB6VbvDuibPes6IkuOCcGte9j3WrdnC5Hvx0oA8l8ZybrZox3Jr5s+Jh5YfUV9DeKpi0smenPWvnT4nP+/dfegDQ+GH/IuP/wBfDf8AoK19YeHECWSk+lfJ3wvOfDkn/Xw3/oK19a6cDHpwx1IoAg1F/Mn56VWlAWEnjngVJMp3ZNU72XEWD0FAHP8AiG6WC1bJ4r5g8WXTX2v3UhOVD4Fe9+OLwxwMfY189X+GvJiOcsTQBRYYqNz6DpUzrgEsce1Qj5mGKAJ7S2eZsleK77w3aARqC2MDsK5DTUIIzkAdT2rsNId1iyAQh4z0zQB1+nT+RkRnIPU1qrfynCoxHr61zFgpcDaCAD0Na6KUcSZ5oA6/SJtmMMdzGtW6mlUNtBY47Vz+llnePA59a1y83lyLv27hjigDmbnUpVnZRuG446darafK0Eq/aHCqzEgHqafe5jvoYsnluT3NUvENnMmqxlgTFtGwUAdlqEnnxxNCnyhewqKzsW8zeRkdxTdHlWPTwtw2SB90dallvWAKwnalAGlHMIR6AcfSnR3hLk859TXPi63Eh5MKP1pGu1I2BHIPocCgDpJNX2/KH59qaL0scjOfU1z8GFw2wge5q0LpiQI14oA6CC6LL8xOKtWIeW5B5CepqhpqvIuXA+prbsYgkil3A9hQB1NlhYlHtV4L8oOaoWjKyArg471e8wFBnrQBUvDhTXGa62VauzuAHDYrjfECbd2aAPKfFgBRzXj0sZXxNZZ/5+oz/wCPivZPE33ZOleR3q48TWJx/wAvEf8A6GKAPQqKKKAON+Kn/Iv2/wD19L/6A9cL4OtftniWwhIyPMDH8Oa7r4qf8i/b/wDX0v8A6A9YHwlhE3i6Mnnauf1oA+xPhlp6lEdx8ka7jXasvmFs881leDLXydCaRRhmIX8K2E+VHY0AUNSlSC1kuH4WMHH1r5T+L+q+ZNMGO5mfhR1r6V8bTNa+HpmOd3UKK+UvEkE2t66U2N8h+YgcCgDC0LTWuyvys0hIyFGfwr2Pwz4ejso422hpiM4A+7UHgvw6lpCrouNv3j/jXcRiKAjYMnscUAOitliGcY9h61O1wqKVUBSOp9vSql1dMQNoJ4wQKabB5CHndVXHCKcUATLdRzPtcEqAQxA4qJ2jKDy4A0Y+8c5OfWlkhjPyo3yj+73qzaRQxMpdXzngCgCOyO59qQIoPQ1rxyxwou9QMH9asW9nCkQmccg9zVXyo5rkKVBOex4oA27XUHiRBGi7T1B7itO2hiuWLIpC9cHtWcgihUtIvA4rQ027Plg8DJxxQBQ8QXgtY0jjXd1IJ7e9cI8MtzKksbnDOcEjqK6jWnFxcTCXKxQJnOOprnNPv4pZQigrtOQSecUAdNDujto08vjHVu9TS3aMipG2B39AajF9GLPcFdxwBjmqEsqZDW7BieMdhQBPdb2G1ZAVPoa09I0+WPMkqkAAbT61zpvYoHVJQTuPRecV22jRRJaLJFI4VuzHINADJbd2XOSajVAF2k5rUuJVwdxVh+VZ80owAsbBfbkUAMfAHB6VSS+UTbSM4PXNTXTgccqTTNItPNu0Dc5PcUAdKkhVFJBGRn6isq9l3Sb1JwevvW9NGP3in7pBA9q5yQHymDDkGgCxaswdSGOK17+b5FI4BGawLdiDg9umK0buXNqpz2oA8g8XSBby5APyhj/Ovnj4nH/Sj3zXuvimTN1cEnqzV4L8S2zOnPfmgDa+F3/IuSf9fDf+grX2FBGFtFAHAFfHvwvGPDkn/Xw3/oK19lWyZt+DkYoAxLkDkd6wNSkyxUHgCug1RhHuHeuTvss7EUAeafEa4YIQM88V41cYWR2PXNeq/FO6Fvbru43N+deQ3k/msSOBQBBM+9h6VNbx5eqwzkYrW0e2kmcnbwOtAGhp1s0i4xwPwrsdNjPlokgBRegx0rN0+zBYbyBnjrXVWVsMEIu7H8VAEtvEgICg5Patqy0zz5BvIC0ywtQicD5v1rpNHtmdwijBPWgDa0OyihgJ8oHA6mpnhQbsIAOtbFvZeVaew6msXWJhDauQR6ZoA58wW39oNPMVby+QKqazqUV7ImI0TbwvrWT4guzAi+S/PdjXD6jrstsfMjdZCDwTxigDs31FbcuJsg5wB60hvTcR4fMYPf1Fcm9+HaG5lXcXAJXPQ1oTXUkrKVGW2/KBQBoXV2AQiMyqB1PWpdPneUEoWlZao2tk0wEk3UnoK3LCBbUBVxGevuaALVqszjdOcD+7WjGACCB+JqpHcg8MhHvVS/v3ClYskd8daAOlj1RIht3A1JFrAMgLPgfWuLF22MkEDuaz5LvfcBUcnJx1oA9w0bUiQpVgQR0rf+1kx5XGa878KrM0MSnjAxk13FvDIkYyM+9AFxJS8bFq5jxIf3ea3d+ARXN+IXzGRQB5d4mPyvXk94P+Ki08/wDTxH/6EK9U8SnKy+1eV3XOv6f7XMf/AKEKAO/ooooA434qf8i9b/8AX0v/AKA9Z/wRhM3i9gBnCD/0IVofFT/kX7f/AK+l/wDQHq5+zZafaPFs0rD5BsXP45/pQB9lW6ta21rDGdpVBxTr+4IVI1AUnlsVZMYM+5jyAMVl6jkwzMTggcH0oA4b4i62y6dcRpz8u1eeprx3wnpckspmmLSSyuWfPv6V2vjcPLeeTktu+6vqKtaJp4treOTYFOOvoKALlrEtlGlsgyPbsajvZ47dxGV8ybuFPSqV9eEOyW7lmY/M39BUtja7wrOCec/WgCzp6NJmXaPkPAJzzV6O23tucs7nqTViws2YZ28HpWzDZqg5Xr6daAMy1tf9gHFXYrdY13bSWPT0FacUGEBbAUc4qvdMD1IHp7UARiNZ7aZZGBKfMPSqumROblJwp2BuB2qeALn5gz/ypFkfzN7MEjUcIvWgC3fCaVdkQUJk5ye/rV+Arp2m28TkNNKeCO5rkbzV5bidc4EWcKq8cepNdFbQTXqW87MdicKOwxQBm+K7XyJVi81fMmjy6571x40yW2IdpESQnGM5zW14mvca4r3Kbsrtj9vrUNlZh7gG4XcJFLZz3oAtWcUhDxghEIyAD0o+yTLnK4QnII6Z9aqQSxWzyGJCADjPOfzqe5vZzzG21SM4Pf60AQonlzEurStjAb/Cun0yW4EEcSttjPGDxisrRd0bkxKZGPUnpn2rfWeB8/aFaKXHBZePzFADpcrzuBXHTNVhctHJlQAPrT2PYGNs+hqrJbyK3JyD+dAFiW73Z3Bj9BWpoZbz1aJQCOSawHBjUZJz1rovDokS1kmdScnA+lAGreyS7CQcgnOaxp/9ae+a0b25QKE5w3SubupTg4PK+9AFpGKz7cGtG+UrppdeoGa5uG6ZZFbJZRx710GrS+Vp8Tf3lz+FAHhXimbbczY/vGvCviFJvukGc8mvafFxMd5cr2BOPpXg/jSXzL8D0BoA7T4X/wDIuSf9fDf+grX2RazLHalm9K+OPhf/AMi5J/18N/Ja+tJJcWoX1oAo3rGedj2NZN1DtJ4zW8PLIG4H61lalKiZ27SKAPnv41s32i1QjC5NeWFCx4GK9U+M7ia+teGAANeceSe3WgCKGAsQCOPaut0+322qCNSAe3c1kaZZSNIONvbJ7V2FhAyukeVCepoAk06zyVyDkc4rq7FfLQA1VsIVU/LjPbNdBp1oS++fp15oAu6Lam4mHmHan96ux0+O3t8+UwZhXOwSkgLEu1K0o5Fij4OM0AdTJcIYCrOPmHQdq4zxA6xLtZ8FugPepp7wRx5ViSO9cjrV093dqHfLdOvSgDB18A27SSNwCeDxXASI01vKgI4OQe5Nd74kgY6Y7JlgOhHeuO06aBT5RXJJ+c46UATeHLSWSJlnBKr0HWvQ9L063kslaQbAo4Ud65vTLVLZlMDl1lz1rftmaCTYWJz2zQASBk+WULhfuBeMU8TSxBTLcRLn+8M1i6xqE9vJJuUEDufSsmDUXZPmAZW9R0oA626vJmAEbQtjoQawdQvrwN8skQx6NVB55BjDZX0Axio/JebDyqdueQKAL1ncalcOAZY9p4xXSaDpwjnV7rDMTkYrmrOQRkBQoAHAHU1v6Q1zKwZiVQHp3oA9Z0ZP3KbF4xXYwfLapkg8VxHhm6ZIVjfO0966drkxqFHTFABMF3tzjmuZ8QKQjenrWwl15suH6k9aoayAY3B9KAPJfEn3ZBXll0Ma/Yf9fMf/AKEK9S8T8CQCvLbo58Q2Az/y8R/+hCgDv6KKKAOO+Kf/ACL9t/19L/6A9dX+y7YNPqGVB/eTZJ9hXKfFP/kXrf8A6+l/9AevWv2TtO26JcX7DCojKp/2mOP5UAfRG7JJ/vNx9KyfEu6PTwYxhnOKveZiaIHstUvEMifYkD42hS/NAHgGt6pcT+J2w58uM7EFaX2mbywpc5PXmsvUIj/b8/lozMfmBA6Zre0nS55Rlo2x6txQBBa25aUYUk+1dbpdhnDPyBSWmnJERvXmtu3i+UZ4HtQBPbRRxqBje3bHQVZV40ztGT3JNVmfYMngVVM/mNzgKKAJrm4eVmVQcdBUZgVURps5PQUyOXJYqNqL3Peo7iVnG4dW4+goAle8XYUhTCqDzWeVxOjHdKT+GKsxx/JtBqsyPI/B2oOCfWgCK40uA3UG9sE/MVHODmr2teK7bQbSK1KtIT2Tr/8Aqqjcypblp3cBVGMnp9a4u8uYdTvJJ1kDRqAW9sUAdL4kjeYQaiFzDwyhRnr2rV0m4S4tZEmiO4KCmPU9qraNKL+yijRsLjZnHTFXbBItIvo4kcslwcqZD0PfFAGddjbIXlUqOhUVRubkHKgBQOmP61reKIlilJj+YMPwzXHATyXQgRG3Z+7QBsWV88W/5sDjNaceqTFV3fMegzWZZwOAEkQHuSe1aUdqGwowB/OgDQs72GdAk0ZR8/eX/CtWGAxDfBdCQnqD/UVjpb4TG0FlGM55NXIJPL2nkY9elAFmNWnuAHQbgeqjiu0toxFa28bgKoTJrjIH3zhdx3Mw6dK6u6b/AETOfurtoAydSlT5CDxiuW1CZvtJb+Fjniti6ctGf4wBjIrKeEvgsDt6fWgCfTo/MlUt93NaPimYR2iJngDFR2MW14/7vQe1ZvjW5C5GeMUAeP8AjSZWe5kzweK8B8SyiTUn9BXtXje48u0mJ6mvCNSfzbyVvegD034X/wDIuSf9fDf+grX1iFMkCkdq+Tvhd/yLcn/Xw3/oK19d6WgaHDc5FAGfKhVTgVyOsTHcyg967bWQLS2dz6V5zfSl959aAPN/iPG8tvDLjIRiDXnq2/mv/dXNen+NYy+mbcd81xunWqtIrOgJHQUAS2NmUVAePT3rptM05i+X2hR+dQQ2uMNGMgfpWvZxMuMAk9zQBrafZrEQxUknpW1DGN2+UmqGm5wNx+X3q3NMBlh9APWgC2JsJnhUFQy3DMwI+7VKdpFG2QEN6elSR5CqcZbsDQBJeyBIAT0AztrkdQuWSKR2GGboB1rpLqXAZjzWBeqsgBk/jPAoAxr/AFOSLRmMpxkfKh61xkd7agLInyksd1aXji7MUaKCBtPAHeuOa/ady8oQLjhVGBQB6Zouqwx7RFGZBjOSeBWtea/bSWw8qAGXOCd3868r0C7CSuQzDPAGetb2ltEt0UMmFb7ynvQBv6rJJcbGtwqBuCCcg1DbaVduciMrx/DyKqfOUA2OVU4ABrX0wiLhXuUc+hyKAHw6ZJHtabk+npUz2zSkdR7gYq/HG4Yv9pJx/eFNuHkIDLOi470AJaWqQktsHPdqWCSaW+CxZVQe1MEk7xFGuY2DdMDNaGiosLgE7iTQB3ehTssYVhyK6Bpy0WMmuU0lrhbpTHEzDPTHFd2bNXjWQoBkcr6UAULGImUs3T+dV9bf92xPpWwIlUEqea53XnIjYHrQB5f4obhzXlVyc+I9P/6+I/8A0IV6h4pbEb5NeVTNnxLp/H/LxH/6EKAPSKKKKAON+Kn/ACL1v/19L/6A9fSvwF0r+yfhhosRXElzF9qfj+90/SvnT4gWrX2n6dap1lvo0/8AHXr6s8HFYdCtI04SG2jjUfRQKAN8tvnDAcBa434gao9vaui5O5QuBXXxENbkrnPGa8/8ejEhYgnacfnQBRsBEyQtFDmYLjLdB/jWrAjucsee5qjoqfuhkdutdBbwYXc2B6A0ALDCFj3N+ApysTnPQdalY7Vy2M/zqpNOCCoHv9aAG3Eu4E8BewqB+h7lv0oOWG5sbRSxNtZmYZzQBI6bIY0U5Y8n2oKDCIBk9frU8MavJkt2zSyrlyVAVR3PagCCRVAAbnAyRUMSNcS5IKxIMkCrDtEuMN16Z71HPcJHYyvuEaoMljxxQBx3jO8R2itUk2HOTnofauLkaSHU4o5I1THzttOVYVB4i1X7RqbGcugXnA7VUhnWK0MhYuWACA8kCgD0zwnqwTUL7HEceCqdgMdq29Qu47iNCRjJ3K3cEdhXn3g8s/2glv3rcEY61018zmKMwKWbbjaO1AEurXdw21owTG3bGataXaW09tO1/MkVyuDH1BHqa5pruaFCzFm78Hit7SEgu5N7sd6rw/UEemKAN61eNYQG23MWOrDLY+tWYls5F2oGQ+np+FZcq/YX3RgsDzkdKcmq7Sm+JH564ww/GgDWEcTLiCRS3oeDVG43kmNOHzzmnieyucHDRueuPWltoPOuAgn3p2PcfWgDQ8PQSJc5YAoOc9cVuahcbdgQfKRyPWp9Ls47W0Dn5mfgkVVv9gKZ/hGKAMN4jHO+TkE1G8g5EmM+tS3kuSG9aznbcwyc80AbWmMGmRTyDXFeOrvF9JEW4Tge9dbp0wSOadukKEmvMPF955yPKx+YHr9aAPLPiDeZt3QHqDmvH5Dlj616H44uN0DnOecV52x5oA9W+F3/ACLcn/Xw3/oK19eaR/qxmvkP4Xf8i3J/18N/6CtfXekgrFlu3NAGf42nC26x9yK83lOcsa7fxcxkkDE5A7Vw8wyx3cCgDO1a0S906RCPmxwa8+t08qV0PBU4NeowoDx2rkdS0pf7WkKjAJzQBDpkDPIryN8o7CugjDMQqDA7n1qOztAqKgXCitBYxEeKAHR/IuGzQ5MjZP4YqNnyeT+FXLaPcBxwaAF+z7YhI5J+tIqs+5h09au3UZKKCcKOgpt1m0tA0gCluQD296AMTUJUiwrHk9B3Ncn4h1JLedSx6dFFaGtanBaMzv8ANKfu5NeW6xqrTXs0jSBsd+w+lAFXxLqHn3shbnngelYKSFjio7mZpXZmOSTnNNjPz4NAGxpzrC0ZwSynmtmPMl0sq/xHp6Vzls5dxtH1rqdDAhuA7fMD1BoA6jSftNteKhPyOO/INbKy+TIVIKgnoKjsUhnKMJB5idENM1yC+tnEsEQeNh29aAJLu5AXzI3JH1rKuLwuSQDtPoarlJ5OSjK7DkHgVXMN2Dh4T9RzQBLDePCTgnntW3otzdTupVTgHOcVgRo4jZ2UDbxmuo8IyTszGUHyiPl44oA9X8NXxlt4B/EvBzXZPcbVCkZBFcD4fbDwlO55rsJpeA3tQBLFJvyc/hXPeI8GMt+FbFjkgse9YXiJv3DjPfigDyvxW37t68vI/wCKisOf+XiP/wBCFek+LWOx+Tj0rzJW/wCKjsunNzH/AOhCgD02iiigCtcW32nUdKBH3Lnf+UUlfQmhExaLDjoVAP5V4ZpoDatZKerO+Pr5bn+le86amNFhHHC0AasVx5ULZ/iGKw9ctVu1ZWGQy96tRSb9ozwKhuZf3gRvpQBR0ez2W6luSB+VWZLlRuEa59zT9zW9vIV9KoQLuJLHrQBbDsYy0nIAqnu3tlj15+gp1xOr4SL7gP5momBJATt1oAfMckKudoFKgyBjgUqr90FgfWn9eAeO1ADt+B04qtc3ZdyOoByR2NM1G5WFfKQjP8R9ayfPfG4cnpjFAGlC3nzrg+/+6KxviBqKWmhSJG2N8gHPpWnFJ9nhB7sMMf6V5Z8YdXaCCJOCMEEk9KAOJ1G/e5mZ2kHLdjkkZ4rUtWGnGCaRWeKXgKOrE+vpXIW11ECCyEOOFOf6Vo2uo3ThMMNi/KiY4J9TQB6z4QVLc3yxAqWw6nHU1OdY8q7uGVXxKpj6/wAqzfB963l75VDFEyGzjPtViZYGWVzCI/mJB9KANaO3S6MawHdtwpXuc10WlW4sJDEyBdwxg9mrntJWBroiKUxho/8AWY4JrUubi9jVZEcSnjLdTkUAaV1dmIiJk2nOSTzmqUkBkTehOT2B61dl1AzWiSXNspfjfx/I0y2ntJFAQGI56noKAKiJLG/zbsH/AD1rW0KPfcHy2B9XBzTLhRKiJJGpU85U9a19BtkguE2KvzHt0oA7FF2aZEOpUZrEunDu4JOc5rTv5sICvAAxj1rm72UxynJJHb2oAr3p6jpnmsned4BJ+laFxKGYMpyarCLzJ0C8g9KAE1K4Fro8qZw03H4CvKfFdz/ovH8TV6B4wn23ogU/LCgH4mvK/FE/nSkDogxQB5f4xl/dhfU1xp610ni6XM4TPOeRXNGgD1j4Xf8AItyf9fDf+grX2DbLssmPfFfH3wu/5FuT/r4b/wBBWvsPYzW4UdKAOS1pWkcgjIrl7uAowOOK9HurDfGQwzXNajYCPccE+1AHLxrlsfpVa/t1Em7HJ71pzQSRsXUHH0pksPnRhgPmxQBQhjCJzgmqtzLltoI49KluTJGduCKS3s3lOWGD70ARQoWYZrashhQOv4UttppwCxGfQVNOFtIiZCFz0HrQA55IkJeToozXIa/rSzFyzMVHAAp2vaqEyu7AxXn2vaiXhbD4RRzz+tAHO+K9Z8/UJAGOBwK427n3uVB474pNRuDcXcjKx25/Oq1ADwwxT4yWNQVKp29DQBt6fhGViOO9b9tcRedlsqG/KuUtpgHALcGrctwSMITigDuhdBRELeZseoqyl59rjaBrxleIZCuODXD2szOI8sVArU+0ZKToM7eGz0NAGpOJS+Rcru/u7yKlsbLUppVaO5wPTzKpywG4CHHBGRir2mmW3YGYEY6UAbqWF1J5f2kxsAckiuxsYE8hTGAoUdMVydtqSMoEjELnqK7Tw1Nazq0IIIcYAcYoA3/CrhnMbL8y8jiunkc7cVj6JbNEzLsCkdOK2BEzEHkgdRQBbt0CQZ7muY8TNhCAa6VnxBXIeI5dwb2oA8s8WtgMK8yhbHiSx97qL/0MV6J4vkwrH2NeaWz7vEOne95Ef/HxQB65RRRQBCLsWWveH5XOEN+Eb6NHID/OvpKxhA0rb/d4r5P8c3P2O20q4JwI7+Mk+21819XeDbj+0/CtrcZyxXa/1AxQBTj+R+nU1HrA2BJB1FW7mEoxOOM1Wu4TPEAM5BoAiR1nsiIxxVC7fy12IPqcVp2lq0K5OCPSqEyO9ywYbVB60AMsosgs3ygfrUvA4Qd6e7qNqZwO3vTHlWOMtt6dMnmgCQKFUE8DnJqtdXcdtCTnDEYB9Kzb7VVhBdnAHYVzl/e3d7IBawSvxycYGaANC4vUL53Zz1pi6gjOqwnJzkfWqUHh7VrtlMjpH6YGcV0emeCDAqvcXDe54FAFW71AW1sWIX5f5mvAvi9qjXWo20cb5KuckdB7/WvafH2jzmJYdHu45Jzz5TH8ua+ffG+m3un20hv4JBKXzvPIHrzQBiwzKtwkaEOS3LGup063luGRIxngkD2zXB2D7plC5yG4xXpfh8YWJtu3nIIP3RQB3EyfZre1jRirfKVA9qvtfJdPPDO2TtDKcY5FYF3OHv1JZQka9z1ppnX7d14Ycv7YoA6HTLp4v3ufmTAA7EV0E8uYYpYnKbuc+9cnpBVcwPu2OMKc8g+ldHp+26gazI/eIdyY7j0oA1dH1EibyJgsiPwee/rWqqRv8hX5M8cVzsVnIkwm2YC8Yz39a25WkWHziApA5GeBQBoQwFAFgbdGDypPSt/SrcrcRSdADyPWuU0q+818Ao5Tkgda7jSoxLZvNnouAKAJL+Tco4xzWBfyhpX47VYubpxwex6Gsi5uMuQ3BPcUAVJJdsgXHB6e1bOjRbsg9SM1jSR+p+Y9K17OXyrKaYcbEJoA888U3pa/vJAckuVUV55rT4iYkj3rqNfmL3Lvztbkf1rgfFN4IraQ5PQ0Aea+IZxNqDgHIXisqpJnMkruTksc1HQB6x8Lv+Rbk/6+G/8AQVr7MgxsAPSvjP4Xf8i3J/18N/6CtfZETjaM0AOmAINZVxGskmCAQKvyyjBC8mo4ISzZx1oAzjYQv/yzBP0pYtKSPpEgB9q6CK346YqwsAA6UAc82j2snLwoT64qN/D9qeVjUH6V0jQgVG6Y4oA5O40bYp2AfhXC+JrG5EhKKxI4A9K9fkjyDWHqOi/aMlTyfWgD5w8SyNZwySXm5FHc968m1zUpb8usRKQjt3NfW2tfD59RfMrI69lYcCuG8QfBRZwWtoY0b1RsGgD5lwKO1el+Ivg14l03fJaQC5jznap+avPtQ06+02Vor+0nt3U4IkQrzQBWFKDTc+1GR60ATbvSrtu2QvcVm5GO1aGmuN46EryM9KANWFHGxtuVJ6itLTmdLht6nyicFTVCx+1KxkhkVUPVc1qCXU43ilCq6sepUEUAdBBCz/u9uF/gYU3y5In/AH+eDjB71WtdYvbKUmRFbvtCcCtCbV21FMTQKCRkMikGgBjXtvZFXMe5j2PQV3HhXUY79UkhTYyEZrx+T7RcXxCqzAtj6V6j4Ps208+T2dQw+tAHsGg3DzbiV4Q4JNa7YQ8d6zvD8YjsN54LDPNWJpcOp7YoAkuOICa4nX34au0mOYAR3rhfEZ2lxQB5T4zkOJOxxXm9m3/FRaUP+nuL/wBDFd741c4fpxXn2nnPifSs/wDP1H/6GKAPaKKKKAON+Kn/ACL1t/19L/6A9e/fs1+I11bwj5Ej5kRRkejLwf6GvAfip/yL1v8A9fS/+gPW1+zB4gNh4nk093xHNhlH6H+lAH1PqZ2554zVWNwYuDVnURujcd1NULX0B4NAFxDnrwarX0DPwBgEdRUqkq3PrUqSqVIb8qAMRtNuCQVKn8asQ6A86Dz5D/wE1sRmMdBmpluQOvT0oAxB4PtS25mJY925q5b+G7eLGWJA5xV5rxQ2N1ElwzKSOgoAGt47ePESovHBxXP6pDe3AKo6hfUn+lX57onP61Ua5O7bzjvQBymo6HcSCRjnft4xyW9q43XNEZ7KSOX5gQcpIuQfwr15ykpHt3qte2FveRATRjKjhu9AHy3Y+B7e7mLRKYJo3IGD8px7GtC80/UdFWN5U823VsF1GSPqK9Y17w9LaXDXNrErqV+ePHOfUVStphfwrDIuQDhlI6H1oA8hk1XzrmRVbndnIHJrZtJhOYIY3w5OWX1A7V03ib4fw3Vw1xZL5MxU4ZOMn3FcO+l6no1yguoJCqj/AFqgkGgDuIbudIfmiwfv5ArqtK1YsUlZVCN8sh2AP+fpXA6FqLAuZGDBs4QjpXU6XeQMWjl2oGIxmgDpluIjI0ZO3dyuQeaZe3bxwCOX7pOQe1VLmSIMSXXII+XP60y+t1ubRvLLOR/BnpQA/SLkC+DKm/aRyO9etW0yRaZC2CpbOa8w8O2cjPCnlkMCBx0r0a+mWO0EYOdo20AZN9OC3rnpWZcAH5jzilncI/36rzyYzx196AGtLhwCRV6+m8nwtdPnBf5R+VYTSbrsoM9OtXfF0hg0KKBT94igDzTX5toQZ/hNeVeNLwmJgCeeDXfeIrjMkgzwvArybxVceZcBBz3oA580UUUAesfC7/kW5P8Ar4b/ANBWvrmN8vgk18jfC7/kW5P+vhv/AEFa+soW/eA5oA0I05A61pWsOADVK0+dwBWwi4WgBAMdqXFOprAkcUAI5FQtjnmnshx0qNkc9hQA0gU0AGnbG9KQxtQAbVqCZFx0qdYiPrSPGxHSgDLlgV8gqK5nxFoFnfQst1aRTD/aUGu0aEnoKie2ZhgrQB80eNPh1ZTLL9itVhfqABxmvMY/B0sdy0F3E0Lg4yw4P419o32hiYH5M1gX3hCO5XbJAD6HFAHzRD8O0njDIoz0JFRL8OJI3bJZRjjbX0jB4ONjyq7k9O9XINDjdjvjBHuKAPmCTwZewKDA3m54weMVVSC5smNu4eMEdW6Z9jX1Pe+GrN02+SB7jiuY1nwNFPCyRgbTyAw70AfPhuriEY3cjvW7pN81wnl3IzEwxgHH41f8S+BL7Si0kUbNGDnbjNc9ZEghDkPnG08YoA1FhSzuQ9gmFJ5zzzXcWk8skduxCiULgnHWsDRLJnI8xD5bHv2Nd5Y6SzmFwQAvGDQB2+jlxpqbidxAomcmQjsKkCvFAo/hAqqGYnp3oAvMxFpz1rhvEj/PJxXczDbaDI7ZrgfEJ/1hNAHkPjI5L/WuC0058VaYD2uov/QxXdeLm+dxXBaSd3iuwP8A09xf+higD26iiigDjfir/wAi9bf9fS/+gPXI/DfUG03xlp06ttzIFP411vxV/wCRet/+vpf/AEB68ysrhrW7huE+9G4cfgaAP0FhuhdWcU6kFZog344qpYyBgeeQcVgfD7Vk1Pwnp9zEQUZNv074rRjl8q9cdn5oA3uGHGM96pzJKc7PwpY5sgGpFkoAYonAACn61JmRhhVO6nNIfWhXPrQAfZ5WXkYPWp1hk2Y7ULLThMc0AVGsJRkAjBqP+zZA2SQRWh5xz7U4S+9AFJrFsA56VH5Dkc/gavvPjiomnoAzLi0dsAgFayp9Ch88ShFVyeSO9dIZweuDUTFCOnNAGBdadLF80WJFx07iqdvYxOW+0R5JGMEV0+QOD1qKeOKVCGHPr3FAHnWteBIbkmWxxHIDkbeMe3vXIXem6hpt8qTx4ycK+OK9ilm+yPhs7OzVFeJZ6jayRXShlIyDjkH1oA840+R7uQeaC0gG0c9a3NFy9w0Zxz0x6+9YlzZT6bdPDKQ4XJWRTgOO1WdEBE8cisyyZ6CgD07QbBiZQuBtGRzVfUJ2RijZOD1q1b3nk2a8bHAyStY9/d7gzcMc9fWgDPu5izljVU3Z2so5I9abeTgqR0JrOWQeYOcdqANjTozLcRf3t2DUfxCuvKt1x2+Vfyq5oKgSljwcZrk/iTdhriKMN8qZJ9zigDzPX7jarc9q8q1OYzXkje+K7nxTebIZjnkV56Tkknr1oASiiigD1j4Xf8i3J/18N/6CtfWEea+T/hd/yLcn/Xw3/oK19W2jhsUAb2krkbq11qhYALEtaAoANtG3ilFLQAwik2+1SGj0oAi20hSpqCBQBEEzSOvtxU4FIw46UAVSKVAM808rSoOaAG7BSCIHtUwHWnIKAIPsynsKjfTYiSVG0mr4C1IooAwZ7IL/AAms6e1Rz1wR7V10kYYcis+5s0YnAxmgDk7nS0lUq2x19DXAeLfhxYXsbTWSiC6P8QFesS2OH5Yiql1asSB96gD5nh0fWND1cQ3od7YnAcc4r0/TrUvBCUzxgmu/k0WG4iP2iNWB9RUQ0OOAq8QwFGNtAGc5DQqnbFRW8H73BGcc1O/y3DIRx2FXYYxtHGDQBS1T5bc49K868RthWFegaw3ykCvO/EhOG5oA8i8WH53AzXB6GQ3ifTzjH+lx/wDoYrtvFr4MpzjAPNcN4dOfEWmn1u4v/QxQB7pRRRQBxnxV/wCRet/+vpf/AEB68rFet/Eq0uL3QoI7OCWeQXKsVjQsQNrc4H1Febf2Dq//AEC73/vw3+FAHvv7OWv7tHm06ZvlRgVyehr1i+lKSofRsV80/CFL/SdYuFu7W5t4ZEzvkjKjI9zXvL6za3FuPMuYQxAzlx1oA6aC72nB6Gr8coYDmuQg1ez8tS13bg+hkFXrbW7FOGvrbH/XUf40AdL5lOWT0rEGuab/ANBC0z/12X/Gj+29N/6CFp/3+X/GgDoA4xTt+e9YSa7pmOdRtP8Av8v+NSDXdL/6CVn/AN/l/wAaANoOKN/HFYw13Sv+glZ/9/l/xoOvaX/0ErP/AL/L/jQBrSPUZesz+2tLbJ/tKy/G4Qf1pDrWmD/mI2X/AIEJ/jQBoE0m8DpxWYdZ03P/ACELP/wIT/GmNrOm/wDQQs/+/wCv+NAGrvBPXmkYggjP5Vkf2zpv/QQtP+/y/wCNB1nTf+ghaf8Af5f8aANCaBZFIYgg9jWNe2UlujNDlo+4HarP9t6bn/kIWv8A3+X/ABpw1vTMc39p/wB/l/xoA5e7ieUtnEi9gTzVvw7YiItcyKMjOwGrGpXWlOTLBe2YfuBKvP61Qj1SyxtNzEBjn5xQBvQ3BJJc4DDGKzrp1PmbfxqlNqNsjKUu7cqOn7wcVn3eoQM7kTxkn/bFADrqQqvPPvVOEl7gf3ciq73MbnBlX/voVLZTwfaYw00aru6lgABQB1tq4t4Gb+IivN/iBcYuBnqQa7O61O1ZWCXEOOgAcV5t4/eW5uwbSN5hg8xgt/KgDyrxXdb5ViX1ya5w9a3NQ0jV57uST+zL4gnj9w3+FVf7B1f/AKBd9/34b/CgDNpK0/7B1f8A6Bl9/wB+G/wo/sHV/wDoF33/AH4b/CgD0b4Xf8i3J/18N/6CtfUWnyhmUV8x/Di1uLPQJI7uCWCQzsQsilTjC84NfQVhrGnI4LX9sMesq/40AekWLjy1rRQ5FclYeJNGCAPqtgv1uEH9a1YvE+ggc6zpo/7eU/xoA2+9LisgeKNA/wCg3pv/AIFJ/jTv+En0D/oN6Z/4FJ/jQBrGgDPWsr/hKPD+P+Q3pn/gUn+NJ/wlOgZ/5DWmY/6+k/xoA18UuKyf+Eo8P/8AQb0z/wACk/xpB4o8P/8AQb0z/wACk/xoA2FXFDLkVlDxT4f/AOg5pn/gUn+NB8U+H/8AoOaZ/wCBSf40AaDL+FAFZh8UeHz/AMxvTP8AwKT/ABoHifw/n/kN6Z/4FJ/jQBqYpyisr/hKPD//AEG9M/8AApP8aT/hJ/D+f+Q3pn/gUn+NAGuCRUi1h/8ACUaB/wBBvTP/AAKT/GpF8U+H/wDoOaZ/4FJ/jQBtnpUZGay/+Ep8P/8AQc0v/wACk/xph8U+H/8AoOaZ/wCBSf40AXZ4t3FVTHzyOahPifw+T/yG9M/8Ck/xqOXxL4fPI1rTP/ApP8aALJj4qBULkjHAqFfE2gD/AJjWm/8AgSn+NRr4k0HJP9s6b/4Ep/jQBU1GxzJvH3qgiBC5I6VYuvEeht93V9PJ/wCvhP8AGsybXtH2nbqlifpOv+NAGVq8h+bivOfEsh2tXb6rq2nuG8u9tW/3ZV/xrgPEE6S7vKdJM/3TmgDyHxhKfLlz71yfhv8A5GDS/wDr6i/9DFdh4t0++nicQWdxISf4Iyf5Vz+g6LqcWt6dJLp14kaXMbMzQsAAGGSeKAPZKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normal lateral chest radiograph.",
"    <br>",
"     (B) Lateral chest radiograph demonstrating hyperinflation with flattened diaphragms and increased retrosternal airspace in a patient with alpha-1 antitrypsin deficiency (AAT).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7217=[""].join("\n");
var outline_f7_3_7217=null;
var title_f7_3_7218="Patient information: Elder abuse (The Basics)";
var content_f7_3_7218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/20/2370\">",
"         Patient information: Mild cognitive impairment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/22/32098\">",
"         Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Elder abuse (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/elder-abuse-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H94547902\">",
"      <span class=\"h1\">",
"       What is elder abuse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Elder abuse is any action taken by a person who has an ongoing relationship with an older person that harms the older person. (&ldquo;Older person&rdquo; in this case means anyone older than 60 or 65.)",
"     </p>",
"     <p>",
"      Elder abuse can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Physical abuse, such as hitting, kicking, or pushing the older person",
"       </li>",
"       <li>",
"        Sexual abuse, such as raping or forcing the older person to remove clothing or do any sex act",
"       </li>",
"       <li>",
"        Psychological abuse, such as insulting or threatening the older person",
"       </li>",
"       <li>",
"        Illegal or inappropriate use of the older person&rsquo;s money or property",
"       </li>",
"       <li>",
"        Abandonment, meaning the older person is left alone without care",
"       </li>",
"       <li>",
"        Neglect, meaning that the older person does not get the care he or she needs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Neglect may be the most complicated item on this list, because it can involve self-neglect. Self-neglect is when the older person does not care for him- or herself properly. Neglect, in general, can mean that the older person:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Does not get all the food and water he or she needs",
"       </li>",
"       <li>",
"        Does not get all the medicines he or she needs, or gets them at the wrong times or in the wrong doses",
"       </li>",
"       <li>",
"        Does not get bathed or dressed properly, or is left with dirty clothes or untreated sores or wounds",
"       </li>",
"       <li>",
"        Is forced to live in dirty conditions or in a home that is too hot or too cold",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94547909\">",
"      <span class=\"h1\">",
"       Who is at risk for elder abuse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Elder abuse is most common among older people who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are women",
"       </li>",
"       <li>",
"        Are older than 80",
"       </li>",
"       <li>",
"        Need help caring for themselves",
"       </li>",
"       <li>",
"        Have trouble thinking clearly",
"       </li>",
"       <li>",
"        Are depressed",
"       </li>",
"       <li>",
"        Had a broken hip at some point",
"       </li>",
"       <li>",
"        Had a stroke at some point",
"       </li>",
"       <li>",
"        Do not have a lot of social connections",
"       </li>",
"       <li>",
"        Are poor or have trouble paying bills",
"       </li>",
"       <li>",
"        Have family members who are ill or who recently died, or whose family has stress for other reasons",
"       </li>",
"       <li>",
"        Are being cared for by family members who",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Have problems with drugs or alcohol",
"       </li>",
"       <li>",
"        Are depressed, violent, or antisocial (which means they do not relate well to other people)",
"       </li>",
"       <li>",
"        Rely on the older person for money or financial support",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94547916\">",
"      <span class=\"h1\">",
"       How can you tell if an older person is being abused?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Older people who are being abused can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cuts, scrapes, bruises, burns, and broken bones",
"       </li>",
"       <li>",
"        Weight loss or obvious lack of food",
"       </li>",
"       <li>",
"        Dehydration, meaning the older person is not getting enough water or fluids",
"       </li>",
"       <li>",
"        Pain, soreness, bruising, or bleeding in the anal or genital area",
"       </li>",
"       <li>",
"        Infections that are spread through sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another sign of abuse is sores that form on the skin when a person sits or lies in 1 position for too long. These sores, called &ldquo;pressure ulcers,&rdquo; do not always mean someone is being abused. But they are more likely to happen in people who are not being cared for the right way.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94547923\">",
"      <span class=\"h1\">",
"       Who usually does the abusing?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In 9 out of 10 cases, the abuser is a family member&mdash;usually the older person&rsquo;s husband, wife, or adult child. In some cases, the abuser is someone who cares for the older person in a hospital, nursing home, or other setting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94547930\">",
"      <span class=\"h1\">",
"       Is there anything I can do to prevent or stop the abuse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a loved one who is older, the most important thing to do is to keep in touch with him or her. If you suspect any problems, ask him or her about it, or bring it up with his or her doctor.",
"     </p>",
"     <p>",
"      You can also call Adult Protective Services in your state. To find the phone number for Adult Protective Services, call directory assistance (4-1-1) and ask for the Department of Social Services or Aging Services.",
"     </p>",
"     <p>",
"      You can also check online at",
"      <a class=\"external\" href=\"file://www.eldercare.gov/\">",
"       www.eldercare.gov",
"      </a>",
"      and search by &ldquo;elder abuse.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H94548012\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=see_link\">",
"       Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=see_link\">",
"       Patient information: Mild cognitive impairment (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/3/7218?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16418 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7218=[""].join("\n");
var outline_f7_3_7218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94547902\">",
"      What is elder abuse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94547909\">",
"      Who is at risk for elder abuse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94547916\">",
"      How can you tell if an older person is being abused?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94547923\">",
"      Who usually does the abusing?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94547930\">",
"      Is there anything I can do to prevent or stop the abuse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94548012\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/20/2370?source=related_link\">",
"      Patient information: Mild cognitive impairment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=related_link\">",
"      Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7219="Besifloxacin: Pediatric drug information";
var content_f7_3_7219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Besifloxacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/4/16451?source=see_link\">",
"    see \"Besifloxacin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/28/9668?source=see_link\">",
"    see \"Besifloxacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7804386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Besivance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14944302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Besivance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F9729706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F9729715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/4/16451?source=see_link\">",
"      see \"Besifloxacin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Children &ge;1 year and Adults: Bacterial conjunctivitis: Instill 1 drop into affected eye(s) 3 times/day (4-12 hours apart) for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7828836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Besivance&trade;: 0.6% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7828805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9729716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Wash hands before and after instillation. Shake bottle once prior to each administration. Avoid contaminating the applicator tip with affected eye(s).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9729712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store between 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9729707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial conjunctivitis (FDA approved in ages &ge;1 year and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7828817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Ocular: Blurred vision, conjunctival redness, irritation, pain, pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9729709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to besifloxacin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9729724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact lenses should not be worn during treatment of ophthalmic infections.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9729710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not inject ophthalmic solution subconjunctivally or introduce directly into the anterior chamber of the eye. Prolonged use may result in fungal or bacterial superinfection; discontinue use and initiate alternative therapy if superinfection occurs. Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7835465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7828807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7828808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral besifloxacin has been shown to be fetotoxic in animal studies at doses that were also maternally toxic. Quinolone exposure during human pregnancy has been reported with other agents (refer to Ciprofloxacin, Ofloxacin, and Norfloxacin monographs). The low plasma concentrations of besifloxacin following ophthalmic use (&lt;1.3 ng/mL in nonpregnant patients) should limit fetal exposure.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9729725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of infection or hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9729713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits both DNA gyrase and topoisomerase IV DNA gyrase is an essential bacterial enzyme required for DNA replication, transcription, and repair. Topoisomerase IV is an essential bacterial enzyme required for decatenation during cell division. Inhibition effect is bactericidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9729714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: ~7 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9729726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/28/9668?source=see_link\">",
"      see \"Besifloxacin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contaminating the applicator tip with material from the eye, fingers, or other source. Discontinue use immediately and contact a physician at the first sign of a rash or allergic reaction.  Finish the entire course of therapy even if feeling better. Skipping doses can lead to decreased effectiveness of the medication and bacterial resistance. Do not wear contacts when you have an eye infection or when you are using this medication. Wash your hands thoroughly prior to use. Invert closed bottle (upside down) and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back and, with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cambau E, Matrat S, Pan XS, et al, &ldquo;Target Specificity of the New Fluoroquinolone Besifloxacin in",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      ,",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      and",
"      <i>",
"       Escherichia coli",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2009, 63(3):443-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7219/abstract-text/19147516/pubmed\" id=\"19147516\" target=\"_blank\">",
"        19147516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karpecki P, DePaolis M, Hunter JA, et al, &ldquo;Besifloxacin Ophthalmic Suspension 0.6% in Patients With Bacterial Conjunctivitis: A Multicenter, Prospective, Randomized, Double-Masked, Vehicle-Controlled, 5-Day Efficacy and Safety Study,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2009, 31(3):514-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7219/abstract-text/19393842/pubmed\" id=\"19393842\" target=\"_blank\">",
"        19393842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13084 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7219=[""].join("\n");
var outline_f7_3_7219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7804386\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944302\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729706\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729715\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828836\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729716\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729712\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828817\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729709\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729724\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729710\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298854\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7835465\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828807\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7828808\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729725\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729713\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729714\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729726\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/4/16451?source=related_link\">",
"      Besifloxacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/28/9668?source=related_link\">",
"      Besifloxacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7220="Acetaminophen and pamabrom: Drug information";
var content_f7_3_7220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and pamabrom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/33/34324?source=see_link\">",
"    see \"Acetaminophen and pamabrom: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6834944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cramp Tabs [OTC];",
"     </li>",
"     <li>",
"      Midol&reg; Teen Formula [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Women&rsquo;s Menstrual Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6834948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Diuretic, Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6834963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Menstrual symptoms:",
"     </b>",
"     Oral: Acetaminophen 650-1000 mg and pamabrom 50 mg every 4-6 hours as needed (maximum: 8 caplets/tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6834962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6834964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Midol&reg; Teen Formula: Acetaminophen 500 mg and pamabrom 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tylenol&reg; Women&rsquo;s Menstrual Relief: Acetaminophen 500 mg and pamabrom 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cramp Tabs: Acetaminophen 325 mg and pamabrom 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6834946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6834949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms associated with premenstrual and menstrual symptoms (eg, cramps, bloating, water-weight gain, headache, backache, muscle aches)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6834943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6834954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See Acetaminophen monograph.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6834950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Acetaminophen may cause hepatic toxicity with acute overdose; in addition chronic daily dosing has resulted in liver damage in some adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Discontinue use if hypersensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose to &lt;4 g/day in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Should not be used with other products containing acetaminophen. Patients should be instructed to contact healthcare provider if new symptoms occur, if redness or swelling occurs, or pain lasting &gt;10 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6839912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6834957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ms-Aid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-25 mg (2): $0.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Womens Tylenol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-25 mg (24): $3.86",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/3/7220/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8532 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7220=[""].join("\n");
var outline_f7_3_7220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834948\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834963\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834962\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834964\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834946\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834949\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834954\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834950\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298638\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6839912\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834957\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321863\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/33/34324?source=related_link\">",
"      Acetaminophen and pamabrom: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7221="Factitial dermatitis";
var content_f7_3_7221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factitial ulcerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerations created by the patient. Note their geometric appearance. The patient had a severe psychiatric disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7221=[""].join("\n");
var outline_f7_3_7221=null;
var title_f7_3_7222="Trophozoites of Naegleria fowleri";
var content_f7_3_7222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trophozoites of",
"    <em>",
"     Naegleria fowleri",
"    </em>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a Wright's stain of cerebrospinal fluid from the patient drawn at the time of hospital admission (A, bar = 100 microns), an ameba is visible in the center of the field, indicated by the arrow, and abundant polymorphonuclear cells are present. Brain tissue stained with hematoxylin and eosin (B, bar = 10 microns and C, bar = 100 microns) demonstrates perivascular amebic infiltrates and an amebic micro-abscess with surrounding tissue necrosis. Examples of amebae are indicated by the arrows.",
"    <em>",
"     Naegleria fowleri",
"    </em>",
"    &ndash;specific immunofluorescent antibody staining (D, bar = 10 microns) highlights amebic infiltrates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Kemble SK, Lynfield R, DeVries AS, et al. Fatal Naegleria fowleri infection acquired in Minnesota: Possible expanded range of a deadly thermophilic organism. Clin Infect Dis 2012; 54:805. By permission of the Infectious Diseases Society of America . Copyright &copy; 2013 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7222=[""].join("\n");
var outline_f7_3_7222=null;
var title_f7_3_7223="Basic mechanisms and pathophysiology of allergic contact dermatitis";
var content_f7_3_7223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic mechanisms and pathophysiology of allergic contact dermatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Anthony Gaspari, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7223/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/3/7223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2659556\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic contact dermatitis (ACD) is a common inflammatory skin disease presenting with pruritic, eczematous lesions. ACD results from a T cell mediated, delayed type hypersensitivity (DTH) reaction elicited by the contact of the skin with the offending chemical in individuals who have been previously sensitized to the same chemical. ACD is common in the general population and is the most frequent occupational skin disease. Its etiology may be suggested by the body sites of involvement, history of exposure, and morphology and distribution of the skin lesions.",
"   </p>",
"   <p>",
"    This topic will discuss the immune mechanisms and pathophysiology of ACD. The clinical manifestations, diagnosis, and management of ACD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=see_link\">",
"     \"Management of allergic contact dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H629466133\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The understanding of the cellular and molecular pathogenesis of ACD has expanded dramatically. In addition to CD4+ and CD8+ T cells, other cell types, such as natural killer T (NKT) cells and T regulatory cells, have emerged as critical participants (",
"    <a class=\"graphic graphic_table graphicRef71742 \" href=\"UTD.htm?10/29/10716\">",
"     table 1",
"    </a>",
"    ). In the elicitation phase, Langerhans cells appear to play a role in the development of immune tolerance rather than hypersensitivity reaction (as was once thought). B cells also appear to be important during the initiation of ACD by secreting IgM antibody in response to NKT cell-derived interleukin (IL)-4, leading to complement activation and immune cell chemotaxis. As new mechanisms and molecules emerge as a result of advances in the understanding of ACD, new pharmacologic targets will become apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11739289\">",
"    <span class=\"h1\">",
"     HAPTEN-PROTEIN BINDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hapten binding is the initial step in the development of ACD. Contact allergens are low molecular weight (&lt;500 Daltons) chemicals called haptens, which are able to penetrate the stratum corneum barrier of the skin. Haptens are not immunogenic by themselves, but they can be efficiently recognized by the immune system after binding to a skin protein carrier. Haptens may be naturally occurring substances such as urushiol found in the resin of poison ivy, synthetic compounds, dyes, fragrances, drugs, or heavy metal salts.",
"   </p>",
"   <p>",
"    The binding of haptens to skin proteins (protein haptenation) involves the formation of a covalent bond between the electrophilic components of the hapten and the amino acid nucleophilic side chains of the target proteins within the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/1\">",
"     1",
"    </a>",
"    ]. Examples of chemicals containing electrophilic components are aldehydes, ketones, amides, or halogenated compounds. Metal cations (eg, nickel [NIi]",
"    <sup>",
"     2+",
"    </sup>",
"    , one of the most common ACD-associated haptens; and chromium [Cr]",
"    <sup>",
"     3+",
"    </sup>",
"    ) are also well-known electrophiles. Some haptens that are not normally electrophilic (prohaptens) can be converted to protein-reactive species via oxidation or metabolic transformation by epidermal keratinocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional factors influencing the sensitizing ability of haptens include lipophilicity, tridimensional chemical structure, and protein-binding affinity.",
"   </p>",
"   <p>",
"    The most reactive nucleophilic side chains of proteins are found on lysine, cysteine, and histidine. The protein nucleophilicity is influenced by the microenvironment pH and protein location within the epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2312563\">",
"    <span class=\"h1\">",
"     THE SENSITIZATION (AFFERENT) PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitization phase occurs after the first contact of the skin with a hapten and leads to the generation of hapten-specific T cells in the regional lymph nodes. Langerhans cells (LC) and dermal dendritic cells (DC) may be involved in the clinically inapparent sensitization phase. Both LCs and dermal DCs are professional antigen presenting cells and express major histocompatibility complex (MHC) class I and II molecules, which are required for the activation of CD8+ and CD4+ T cells, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LCs are bone marrow-derived, immature epidermal DCs which express langerin (CD207), a C-type lectin associated with the Birbeck granules. Immature LCs form a dense network in the epidermis, where they scan the environment by extending and retracting their dendrites and take up antigens with high efficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/2\">",
"     2",
"    </a>",
"    ]. LCs are able to initiate an adaptive immune response by capturing, processing, and presenting antigens to na&iuml;ve T cells in the paracortical areas of lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the sensitization phase of ACD, the hapten-protein complex is engulfed and processed by LCs, which subsequently migrate to the draining lymph nodes where they present the hapten&ndash;peptide&ndash;MHC complexes to na&iuml;ve, allergen-specific T cells (priming). This process results in clonal expansion of hapten-specific",
"    <span class=\"nowrap\">",
"     memory/effector",
"    </span>",
"    T cells, which circulate throughout the body and are subsequently recruited from the circulation into the skin during the elicitation phase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11739104\">",
"     'The elicitation (efferent) phase'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After cutaneous exposure to the sensitizing hapten, epidermal LC density decreases by approximately 50 percent in the following 24 hours as a result of migration to the regional lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. During migration, LCs undergo a process of maturation and acquire the surface phenotype of a functionally mature dendritic cell. Cytokines released by keratinocytes, in particular interleukin (IL)-1, tumor necrosis factor (TNF)-alpha and IL-18, regulate the migration and functional maturation of dendritic cells. In addition to morphologic changes and decreased ability to capture additional antigen, mature LCs exhibit increased expression of CD83 (a marker for LC maturation), adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1); and co-stimulatory molecules, including CD40, CD80 and CD86 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. The expression of these markers is specific to hapten-exposed LCs, since dermal irritants, which also trigger LC migration, do not result in similar LC surface marker changes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/14\">",
"     14",
"    </a>",
"    ]. The increased expression of these signaling molecules on the cell surface of LCs is important for efficient",
"    <span class=\"nowrap\">",
"     activation/proliferation",
"    </span>",
"    of T cells in the local lymph nodes.",
"   </p>",
"   <p>",
"    Twenty-four hours after sensitization by cutaneous application of a strong hapten, lymph nodes of mice contain LCs and can transfer sensitization if implanted into allergen-na&iuml;ve mice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/10\">",
"     10",
"    </a>",
"    ]. However, studies in LC-depleted mice indicate that contact sensitization is not abrogated in the absence of LCs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/16\">",
"     16",
"    </a>",
"    ]. A population of langerin+ dermal DCs is thought to induce contact sensitization in the absence of epidermal LCs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the end of the afferent phase, hapten-specific T cells that have been primed by hapten bearing DCs are found in the lymph nodes, in the blood, and in the skin. Upon re-exposure to the same hapten, T cells will be activated and massively recruited in the skin (the elicitation phase).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11739104\">",
"    <span class=\"h1\">",
"     THE ELICITATION (EFFERENT) PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of ACD are the result of a T cell-mediated inflammatory reaction occurring in the skin upon re-exposure to the offending hapten (elicitation phase) and mediated by the activation of hapten-specific T cells in the skin.",
"   </p>",
"   <p>",
"    The inflammatory reaction occurs 48 to 72 hours after exposure. As in the sensitization phase, haptens enter the epidermis and react with endogenous proteins. The hapten-protein complexes are then taken up by the antigen presenting cells (APCs) and presented to the antigen-primed T cells recruited in the epidermis and dermis.",
"   </p>",
"   <p>",
"    Although LCs are capable of functioning as APCs, they are not required during the elicitation phase of ACD. Mice depleted in epidermal LCs by treatment with topical corticosteroids or exposure to UVB radiation show a paradoxically higher cutaneous hypersensitivity response compared with control animals, indicating that LCs are dispensable in the elicitation phase and may be involved in the regulation of ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2961194\">",
"     'Regulatory mechanisms of ACD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other cell types that may function as APCs include mast cells, infiltrating macrophage, and keratinocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/20\">",
"     20",
"    </a>",
"    ]. Keratinocytes, which constitutively express MHC class I, have been shown to express also MHC class II and exhibit APC-like properties in response to hapten exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary effector cells of ACD appear to be CD8+ Tc1 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Experimental studies in mice indicated that MHC class I-restricted CD8+ T cells infiltrate the skin as early as six hours after the hapten challenge and induce keratinocyte apoptosis via the",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    or the",
"    <span class=\"nowrap\">",
"     Fas/FasL",
"    </span>",
"    pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Activated T cells release type 1 cytokines, including IFN-gamma and TNF-alpha. Both cytokines are potent activators of keratinocytes and promote the up-regulation of intercellular adhesion molecules (ICAM-1) and MHC class II molecules and the release of chemokines, resulting in a massive recruitment of mononuclear and polymorphonuclear cells and amplification of the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MHC class I knockout mice, which are deficient in CD8+ T cells, or mice acutely depleted in vivo of CD8+ T cells are unable to develop a hypersensitivity reaction to the cutaneous application of the strong hapten dinitrofluorobenzene (DNFB) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/22\">",
"     22",
"    </a>",
"    ]. Conversely, MHC class II-deficient mice, which are deficient in CD4+ T cells, develop a strong reaction to DNFB, supporting the hypothesis that CD8+ T cells are primed in the absence of CD4+ T cells and mediate the cutaneous hypersensitivity response.",
"   </p>",
"   <p>",
"    The role of hapten-specific CD4+ T cells is not completely understood. CD4+ T cells appear in the site of challenge at a later time than CD8+ T cells and may have distinct roles in the inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/29\">",
"     29",
"    </a>",
"    ]. CD4+ Th1 cells, producing high amounts of IFN-gamma and TNF-alpha, display cytotoxic activity against keratinocytes expressing MHC class II molecules and may cooperate with CD8+ T cells in amplifying the inflammatory response. By contrast, other subsets of CD4+ T cells may have a regulatory function.",
"   </p>",
"   <p>",
"    The afferent and efferent phases of ACD are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef50197 \" href=\"UTD.htm?8/46/8936\">",
"     figure 1",
"    </a>",
"    ). The cell types involved in ACD and their functions are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef71742 \" href=\"UTD.htm?10/29/10716\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10309597\">",
"    <span class=\"h1\">",
"     THE INNATE IMMUNITY IN ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate immune cells (dendritic cells [DC], mast cells, natural killer [NK], NKT-cells) play a critical role in ACD (",
"    <a class=\"graphic graphic_table graphicRef71742 \" href=\"UTD.htm?10/29/10716\">",
"     table 1",
"    </a>",
"    ). In addition, antigen presenting cells (macrophages, DC, monocytes, and B lymphocytes) express membrane-bound innate immune receptors called pattern recognition receptors (PPR), which include the toll-like receptor (TLR) family. TLRs are transmembrane receptors that recognize pathogen-associated molecular patterns such as cell wall components (eg, bacterial endotoxin), proteins, and nucleic acids of bacteria, parasites, viruses, and fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/30\">",
"     30",
"    </a>",
"    ]. TLRs also recognize damage-associated molecular patterns, which are released during cell necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/31\">",
"     31",
"    </a>",
"    ]. TLR signaling results in changes in the transcription factors that regulate a multitude of genes, including those encoding important proinflammatory cytokines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In mouse models of contact hypersensitivity, TLR2 and TLR4 recognize low molecular weight breakdown products of hyaluronic acid that are produced by reactive oxygen species in response to exposure to haptens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. In humans, the TLR4 (hTLR4) has been identified as the receptor for nickel, which is the most common cause of ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/37\">",
"     37",
"    </a>",
"    ]. Binding of nickel to hTLR4 requires the presence of two nonconserved histidines (H) in H456 and H458 in the extracellular domain of hTLR4. The binding of nickel to hTLR4 triggers a signal transduction cascade via the nuclear factor for the kappa light chain enhancer in B cells, resulting in the production of proinflammatory cytokines and the activation of DC early in the afferent phase of ACD. Because mice lack H456 and H458, they do not develop contact hypersensitivity to nickel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2961194\">",
"    <span class=\"h1\">",
"     REGULATORY MECHANISMS OF ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulatory T cells (Treg) may have a role in the sensitization and elicitation phase of ACD and in the downregulation of the inflammatory response that was initially attributed to the clearance of the hapten from the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Tregs are a heterogeneous cell population that includes natural Tregs (CD4+CD25+Foxp3+ cells) and inducible Tregs (Tr1- and Th3-cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/4,40\">",
"     4,40",
"    </a>",
"    ]. The skin contains predominantly inducible Tregs, which can be triggered by Langerhans cells or dermal dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Following exposure to a contact allergen, Tregs can lower or suppress the process of sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. During the elicitation phase, they can suppress effector T cells in the lymph nodes and inhibit the influx of leukocytes through IL-10 or CD39 mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Tregs may also be involved in the control and eventual termination of the inflammatory response in ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20479985\">",
"    <span class=\"h1\">",
"     MECHANISMS OF TISSUE DAMAGE IN ACD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early phase of ACD, tissue damage is mostly due to CD8+ T cell-induced apoptosis of keratinocytes bearing the hapten-protein complex on MHC class I molecules, via the",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    or the",
"    <span class=\"nowrap\">",
"     Fas/FasL",
"    </span>",
"    pathway. The induction of keratinocyte apoptosis is accompanied by a rapid cleavage of CH1 intercellular adhesion molecules (E-cadherins). The loss of intercellular adhesion and the infiltration of lymphocytes in the epidermis are responsible for the intercellular edema and vesiculation as well as the typical spongiotic appearance of the epidermis in ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7223/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 1 cytokines, released by infiltrating CD8+ and CD4+ T cells, in particular IFN-gamma, stimulate keratinocytes to release cytokines and chemokines, resulting in the massive recruitment of activated T cells, neutrophils, macrophages, and eosinophils which form the cellular inflammatory infiltrate in the dermis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H629466159\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic contact dermatitis (ACD) is a delayed type hypersensitivity reaction elicited by the contact of the skin with the offending chemical in individuals who have been previously sensitized to the same chemical. The understanding of the cellular and molecular pathogenesis of ACD has expanded dramatically. In addition to CD4+ and CD8+ T cells, other cell types, such as natural killer T (NKT) cells and T regulatory cells, have emerged as critical participants (",
"      <a class=\"graphic graphic_table graphicRef71742 \" href=\"UTD.htm?10/29/10716\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H629466133\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hapten binding is the initial step in the development of ACD. Haptens are low molecular weight (&lt;500 Daltons) chemicals that are able to penetrate the stratum corneum of the skin. Haptens are not immunogenic by themselves but can be efficiently recognized by the immune system after binding to a skin protein carrier. (See",
"      <a class=\"local\" href=\"#H11739289\">",
"       'Hapten-protein binding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the clinically inapparent sensitization phase, Langerhans cells and dermal dendritic cells initiate an adaptive immune response by capturing, processing, and presenting antigens to na&iuml;ve T cells in the paracortical areas of lymph nodes. In the elicitation phase, the clinical manifestations of ACD are the result of a T cell-mediated inflammatory reaction occurring in the skin upon re-exposure to the offending hapten and mediated by the activation of hapten-specific T cells in the skin. The primary effector cells of ACD appear to be CD8+ cells (",
"      <a class=\"graphic graphic_figure graphicRef50197 \" href=\"UTD.htm?8/46/8936\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2312563\">",
"       'The sensitization (afferent) phase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11739104\">",
"       'The elicitation (efferent) phase'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/1\">",
"      Divkovic M, Pease CK, Gerberick GF, Basketter DA. Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization. Contact Dermatitis 2005; 53:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/2\">",
"      Kaplan DH, Kissenpfennig A, Clausen BE. Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 2008; 38:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/3\">",
"      Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/4\">",
"      Vocanson M, Hennino A, Rozi&egrave;res A, et al. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 2009; 64:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/5\">",
"      Bergstresser PR, Toews GB, Streilein JW. Natural and perturbed distributions of Langerhans cells: responses to ultraviolet light, heterotopic skin grafting, and dinitrofluorobenzene sensitization. J Invest Dermatol 1980; 75:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/6\">",
"      Weinlich G, Heine M, St&ouml;ssel H, et al. Entry into afferent lymphatics and maturation in situ of migrating murine cutaneous dendritic cells. J Invest Dermatol 1998; 110:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/7\">",
"      Steinbrink K, Kolde G, Sorg C, Macher E. Induction of low zone tolerance to contact allergens in mice does not require functional Langerhans cells. J Invest Dermatol 1996; 107:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/8\">",
"      Larsen CP, Steinman RM, Witmer-Pack M, et al. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/9\">",
"      Lukas M, St&ouml;ssel H, Hefel L, et al. Human cutaneous dendritic cells migrate through dermal lymphatic vessels in a skin organ culture model. J Invest Dermatol 1996; 106:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/10\">",
"      Moodycliffe AM, Shreedhar V, Ullrich SE, et al. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med 2000; 191:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/11\">",
"      Nuriya S, Yagita H, Okumura K, Azuma M. The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Int Immunol 1996; 8:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/12\">",
"      Zhou LJ, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 1995; 86:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/13\">",
"      Leh&eacute; CL, Jacobs JJ, Hua CM, et al. Subtoxic concentrations of allergenic haptens induce LC migration and maturation in a human organotypic skin explant culture model: a novel method for identifying potential contact allergens. Exp Dermatol 2006; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/14\">",
"      Aiba S, Terunuma A, Manome H, Tagami H. Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur J Immunol 1997; 27:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/15\">",
"      Toebak MJ, Gibbs S, Bruynzeel DP, et al. Dendritic cells: biology of the skin. Contact Dermatitis 2009; 60:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/16\">",
"      Bennett CL, van Rijn E, Jung S, et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005; 169:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/17\">",
"      Poulin LF, Henri S, de Bovis B, et al. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 2007; 204:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/18\">",
"      Bursch LS, Wang L, Igyarto B, et al. Identification of a novel population of Langerin+ dendritic cells. J Exp Med 2007; 204:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/19\">",
"      Grabbe S, Steinbrink K, Steinert M, et al. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J Immunol 1995; 155:4207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/20\">",
"      Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/21\">",
"      Nakano Y. Antigen-presenting cell function of epidermal cells activated by hapten application. Br J Dermatol 1998; 138:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/22\">",
"      Bour H, Peyron E, Gaucherand M, et al. Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 1995; 25:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/23\">",
"      Martin S, Lappin MB, Kohler J, et al. Peptide immunization indicates that CD8+ T cells are the dominant effector cells in trinitrophenyl-specific contact hypersensitivity. J Invest Dermatol 2000; 115:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/24\">",
"      Vocanson M, Hennino A, Cluzel-Tailhardat M, et al. CD8+ T cells are effector cells of contact dermatitis to common skin allergens in mice. J Invest Dermatol 2006; 126:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/25\">",
"      Gocinski BL, Tigelaar RE. Roles of CD4+ and CD8+ T cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion. J Immunol 1990; 144:4121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/26\">",
"      Vocanson M, Hennino A, Chavagnac C, et al. Contribution of CD4(+ )and CD8(+) T-cells in contact hypersensitivity and allergic contact dermatitis. Expert Rev Clin Immunol 2005; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/27\">",
"      Akiba H, Kehren J, Ducluzeau MT, et al. Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol 2002; 168:3079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/28\">",
"      Kehren J, Desvignes C, Krasteva M, et al. Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity. J Exp Med 1999; 189:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/29\">",
"      Traidl C, Sebastiani S, Albanesi C, et al. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes. J Immunol 2000; 165:3058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/30\">",
"      Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/31\">",
"      Sloane JA, Blitz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. Neuromolecular Med 2010; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/32\">",
"      Martin SF, Dudda JC, Bachtanian E, et al. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med 2008; 205:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/33\">",
"      Martin SF, Esser PR, Weber FC, et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011; 66:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/34\">",
"      Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 2006; 177:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/35\">",
"      Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/36\">",
"      Stern R, Kogan G, Jedrzejas MJ, Solt&eacute;s L. The many ways to cleave hyaluronan. Biotechnol Adv 2007; 25:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/37\">",
"      Schmidt M, Raghavan B, M&uuml;ller V, et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010; 11:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/38\">",
"      Cavani A, Nasorri F, Ottaviani C, et al. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003; 171:5760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/39\">",
"      Reduta T, Stasiak-Barmuta A, Lauda��ska H. CD4+CD25+ and CD4+CD2+high regulatory T cells in disseminated and localized forms of allergic contact dermatitis: relation to specific cytokines. Folia Histochem Cytobiol 2011; 49:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/40\">",
"      Honda T, Miyachi Y, Kabashima K. Regulatory T cells in cutaneous immune responses. J Dermatol Sci 2011; 63:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/41\">",
"      Yoshiki R, Kabashima K, Sugita K, et al. IL-10-producing Langerhans cells and regulatory T cells are responsible for depressed contact hypersensitivity in grafted skin. J Invest Dermatol 2009; 129:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/42\">",
"      Ring S, Karakhanova S, Johnson T, et al. Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol 2010; 125:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/43\">",
"      Dubois B, Chapat L, Goubier A, et al. Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. Blood 2003; 102:3295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/44\">",
"      Ring S, Enk AH, Mahnke K. ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions. J Immunol 2010; 184:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/45\">",
"      Honda T, Otsuka A, Tanizaki H, et al. Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase. J Dermatol Sci 2011; 61:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/46\">",
"      Ring S, Sch&auml;fer SC, Mahnke K, et al. CD4+ CD25+ regulatory T cells suppress contact hypersensitivity reactions by blocking influx of effector T cells into inflamed tissue. Eur J Immunol 2006; 36:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/47\">",
"      Ring S, Oliver SJ, Cronstein BN, et al. CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J Allergy Clin Immunol 2009; 123:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/48\">",
"      Tomura M, Honda T, Tanizaki H, et al. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 2010; 120:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7223/abstract/49\">",
"      Trautmann A, Altznauer F, Akdis M, et al. The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J Invest Dermatol 2001; 117:927.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13653 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7223=[""].join("\n");
var outline_f7_3_7223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H629466159\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2659556\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H629466133\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11739289\">",
"      HAPTEN-PROTEIN BINDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2312563\">",
"      THE SENSITIZATION (AFFERENT) PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11739104\">",
"      THE ELICITATION (EFFERENT) PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10309597\">",
"      THE INNATE IMMUNITY IN ACD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2961194\">",
"      REGULATORY MECHANISMS OF ACD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20479985\">",
"      MECHANISMS OF TISSUE DAMAGE IN ACD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H629466159\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13653|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/46/8936\" title=\"figure 1\">",
"      Allergic contact dermatitis mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/29/10716\" title=\"table 1\">",
"      Cell types involved in ACD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=related_link\">",
"      Management of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7224="Clinical manifestations and diagnosis of anthrax";
var content_f7_3_7224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of anthrax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Kenneth H Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7224/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/3/7224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthrax, caused by Bacillus anthracis, is an uncommon illness in the United States. From 1980 through 2000, only seven cases of anthrax were reported to the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2001, 22 confirmed or suspected cases of bioterrorism-related anthrax occurred in the United States, when B. anthracis spores in powder-containing envelopes were sent through the mail [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Subsequent sporadic cases have occurred rarely in the US, such as in individuals exposed to contaminated animal hides while making traditional drums. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of anthrax will be reviewed here. The pathogenesis, epidemiology, treatment, and prevention of anthrax are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"     \"Treatment of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=see_link\">",
"     \"Prevention of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major anthrax syndromes: cutaneous, inhalation, and alimentary tract anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous anthrax is the most common form of the disease. Naturally occurring cases of cutaneous anthrax develop after spores of B. anthracis are introduced subcutaneously, often as a result of contact with infected animals or animal products. Cuts or abrasions increase susceptibility to cutaneous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Spores vegetate and multiply, and the antiphagocytic capsule facilitates local spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incubation period is usually five to seven days with a range of 1 to 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, during an anthrax outbreak in Sverdlovsk, Union of Soviet Socialist Republics, cutaneous cases developed up to 13 days following the aerosol release of spores [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/13\">",
"     13",
"    </a>",
"    ]; an outbreak in Algeria was reported with a median incubation period of 19 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 90 percent of cutaneous anthrax lesions occur in exposed areas such as the face, neck, arms, and hands. The disease begins as a small, painless, but often pruritic papule and quickly enlarges and develops a central vesicle or bulla, followed by erosion leaving a painless necrotic ulcer with a black, depressed eschar (",
"    <a class=\"graphic graphic_picture graphicRef73444 \" href=\"UTD.htm?14/47/15092\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/8\">",
"     8",
"    </a>",
"    ]. Extensive edema of the surrounding tissues, due to toxin release, is often present along with regional lymphadenopathy and lymphangitis (",
"    <a class=\"graphic graphic_picture graphicRef74874 \" href=\"UTD.htm?20/23/20853\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Systemic symptoms, including fever, malaise, and headache can accompany the cutaneous lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/11\">",
"     11",
"    </a>",
"    ]. In one case during the bioterrorism (BT) event of 2001, a microangiopathic hemolytic anemia, thrombocytopenia, coagulopathy, and renal dysfunction developed in a seven-month old child; these manifestations resolved following treatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, the case-fatality rate of cutaneous anthrax is &lt;1 percent with antibiotic therapy; however, without appropriate therapy, mortality can be as high as 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An outbreak of anthrax occurred in heroin users in Scotland in 2009 and 2010, which caused a skin and soft tissue infection in most patients. (See",
"    <a class=\"local\" href=\"#H365640039\">",
"     'Outbreak in heroin users'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation anthrax results from the inhalation of B. anthracis spore-containing particles. This may occur when anthrax spores are aerosolized while working with contaminated animal products such as wool, hair, or hides. It has also resulted from inhalation of a weaponized and intentionally released spore preparations.",
"   </p>",
"   <p>",
"    Inhaled airborne particles &gt;5 microns in size are either physically trapped in the nasopharynx or cleared by the mucociliary escalator system. In comparison, inhaled particles &lt;5 microns in size can be deposited on alveolar ducts or alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/11,17\">",
"     11,17",
"    </a>",
"    ]. B. anthracis spores are phagocytosed by alveolar macrophages and transported to mediastinal lymph nodes. There they germinate, multiply, and release toxins, causing hemorrhagic necrosis of the thoracic lymph nodes draining the lungs, which results in a hemorrhagic mediastinitis, and, in occasional cases, a necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/18\">",
"     18",
"    </a>",
"    ]. The organisms then become blood-borne, causing bacteremia and, in some cases, meningitis.",
"   </p>",
"   <p>",
"    The incubation period for inhalation anthrax is estimated to be one to seven days, but was reported to be as long as 43 days for fatal cases in the 1979 outbreak in Sverdlovsk [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/13\">",
"     13",
"    </a>",
"    ]. Information from a single case report suggests that the incubation period can be as short as one day [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/19\">",
"     19",
"    </a>",
"    ]. This case report describes an office worker at a textile mill who developed inhalation anthrax one day in 1961 following exposure in a grossly contaminated, dusty carding room in the mill; she previously rarely entered the mill.",
"   </p>",
"   <p>",
"    During the bioterrorism (BT) event in the United States in 2001, the time between known exposure and symptom onset ranged from four to six days, with a mean of 4.5 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In primate studies, spores have been found in the lungs up to 100 days following exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/22\">",
"     22",
"    </a>",
"    ], and inhalation anthrax has developed up to 58 days following experimental aerosol exposure in primates receiving 30 days of postexposure antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of the disease is usually biphasic. Prodromal symptoms of inhalation anthrax are nonspecific and variable, complicating assessment and diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/5,24,25\">",
"     5,24,25",
"    </a>",
"    ]. Early symptoms, such as myalgia, fever, and malaise, may mimic those of influenza. However, a variety of symptoms less suggestive of influenza may also be present such as nausea, hemoptysis, dyspnea, odynophagia or chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/26\">",
"     26",
"    </a>",
"    ]. Prodromal symptoms last an average of 4 to 5 days and are followed by a rapidly fulminant bacteremic phase with the development of progressive respiratory symptoms, including severe dyspnea, hypoxemia, and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/9,19\">",
"     9,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fulminant phase is a catastrophic illness that almost uniformly leads to death within days. It does not appear that modern intensive care has changed the outcome once the fulminant phase is reached. However, antibiotic therapy can be successful if initiated during the prodromal phase of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/13,19,21,26\">",
"     13,19,21,26",
"    </a>",
"    ]. For instance, 6 of 11 cases (55 percent) associated with the 2001 BT event in the United States responded to treatment, but none of the five patients who required mechanical ventilation or tracheostomy survived [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"     \"Treatment of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The challenge for the clinician is to appropriately treat patients during the prodromal stage, even though anthrax is a rare disease with a nonspecific and variable presentation. Imaging studies can aid in establishing the diagnosis. Widening of the mediastinum, secondary to mediastinitis, is considered a classic finding in inhalation anthrax (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51574 \" href=\"UTD.htm?3/21/3410\">",
"     image 1",
"    </a>",
"    ) and 7 of the first 10 cases associated with the 2001 BT event had this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other chest radiographic findings seen with inhalation anthrax include hilar abnormalities, pulmonary infiltrates or consolidation, and pleural effusion. One or more of these abnormalities were documented in all 11 cases associated with the 2001 BT event. The abnormalities, however, were often subtle, and chest radiographs obtained early in the course of illness were interpreted as normal in 3 of 11 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/21,28,29\">",
"     21,28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Distinction from common respiratory infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As with any form of anthrax, hematogenous spread can result in lesions in other organ systems, including hemorrhagic meningitis and submucosal gastrointestinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. Inhalation anthrax is usually fatal; among 71 cases in the world's literature from 1900 to 2005, excluding the six survivors during the 2001 BT event, the mortality rate was 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"     \"Treatment of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alimentary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alimentary tract anthrax presents as one of two clinical forms, oropharyngeal or gastrointestinal anthrax. B. anthracis has been reported to infect all regions of the alimentary tract from the mouth to the ascending colon. The disease develops following the consumption of undercooked infected meat from animals infected with anthrax, and tends to occur in family clusters or point source outbreaks.",
"   </p>",
"   <p>",
"    Gastrointestinal involvement is likely to be more common than oropharyngeal disease, but its incidence is probably underestimated because it occurs mostly in medically underserved areas. The incubation period is estimated to be one to six days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/30\">",
"     30",
"    </a>",
"    ]. Following ingestion, the spores infect the alimentary tract epithelium. Necrotic ulcers, often similar to eschars on the skin, are surrounded by extensive edema of the infected intestinal segment and its adjacent mesentery; mesenteric lymph nodes may be enlarged and hemorrhagic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]. Ulcerations can occur in the stomach, esophagus, and duodenum and may result in gastrointestinal hemorrhage. The case-fatality rate of gastrointestinal anthrax is estimated to range from 4 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/11,32\">",
"     11,32",
"    </a>",
"    ]. The lower estimate is derived from point source outbreaks studied by public health officials in Uganda and Thailand, where large numbers of people ate uncooked meat from animals that died of anthrax. Most of the people who ate the uncooked meat became sick with gastroenteritis, which cleared with oral antibiotics.",
"   </p>",
"   <p>",
"    One series described more than 100 patients in Lebanon with gastrointestinal anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/31\">",
"     31",
"    </a>",
"    ]. The illness generally started with asthenia, headache, low grade fevers, facial flushing, and conjunctival injection. This was followed by abdominal pain of variable intensity, nausea, vomiting, and to a lesser extent, diarrhea. Typically, patients at this point had ascites and intravascular depletion. Later, the abdominal pain tended to become more severe and patients had progression of ascites and hypotension. At surgery, segmental disease was usually found in the distal small bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proximal colon. Although they do not cite the survival rate, most patients (even those who required surgery) survived.",
"   </p>",
"   <p>",
"    The oropharyngeal form of anthrax is less frequent and also develops following consumption of undercooked, contaminated meat. Edematous lesions develop, which progress over one to two weeks to necrotic ulcers covered with a pseudomembrane. Edema and painful swelling may develop in the oropharynx and neck, accompanied by cervical lymphadenopathy, pharyngitis, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. The mortality from this disease can be substantial even with parenteral antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis has been reported in association with cutaneous, inhalation, and gastrointestinal anthrax cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/34\">",
"     34",
"    </a>",
"    ]. About one-half of patients with inhalation anthrax will develop hemorrhagic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/18\">",
"     18",
"    </a>",
"    ]. Cerebrospinal fluid analysis reveals an elevated protein (70 percent), low glucose (37 percent), and a positive Gram stain (77 percent) and culture (81 percent) (",
"    <a class=\"graphic graphic_picture graphicRef56832 \" href=\"UTD.htm?5/21/5458\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/34\">",
"     34",
"    </a>",
"    ]. Parenchymal brain hemorrhage may be so severe that a grossly bloody lumbar puncture may be confused with a traumatic tap. Delirium or coma follows quickly and refractory seizures, cranial nerve palsies, and myoclonus have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/6,34\">",
"     6,34",
"    </a>",
"    ]. A review of 44 well-documented cases found that 75 percent of patients died within 24 hours of presentation with an overall survival of only 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365640039\">",
"    <span class=\"h2\">",
"     Outbreak in heroin users",
"    </span>",
"    &nbsp;&mdash;&nbsp;An outbreak of anthrax occurred in Scotland between December 2009 and December 2010 among 119 heroin users, especially among those who had injected heroin; there were 47 confirmed cases, 35 probable cases, and 37 possible cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/35\">",
"     35",
"    </a>",
"    ]. Among the 47 confirmed cases, 93 percent presented with a skin and soft tissue infection (SSTI). The typical eschar of cutaneous anthrax was absent in all but one patient, and most patients had disproportionate edema compared with typical cases of cutaneous anthrax and bacterial SSTIs. Twenty-five patients underwent surgical debridement. Twenty-two patients (55 percent) had gastrointestinal involvement, 14 (33 percent) had central nervous system involvement, and two (5 percent) had respiratory tract involvement. Some patients developed features of systemic anthrax infection, such as hemorrhagic meningitis, multi-organ failure, and bleeding diathesis.",
"   </p>",
"   <p>",
"    The epidemiology of the outbreak is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link&amp;anchor=H365639688#H365639688\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Association with heroin use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the rarity of anthrax in the United States, most clinical microbiology laboratories do not offer a full array of diagnostic tests for optimal and rapid diagnosis of anthrax. Because of the public health implications of any form of anthrax and the rapid course of inhalation anthrax, clinicians and their supporting laboratories should coordinate the diagnostic evaluation as rapidly as possible with the state health department and, with their assistance, the appropriate Laboratory Response Network (LRN) reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Laboratory Response Network'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several diagnostic tests are available. Standard culture and susceptibility testing can be done as for other pathogens, although most clinical laboratories can offer only presumptive identification of B. anthracis with confirmation at a reference laboratory. The organism can be identified by direct observation through immunohistochemical (IHC) staining [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Standard or real-time polymerase chain reaction can be performed on a variety of isolates, including blood cultures, tissue samples, and blood samples [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/39\">",
"     39",
"    </a>",
"    ]. Susceptibility to lysis by gamma phage differentiates the organism from Bacillus thuringiensis. In late acute infection or in convalescence, antibodies to protective antigen can be detected both qualitatively and quantitatively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Criteria for diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2001, the CDC developed interim case definitions for anthrax.",
"   </p>",
"   <p>",
"    A confirmed case of anthrax was defined as a clinically compatible case that was laboratory confirmed by the isolation of B. anthracis from the patient, or by laboratory evidence based on at least two other supportive tests using nonculture methods for detection of B. anthracis. Supportive laboratory tests include the Laboratory Response Network (LRN) polymerase chain reaction assay, immunohistochemical staining (IHC) of tissues, and an anti-protective antigen (PA) IgG detected by an enzyme-linked immunosorbent assay (ELISA) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A suspect case was a clinically compatible illness without isolation of B. anthracis and with only a single supportive test, or a clinically compatible case epidemiologically linked to a confirmed exposure to B. anthracis but without corroborative laboratory evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory Response Network",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Laboratory Response Network (LRN) was established in 1999 by the CDC, the Association of Public Health Laboratories (APHL), the Federal Bureau of Investigation (FBI) and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for the rapid identification of select agents including B. anthracis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/36\">",
"     36",
"    </a>",
"    ]. The LRN is part of a linked hierarchy of sentinel, reference, and national level laboratories. There are LRN reference laboratories (generally state public health laboratories) in all 50 states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specimen collection and transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Details of specimen handling and transport should be established through consultation with the local microbiology laboratory, the state health department and the LRN reference laboratory. In general the guidelines below should apply:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specimens of stool, sputum, pleural fluid, CSF, and blood stored at 2 to 8&ordm; C",
"     </li>",
"     <li>",
"      Swabs at room temperature",
"     </li>",
"     <li>",
"      Fresh tissue samples frozen",
"     </li>",
"     <li>",
"      Formalin fixed specimens at room temperature.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood specimens for PCR testing should optimally be collected in tubes containing EDTA or citrate as anticoagulant and not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Isolates of Bacillus can be transported on most nonselective laboratory media at room temperature. Specific information on specimen types, volumes, and transport conditions is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef65814 \" href=\"UTD.htm?9/49/10013\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH BY CLINICAL SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inhalation anthrax",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Distinction from common respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish potential inhalation anthrax cases from more common disorders such as community-acquired pneumonia (CAP), influenza, and influenza-like illnesses (ILI). As mentioned above, this may be difficult. If the patient has influenza, a positive test for this disease can allay concerns about anthrax. The epidemiologic setting is important, especially with regards to occupational history and hobbies (eg, drum maker) or if there is an association with other cases as in the occurrence of a suspected bioterrorism (BT) event.",
"   </p>",
"   <p>",
"    The BT event of 2001 illustrated the importance of screening for inhalation anthrax because the window of opportunity for successful treatment is narrow once symptoms appear. Clinical signs more frequently associated with inhalation anthrax compared to CAP or ILI included shortness of breath, nausea, vomiting, altered mental status, pallor or cyanosis, and hematocrit &gt;45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/27,43\">",
"     27,43",
"    </a>",
"    ]. In contrast, symptoms more suggestive of an ILI included rhinorrhea and sore throat [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/43\">",
"     43",
"    </a>",
"    ]. Unexplained mediastinal widening on chest radiography in a compatible clinical setting should raise the possibility of inhalation anthrax. Other radiographic findings are probably not specific enough to be helpful in an unsuspected sporadic case, but such findings can be helpful in an outbreak situation or if there was a known risk of exposure. In the 2001 outbreak, pleural effusion was more common in patients with inhalation anthrax than in those with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/44\">",
"     44",
"    </a>",
"    ]. Although chest radiographs are almost always abnormal in patients with inhalation anthrax, these findings are sometimes subtle and they may be initially overlooked. Thus, the diagnosis of inhalation anthrax cannot be ruled out even if a chest radiograph is interpreted as normal early in the course of illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Approach to testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing should be performed on specimens from patients being evaluated for inhalation anthrax, including patients with a known exposure or high risk of exposure, patients with a clear epidemiologic link presenting with symptoms of inhalation anthrax, and patients with a clinical presentation suggestive of anthrax in the absence of an alternate diagnosis. The US Centers of Disease Control and Prevention developed recommendations for the clinical evaluation of persons with possible inhalation anthrax during the 2001 bioterrorism event, which are available online at",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5044a5.htm\">",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5044a5.htm",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5043a1.htm\">",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5043a1.htm",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following diagnostic testing of patients with suspected inhalation anthrax is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specimens of blood obtained prior to antimicrobial therapy should be sent for routine culture and for polymerase chain reaction (PCR) testing at a Laboratory Response Network (LRN) laboratory",
"     </li>",
"     <li>",
"      Pleural fluid, if present, for Gram stain, culture, and PCR",
"     </li>",
"     <li>",
"      Cerebrospinal fluid, in patients with meningeal signs, for Gram stain, culture, and PCR",
"     </li>",
"     <li>",
"      Acute and convalescent serum samples for serologic testing",
"     </li>",
"     <li>",
"      Pleural",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bronchial biopsies for immunohistochemistry, if other tests are negative",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cutaneous anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC has developed recommendations for the clinical evaluation of persons with possible cutaneous anthrax, which are available online at",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5044a5.htm\">",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5044a5.htm",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5043a1.htm\">",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5043a1.htm",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/28\">",
"     28",
"    </a>",
"    ]. In an appropriate epidemiologic setting, the presence of an eschar especially with extensive edema out of proportion to the size of the lesion and the presence of gram-positive rods and few polymorphonuclear leukocytes on Gram stain are strongly suggestive of cutaneous anthrax (",
"    <a class=\"graphic graphic_picture graphicRef58039 \" href=\"UTD.htm?20/30/20966\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following diagnostic testing of patients with suspected cutaneous anthrax is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For vesicular lesions, two swabs of vesicular fluid from an unopened vesicle, one for Gram stain and culture, the second for polymerase chain reaction (PCR) testing",
"     </li>",
"     <li>",
"      For eschars, the edge should be lifted and two swabs rotated underneath and submitted, one for Gram stain and culture, the second for PCR testing",
"     </li>",
"     <li>",
"      For ulcers, the base of the lesion should be sampled with two saline moistened swabs and submitted, one for Gram stain and culture, the second for PCR testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a full thickness punch biopsy of a papule or vesicle including adjacent skin from all patients should be submitted in 10 percent formalin for histopathology and immunohistochemistry. In patients not receiving antibiotic therapy or on therapy for &lt;24 hours, a second biopsy specimen should be submitted for Gram stain, culture, and PCR testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/12,37,38\">",
"     12,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alimentary tract anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the reliability of diagnostic testing in alimentary tract anthrax is limited. Culture from stool frequently does not yield B. anthracis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/30\">",
"     30",
"    </a>",
"    ], but Gram stain or culture of oropharyngeal lesions or ascitic fluid may be positive (",
"    <a class=\"graphic graphic_picture graphicRef58039 \" href=\"UTD.htm?20/30/20966\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/31\">",
"     31",
"    </a>",
"    ]. Blood cultures may also be positive when collected prior to initiating antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/31\">",
"     31",
"    </a>",
"    ]. Serologic testing for antibodies against protective antigen were positive in seven of 10 oropharyngeal anthrax cases tested [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7224/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following diagnostic testing of patients with suspected alimentary tract anthrax is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood cultures and blood for polymerase chain reaction (PCR) testing obtained prior to antimicrobial therapy",
"     </li>",
"     <li>",
"      Ascites fluid for Gram stain, culture, and PCR testing",
"     </li>",
"     <li>",
"      Stool or rectal swab for Gram stain, culture, and PCR testing",
"     </li>",
"     <li>",
"      Oropharyngeal lesion, if present, for Gram stain, culture, and PCR testing",
"     </li>",
"     <li>",
"      Acute and convalescent serum samples for serologic testing",
"     </li>",
"     <li>",
"      If the patient undergoes surgery, affected tissue can be obtained for Gram stain, culture and PCR testing; immunohistochemistry can be performed on formalinized tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three major anthrax syndromes: cutaneous, inhalation, and alimentary tract anthrax. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous anthrax is the most common form of the disease (",
"      <a class=\"graphic graphic_picture graphicRef73444 \" href=\"UTD.htm?14/47/15092\">",
"       picture 1",
"      </a>",
"      ). Naturally occurring cases of cutaneous anthrax develop after spores of B. anthracis are introduced subcutaneously, often as a result of contact with infected animals or animal products. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cutaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous anthrax begins as a small, painless, but often pruritic papule that quickly enlarges and develops a central vesicle or bulla, followed by erosion, leaving a necrotic ulcer with a black, depressed eschar. Extensive edema of the surrounding tissues is often present along with regional lymphadenopathy and lymphangitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cutaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhalation anthrax results from the inhalation of B. anthracis spores into the alveoli aerosolized through either industrial processing; working with animal products such as wool, hair, or hides that are contaminated with anthrax spores; or intentional release, such as the bioterrorism event of 2001 in the United States. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Inhalation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early clinical symptoms of inhalation anthrax are nonspecific, complicating assessment and diagnosis. Initial symptoms, such as myalgia, fever, and malaise frequently mimic those of influenza. However, anthrax-infected patients become dramatically sicker a few days later with the development of progressive respiratory symptoms, including severe dyspnea and hypoxemia. About one-half of patients with inhalation anthrax will develop hemorrhagic meningitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Inhalation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alimentary tract anthrax presents in two clinical forms, oropharyngeal and gastrointestinal. The disease develops following the consumption of undercooked infected meat from animals with anthrax. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Alimentary tract'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the public health implications of anthrax in the United States and the rapid course of disease progression, clinical or laboratory suspicion of anthrax should be followed by rapid testing of clinical samples and early initiation of antibiotic therapy. Immediate notification of the local or state health department and laboratory is essential. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During a potential bioterrorism episode, an important issue is distinguishing inhalation anthrax from more common disorders such as community-acquired pneumonia, influenza, and influenza-like illness. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Distinction from common respiratory infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most accurate predictors of inhalation anthrax are mediastinal widening (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51574 \" href=\"UTD.htm?3/21/3410\">",
"       image 1",
"      </a>",
"      ) or pleural effusion on chest x-ray. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Distinction from common respiratory infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria and case definitions established for diagnosis include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Confirmed case &mdash; A clinically compatible case that is laboratory confirmed by the isolation of B. anthracis from the patient, or by laboratory evidence based on at least two other supportive tests using nonculture methods for detection of B. anthracis (Laboratory Response Network polymerase chain reaction assay, immunohistochemistry of tissues, and an anti-protective antigen IgG ELISA). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Criteria for diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspect case &mdash; A clinically compatible illness without isolation of B. anthracis and with only a single supportive test, or a clinically compatible case epidemiologically linked to a confirmed exposure to B. anthracis but without laboratory confirmation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Criteria for diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach is dependent on the clinical syndrome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic approach by clinical syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/1\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax--Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/4\">",
"      Bush LM, Abrams BH, Beall A, Johnson CC. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/5\">",
"      LaForce FM. Anthrax. Clin Infect Dis 1994; 19:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/6\">",
"      Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/7\">",
"      Swartz MN. Recognition and management of anthrax--an update. N Engl J Med 2001; 345:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/8\">",
"      Wenner KA, Kenner JR. Anthrax. Dermatol Clin 2004; 22:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/9\">",
"      Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/10\">",
"      Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med 1998; 158:429.",
"     </a>",
"    </li>",
"    <li>",
"     Brachman, P, Kaufmann, A. Anthrax. In: Bacterial infections of Humans: Epidemiology and Control, 3rd Edition ed, Evans, A, Brachman, P (Eds), Plenum Publishing, New York, NY 1998. p. 95.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/12\">",
"      Carucci JA, McGovern TW, Norton SA, et al. Cutaneous anthrax management algorithm. J Am Acad Dermatol 2002; 47:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/13\">",
"      Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/14\">",
"      Abdenour D, Larouze B, Dalichaouche M, Aouati M. Familial occurrence of anthrax in Eastern Algeria. J Infect Dis 1987; 155:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/15\">",
"      Freedman A, Afonja O, Chang MW, et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 2002; 287:869.",
"     </a>",
"    </li>",
"    <li>",
"     Quinn, CP, Turnbull, PCB. Anthrax. In: Topley and Wilson's Microbiology and Microbial Infection., 9th Edition ed, Hausler WJ, Sussman M (Eds), Edward Arnold, London 1998. p. 799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/17\">",
"      DRUETT HA, HENDERSON DW, PACKMAN L, PEACOCK S. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond) 1953; 51:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/18\">",
"      Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993; 90:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/19\">",
"      Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980; 353:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/20\">",
"      Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/21\">",
"      Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/22\">",
"      HENDERSON DW, PEACOCK S, BELTON FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956; 54:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/23\">",
"      Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/24\">",
"      PLOTKIN SA, BRACHMAN PS, UTELL M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960; 29:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/25\">",
"      Borio L, Frank D, Mani V, et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 2001; 286:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/26\">",
"      Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/27\">",
"      Kyriacou DN, Stein AC, Yarnold PR, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004; 364:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/29\">",
"      Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/30\">",
"      Beatty ME, Ashford DA, Griffin PM, et al. Gastrointestinal anthrax: review of the literature. Arch Intern Med 2003; 163:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/31\">",
"      Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003; 9:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/32\">",
"      Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002; 8:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/33\">",
"      Sirisanthana T, Navachareon N, Tharavichitkul P, et al. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg 1984; 33:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/34\">",
"      Lanska DJ. Anthrax meningoencephalitis. Neurology 2002; 59:327.",
"     </a>",
"    </li>",
"    <li>",
"     Health Protection Scotland. An outbreak of anthrax among drug users in Scotland, December 2009 to December 2010. A report on behalf of the National Anthrax Outbreak Control Team. file://www.documents.hps.scot.nhs.uk/giz/anthrax-outbreak/anthrax-outbreak-report-2011-12.pdf (Accessed on January 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/36\">",
"      Morse, SA, Kellogg, RB, Perry, S, et al. Detecting Biothreat Agents: the Laboratory Response Network. ASM News 2003; 69:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/37\">",
"      Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003; 163:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/38\">",
"      Shieh WJ, Guarner J, Paddock C, et al. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am J Pathol 2003; 163:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/39\">",
"      Hoffmaster AR, Meyer RF, Bowen MD, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002; 8:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/40\">",
"      Quinn CP, Semenova VA, Elie CM, et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002; 8:1103.",
"     </a>",
"    </li>",
"    <li>",
"     Immunetics, I. Immunetics Quick ELISA Anthrax - PA diagnostic test kit. Boston MA 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/43\">",
"      Hupert N, Bearman GM, Mushlin AI, Callahan MA. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med 2003; 139:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7224/abstract/44\">",
"      Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg 1988; 39:575.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5533 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7224=[""].join("\n");
var outline_f7_3_7224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inhalation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alimentary tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365640039\">",
"      Outbreak in heroin users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Criteria for diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory Response Network",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specimen collection and transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC APPROACH BY CLINICAL SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inhalation anthrax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Distinction from common respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Approach to testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cutaneous anthrax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alimentary tract anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5533\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5533|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/21/3410\" title=\"diagnostic image 1\">",
"      Mediastinal widening inhalation anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5533|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/47/15092\" title=\"picture 1\">",
"      Cutaneous anthrax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/23/20853\" title=\"picture 2\">",
"      Cutaneous anthrax with lymphangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/21/5458\" title=\"picture 3\">",
"      Anthrax CSF gram stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/30/20966\" title=\"picture 4\">",
"      B anthracis Gram stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5533|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/49/10013\" title=\"table 1\">",
"      Specimens for anthrax testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=related_link\">",
"      Treatment of anthrax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7225="Lyme disease: Clinical manifestations in children";
var content_f7_3_7225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lyme disease: Clinical manifestations in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Eugene D Shapiro, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7225/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/3/7225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a tick-borne illness primarily caused&nbsp;by a number of pathogenic genomospecies of the spirochete",
"    <em>",
"     Borrelia burgdorferi",
"    </em>",
"    sensu lato [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <em>",
"     B. burgdorferi",
"    </em>",
"    sensu stricto is the sole cause of the disease in the United States.",
"    <em>",
"     B. burgdorferi",
"    </em>",
"    sensu stricto,",
"    <em>",
"     B. afzelii",
"    </em>",
"    , and",
"    <em>",
"     B. garinii",
"    </em>",
"    and a number of other genomospecies may cause disease in Europe and",
"    <em>",
"     B. afzelii",
"    </em>",
"    , and",
"    <em>",
"     B. garinii",
"    </em>",
"    have been identified in Asia. Lyme disease has a broad spectrum of clinical manifestations. The clinical manifestations vary, in part, due to differences in the infecting genomospecies.",
"   </p>",
"   <p>",
"    The clinical manifestations of Lyme disease in children will be reviewed here. The clinical manifestations of Lyme disease in adults and the microbiology, epidemiology, treatment, and prevention of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=see_link\">",
"     \"Prevention of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Lyme disease depend on the stage of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early localized disease",
"     </li>",
"     <li>",
"      Early disseminated disease",
"     </li>",
"     <li>",
"      Late disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of Lyme disease in children were described in a community-based prospective study of 201 Connecticut children with Lyme disease who were enrolled between April 1992 and November 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. The median age was seven years (range 1 to 21 years). The presenting manifestations were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema migrans &ndash; 89 percent (single erythema migrans: 66 percent; multiple erythema migrans: 23 percent)",
"     </li>",
"     <li>",
"      Arthritis &ndash; 7 percent",
"     </li>",
"     <li>",
"      Facial palsy &ndash; 3 percent",
"     </li>",
"     <li>",
"      Aseptic meningitis &ndash; 1 percent",
"     </li>",
"     <li>",
"      Carditis &ndash; 0.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basic features of Lyme disease are similar worldwide, but there are regional variations, primarily between the illness found in the United States and that found in Europe and Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'United States versus Europe'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY LOCALIZED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Erythema migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema migrans is the manifestation of early localized Lyme disease. Erythema migrans is a rash that appears at the site of the tick bite, usually within 7 to 14 days after the bite (range 3 to 30 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, erythema migrans (including multiple erythema migrans, discussed below) is the only manifestation of Lyme disease that permits clinical diagnosis without laboratory confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ]. During early localized disease (ie, within the first two to three weeks of infection), serologic testing is not sufficiently sensitive to be helpful in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In a community-based prospective study of 201 children with Lyme disease, only 37 percent of those with a single erythema migrans lesion had positive serology for",
"    <em>",
"     B. burgdorferi",
"    </em>",
"    at the time of presentation, compared with 89 percent of those with multiple erythema migrans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema migrans begins as a red macule at the site of bacterial infection by the tick. The most frequent sites for a single erythema migrans lesion in children are [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Head and neck (26 percent)",
"     </li>",
"     <li>",
"      Arms and legs (25 percent)",
"     </li>",
"     <li>",
"      Back (24 percent)",
"     </li>",
"     <li>",
"      Abdomen (9 percent)",
"     </li>",
"     <li>",
"      Axilla (8 percent)",
"     </li>",
"     <li>",
"      Groin (5 percent)",
"     </li>",
"     <li>",
"      Chest (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lesion is more likely to occur on the head or neck in younger children and on the extremities in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Untreated, the rash expands over the course of days to weeks to form a large, annular, erythematous lesion that is at least 5 cm and as many as 70 cm in diameter (median 15 cm). Although the propensity for the rash to develop clearing in the center and a \"bull's eye\" appearance (",
"    <a class=\"graphic graphic_picture graphicRef62480 \" href=\"UTD.htm?19/16/19712\">",
"     picture 1",
"    </a>",
"    ) is well publicized, most commonly the rash is uniformly erythematous (",
"    <a class=\"graphic graphic_picture graphicRef57414 \" href=\"UTD.htm?0/35/575\">",
"     picture 2",
"    </a>",
"    ). This was illustrated in a cohort of 118 adult patients with erythema migrans and B. burgdorferi infection (confirmed by culture or polymerase chain reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/11\">",
"     11",
"    </a>",
"    ]. The lesion was homogeneous in 59 percent, had central erythema in 32 percent, and central clearing in only 9 percent.",
"   </p>",
"   <p>",
"    Erythema migrans lesions usually are flat and without scale; they may be pruritic or burning, but are rarely painful [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. The lesions occasionally may have vesicular or necrotic areas in the center related to an intense inflammatory response (",
"    <a class=\"graphic graphic_picture graphicRef67424 \" href=\"UTD.htm?34/20/35140\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Vesicular-appearing erythema migrans lesions usually are not pruritic; this lack of pruritus and the large area of erythema without vesicles help to distinguish vesicular erythema migrans from contact dermatitis (eg, poison ivy) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythema migrans is annular, but the lesion can vary greatly in shape and rarely is perfectly round. A perfectly round lesion should prompt consideration of other diagnoses, such as nummular eczema or erythema multiforme. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Associated findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized erythema migrans may be accompanied by systemic findings, such as fever (24 percent), fatigue (58 percent), headache (42 percent), neck pain (26 percent), arthralgia (33 percent), or myalgia (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     History of tick bite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of Lyme disease result from tick bites that are not recognized. In a community-based prospective study, only 36 percent of 132 children with Lyme disease and a single erythema migrans lesion had had a tick bite in the preceding month [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. Among these, the bite was at a site different than the lesion in 38 percent (indicating that the infection was transmitted by a different, unrecognized tick).",
"   </p>",
"   <p>",
"    Thus, the absence of a recognized tick bite does not exclude Lyme disease, as long as exposure to a vector tick in an endemic area is a possibility. Likewise, a history of a tick bite on a different part of the body, or in the more distant past, should be viewed as evidence of potential tick exposure rather than evidence that the lesion is not erythema migrans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=see_link\">",
"     \"Evaluation of a tick bite for possible Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of erythema migrans includes a number of dermatologic conditions that usually can be differentiated from erythema migrans by clinical features, such as morphology, size, secondary changes (eg, scale, crusting), pruritus, location,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain.",
"   </p>",
"   <p>",
"    If there is uncertainty about whether a rash is erythema migrans, it is reasonable to observe the rash and follow the patient closely for 24 to 48 hours, provided that the patient is not severely ill. Erythema migrans will persist and increase in size. If the lesion disappears in a few days without treatment, it is unlikely to have been erythema migrans. In the minority of cases in which diagnostic uncertainty remains after 24 to 48 hours of observation, acute and convalescent serum samples may be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of Lyme disease\", section on 'Serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tick bite hypersensitivity reaction &ndash; Tick bite hypersensitivity reactions typically develop while the tick is attached or within 48 hours of detachment [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"       6",
"      </a>",
"      ]. They are usually &lt;5 cm in largest diameter and sometimes urticarial. In contrast to erythema migrans, which enlarge over time, tick bite hypersensitivity reactions usually begin to disappear within 24 to 48 hours.",
"     </li>",
"     <li>",
"      Southern tick-associated rash illness &ndash; Southern tick-associated rash illness (STARI) is associated with an erythema migrans-like rash and mild flu-like symptoms. STARI was first described in patients from Missouri and the southeastern United States. It should be considered in patients with appropriate clinical features who are from non-Lyme-endemic areas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=see_link\">",
"       \"Southern tick-associated rash illness (STARI)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nummular eczema &ndash; Nummular eczema is a dermatitis consisting of spontaneous eruption of one or more circular lesions (2 to 10 cm in diameter) with papules, scale,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      crusting, typically distributed on the trunk or extremities, with sparing of the head. The lesions are intensely pruritic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of dermatitis\", section on 'Nummular dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tinea corporis &ndash; Tinea corporis (ringworm) is a dermatophyte infection that begins as a pruritic circular or oval erythematous scaling patch or plaque that spreads centrifugally. Central clearing follows, while the active advancing border, a few millimeters wide, remains red and slightly raised (",
"      <a class=\"graphic graphic_picture graphicRef71226 \" href=\"UTD.htm?22/13/22751\">",
"       picture 4",
"      </a>",
"      ). Multiple lesions may coalesce to form \"flower petal\" configurations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cellulitis &ndash; Cellulitis is an infection of the deep dermis and subcutaneous fat without an underlying suppurative focus; it manifests with erythema, edema, and warmth. Erythema migrans lesions typically occur at sites that would be unusual for cellulitis (eg, axilla, popliteal fossa, abdomen) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granuloma annulare &ndash; Granuloma annulare is characterized by papules or nodules grouped in a circular configuration; the lesions range from 0.5 to several centimeters in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=see_link&amp;anchor=H35143181#H35143181\">",
"       \"Granuloma annulare\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spider and other bites &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=see_link\">",
"       \"Approach to the patient with a suspected spider bite: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythema multiforme &ndash; Erythema multiforme is an acute eruption characterized by distinctive target lesions (",
"      <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"       picture 5",
"      </a>",
"      ). It has no prodrome and a typically benign clinical course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EARLY DISSEMINATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If Lyme disease is not recognized or treated during the early localized stage, the spirochete enters the bloodstream and disseminates to tissues throughout the body, potentially including the central nervous system and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of early disseminated Lyme disease in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple erythema migrans (",
"      <a class=\"graphic graphic_picture graphicRef75337 \" href=\"UTD.htm?26/16/26883\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cranial nerve palsy (especially facial nerve palsy)",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"     <li>",
"      Carditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Meningoradiculitis (Bannwarth's syndrome), which occurs in adults, is virtually never seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic signs and symptoms, such as fever (45 percent), fatigue (80 percent), headache (70 percent), and arthralgia (50 percent), are common in this stage of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least 90 percent of children with early disseminated Lyme disease have positive serology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiple erythema migrans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple erythema migrans is the most common manifestation of early disseminated Lyme disease in the United States. In a prospective cohort of 201 children with Lyme disease, it was the presenting manifestation in 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary erythema migrans lesions usually appear three to five weeks after the tick bite and are believed to arise through hematogenous dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. They consist of multiple annular erythematous lesions similar to, but usually smaller than, the primary lesion and are more often round (",
"    <a class=\"graphic graphic_picture graphicRef75337 \" href=\"UTD.htm?26/16/26883\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the United States, multiple erythema migrans permit clinical diagnosis of Lyme disease without laboratory confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cranial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial nerve palsies, especially of the facial nerve (cranial nerve VII) are another common manifestation of Lyme disease in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. In a prospective cohort of 201 children with Lyme disease, facial nerve palsy was the presenting manifestation in 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. Among 313 children living in a Lyme-endemic area who presented to a pediatric emergency department with facial nerve palsy, 34 percent had Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/19\">",
"     19",
"    </a>",
"    ]. Factors associated with Lyme disease included onset of symptoms between June and October, fever, headache, and absence of history of herpetic lesions. Because the majority of patients with facial palsy attributed to Lyme disease were diagnosed with Lyme disease based solely upon a positive IgM (for which false-positive results are common), the actual proportion due to Lyme disease may have been smaller.",
"   </p>",
"   <p>",
"    Bilateral palsy of the facial nerves is virtually pathognomonic of Lyme disease (though it rarely results from other conditions, such as lymphoma). The palsy in Lyme disease may be a result of mononeuritis multiplex, which is a peripheral neuritis, or of basilar meningitis with involvement of the facial nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=see_link\">",
"     \"Facial nerve palsy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Facial nerve palsy associated with Lyme disease usually resolves completely with or without antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Antimicrobial therapy is necessary to prevent other manifestations of Lyme disease, including late Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Late disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to establish the diagnosis of Lyme disease in a patient with facial nerve palsy without erythema migrans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/22\">",
"     22",
"    </a>",
"    ]. In such patients, diagnosis depends upon serology. However, serology occasionally may not be positive until several weeks after the onset of facial nerve palsy. If Lyme disease is suspected and initial serology is negative, serology should be repeated three to four weeks later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of Lyme disease\", section on 'Serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Need for lumbar puncture",
"      </strong>",
"      &ndash; In children with cranial nerve palsy and strong clinical suspicion of meningitis (eg, severe or prolonged headache, nuchal rigidity) lumbar puncture may be warranted [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Meningitis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      However, there is controversy regarding the appropriate evaluation and management of patients with Lyme disease-associated cranial nerve palsies and no signs of meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"       6",
"      </a>",
"      ]. The controversy centers on whether all such patients should undergo a lumbar puncture, and if lumbar puncture is undertaken, whether patients with abnormalities of the cerebrospinal fluid (CSF) should receive parenteral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/22-25\">",
"       22-25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some abnormalities will be found in the CSF in a large proportion of children with Lyme disease-associated facial nerve palsy who undergo a lumbar puncture [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/24\">",
"       24",
"      </a>",
"      ]. However, the clinical significance of these abnormalities is not clear [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/22\">",
"       22",
"      </a>",
"      ]. There is substantial evidence that such children (and adults) who are treated with oral antimicrobial agents have excellent outcomes with no or very minor long-term sequelae, even if they have CSF pleocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5,25-32\">",
"       5,25-32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the absence of definitive data, we suggest that children who have facial nerve palsy and Lyme disease undergo lumbar puncture only if they have clinical evidence of central nervous system infection (eg, nuchal rigidity, papilledema, or a very severe headache) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/22,33\">",
"       22,33",
"      </a>",
"      ]. This suggestion is in agreement with the recommendations of the Infectious Diseases Society of America and the American Academy of Neurology [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6,23\">",
"       6,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis is the presenting manifestation in approximately 1 percent of children with Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. The presentation of Lyme meningitis is similar to that of aseptic meningitis. In Lyme-endemic areas during the summer and fall, it can be difficult to distinguish Lyme meningitis from enteroviral and other types of aseptic meningitis unless the patient has erythema migrans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22809?source=see_link\">",
"     \"Viral meningitis: Epidemiology, pathogenesis, and etiology in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=see_link&amp;anchor=H21#H21\">",
"     \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Bacterial infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical and laboratory features of Lyme meningitis and viral meningitis have been compared in several small series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. Features that may be helpful in differentiating between enteroviral and Lyme meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with Lyme meningitis tend to be older (median age of 10.5 versus 5.5 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Children with Lyme meningitis tend to have a longer duration of symptoms before diagnosis (12 versus 1 day) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Erythema migrans (by history or examination), cranial nerve palsy, and papilledema (from increased intracranial pressure) are strongly associated with Lyme meningitis, but uncommon in viral meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/34,35,37,38\">",
"       34,35,37,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The proportion of polymorphonuclear cells in the CSF of children with Lyme meningitis is usually &lt;10 percent, significantly lower than that observed in many children with meningitis due to enterovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In rare cases, increased intracranial pressure may persist despite treatment with antibiotics and may require specific treatment to prevent permanent vision damage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Optic neuritis also has been reported to be caused by Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carditis, manifest by complete heart block, is a rare presenting manifestation of early disseminated Lyme disease in children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. In a prospective cohort of 201 children with Lyme disease, carditis was the presenting manifestation in only 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"     5",
"    </a>",
"    ]. Partial heart block, an incidental finding, may be more common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lyme carditis is usually self-limited, although affected children may need a temporary pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonspecific symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early, disseminated Lyme disease rarely may have only nonspecific symptoms similar to those caused by viruses (eg, with fever, malaise, myalgia) without erythema migrans or other manifestations of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of fever and nonspecific symptoms as a presentation of Lyme disease is not known. However, information from clinical trials of Lyme vaccine, in which subjects had routine serology performed by a reference laboratory, suggests that it is uncommon (&lt;0.3 percent of patients in the trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that children with only nonspecific symptoms not be routinely tested for Lyme disease. It is virtually impossible to confirm a diagnosis of Lyme disease in such patients. Nonspecific symptoms of a viral-like illness from causes other than Lyme disease are common, particularly in children. Given the low prevalence of Lyme disease in the population of patients presenting with isolated nonspecific symptoms, the positive predictive value of serologic test results is low [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/7,43\">",
"     7,43",
"    </a>",
"    ]. Most of the positive results will be falsely positive (",
"    <a class=\"graphic graphic_figure graphicRef73751 \" href=\"UTD.htm?25/0/25614\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H27411155#H27411155\">",
"     \"Diagnosis of Lyme disease\", section on 'Usefulness of serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous case reports of involvement of a large variety of other organ systems during disseminated Lyme disease. However, these reports often are based on a positive serologic test result in a patient with no other evidence of Lyme disease and may be a consequence of either a false-positive test result or a prior infection, rather than a causal association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LATE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late Lyme disease occurs weeks to months after the initial infection if the initial infection is not treated effectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis is the most common manifestation of late Lyme disease. The arthritis is usually monoarticular or oligoarticular and affects the large joints, particularly the knee, which is involved in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6,44-47\">",
"     6,44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a wide spectrum in the acuity of the presentation of Lyme arthritis, and in some instances it may be confused with acute bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/44,48\">",
"     44,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features that may help to distinguish Lyme arthritis from acute bacterial arthritis include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/44,48\">",
"     44,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Lyme arthritis, the affected joint usually is swollen and may be tender, but the pain is less intense than that associated with bacterial arthritis.",
"     </li>",
"     <li>",
"      Most children with Lyme arthritis of the knee can walk without difficulty despite some limitation in range of motion; most children with acute bacterial arthritis of the lower extremity refuse to bear weight.",
"     </li>",
"     <li>",
"      Associated fever is uncommon, and erythema of the involved joint is less common, in Lyme arthritis.",
"     </li>",
"     <li>",
"      In Lyme arthritis, the synovial fluid white blood cell (WBC) count usually ranges from 20,000 to 60,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (but it can exceed 100,000",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      whereas in acute bacterial arthritis, the synovial fluid WBC count is usually &gt;100,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      with a predominance of polymorphonuclear leukocytes.",
"     </li>",
"     <li>",
"      If untreated, Lyme arthritis usually lasts for several weeks before resolving, only to recur, often in a different joint [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/49\">",
"       49",
"      </a>",
"      ]. Acute bacterial arthritis does not improve without treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural history of untreated Lyme arthritis was illustrated in long-term follow-up of 46 children included in the initial description of Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. None of the children received antimicrobial treatment in the four years after the initial diagnosis, and many never received antimicrobial treatment. Thirty-nine of the 46 patients were contacted 10 to 15 years later. Recurrent episodes of arthritis that were not treated were common during the early years after symptoms began. However, by 10 years, recurrent episodes of arthritis had resolved. There are virtually no reports of chronic Lyme arthritis in children.",
"   </p>",
"   <p>",
"    The prognosis for children with treated Lyme arthritis is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/45,50,51\">",
"     45,50,51",
"    </a>",
"    ]. The long-term outcome was evaluated in a telephone survey of 90 children who were diagnosed with Lyme arthritis between 1982 and 1991 (mean age 8.3 years; range 1.9 to 16 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/45\">",
"     45",
"    </a>",
"    ]. All but five children were treated with antimicrobial therapy at a median of two months after onset of symptoms (range 2 days to 5.5 years). Follow-up occurred at a median of seven years (range 2 to 12 years) after diagnosis. None of the patients had evidence of active arthritis, but four reported ongoing musculoskeletal complaints with mild to moderate impairment of activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CONGENITAL LYME DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of increased risk of abnormal outcomes with Lyme disease during pregnancy. Lyme disease in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations of Lyme disease in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5896392\">",
"    <span class=\"h1\">",
"     \"CHRONIC LYME DISEASE\" IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there has been a great deal of publicity about \"chronic Lyme disease\" in both children and adults, there is no evidence that such an entity exists [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6,52,53\">",
"     6,52,53",
"    </a>",
"    ].&nbsp;Indeed, there is no definition of \"chronic Lyme disease\". Numerous studies from different academic medical centers have found that the great majority of patients labeled as having &ldquo;chronic Lyme disease&rdquo; had no evidence of Lyme disease based on either the history or the results of serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"     6",
"    </a>",
"    ].&nbsp;In long-term (median five years) follow-up of 84 children with confirmed Lyme disease of the central nervous system, the frequency of occurrence of nonspecific subjective was similar among cases and controls (approximately 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is substantial evidence that long-term treatment with antimicrobials for &ldquo;chronic Lyme disease&rdquo; is not associated with benefit, but is associated with a variety of potential deleterious effects including death, substantial financial expense, and selection of antimicrobial-resistant bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Moreover, patients treated with antimicrobials for &ldquo;chronic Lyme disease&rdquo; often fail to receive treatment for their underlying illness or for relief of their symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H26#H26\">",
"     \"Treatment of Lyme disease\", section on 'Post-Lyme disease syndrome and chronic Lyme disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Chronic Lyme disease\" probably falls in the category of illness known as medically unexplained symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7225/abstract/54\">",
"     54",
"    </a>",
"    ]. Parents and patients should be cautioned about the lack of benefit and the risks of long-term antimicrobial therapy, as well as the large amount of misinformation about Lyme disease on the Internet. It is important for clinicians to realize that many parents who are worried about symptoms in their children feel dismissed when a clinician brushes aside their fears, simply saying that their child does not have Lyme disease.&nbsp;Such parents and patients may benefit from supportive, long-term relationship with a caregiver who will not dismiss their concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of Lyme disease depend on the stage of the illness: early localized, early disseminated, and late disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early localized Lyme disease is manifest by a single erythema migrans lesion (",
"      <a class=\"graphic graphic_picture graphicRef62480 \" href=\"UTD.htm?19/16/19712\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57414 \" href=\"UTD.htm?0/35/575\">",
"       picture 2",
"      </a>",
"      ). Erythema migrans usually appears at the site of the tick bite within 7 to 14 days after the bite. In the United States, erythema migrans (including multiple erythema migrans (",
"      <a class=\"graphic graphic_picture graphicRef75337 \" href=\"UTD.htm?26/16/26883\">",
"       picture 6",
"      </a>",
"      )) is the only manifestation of Lyme disease that permits clinical diagnosis without laboratory confirmation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Erythema migrans'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"       \"Diagnosis of Lyme disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most cases of Lyme disease result from tick bites that are not recognized. In endemic areas, the absence of a recognized tick bite does not exclude Lyme disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'History of tick bite'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of early disseminated Lyme disease in children include multiple erythema migrans (",
"      <a class=\"graphic graphic_picture graphicRef75337 \" href=\"UTD.htm?26/16/26883\">",
"       picture 6",
"      </a>",
"      ), cranial nerve palsy (especially facial nerve palsy), meningitis, and carditis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Early disseminated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilateral facial nerve palsy is virtually pathognomonic for Lyme disease. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cranial nerve palsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children who have facial nerve palsy and Lyme disease undergo lumbar puncture only if they have clinical evidence of central nervous system infection (eg, nuchal rigidity, papilledema, or a very severe headache). The clinical significance of cerebrospinal fluid (CSF) abnormalities in children with Lyme disease-associated facial nerve palsy and no signs of meningitis is unclear. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of Lyme meningitis is similar to that of aseptic meningitis. Clinical features suggestive of Lyme meningitis include erythema migrans, cranial nerve palsy, papilledema, increased duration of symptoms, and less than 10 percent polymorphonuclear cells in the CSF. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Meningitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not testing children with only nonspecific symptoms for Lyme disease. Nonspecific symptoms are a rare presentation of Lyme disease; in such patients, most of the positive results will be falsely positive. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Nonspecific symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthritis is the most common manifestation of late Lyme disease. The arthritis is usually monoarticular or oligoarticular and affects the large joints, particularly the knee. The pain of Lyme arthritis is usually less intense than that of bacterial arthritis. The long-term prognosis of Lyme arthritis in children is excellent. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no definition for &ldquo;chronic Lyme disease&rdquo; and no evidence that such an entity exists. Long-term antibiotic therapy for &ldquo;chronic Lyme disease&rdquo; has no proven benefit and is associated with potential deleterious adverse effects. (See",
"      <a class=\"local\" href=\"#H5896392\">",
"       '\"Chronic Lyme disease\" in children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/1\">",
"      Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/2\">",
"      Steere AC. Lyme disease. N Engl J Med 1989; 321:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/3\">",
"      Shapiro ED, Gerber MA. Lyme disease. Clin Infect Dis 2000; 31:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/4\">",
"      Nadelman RB, Wormser GP. Lyme borreliosis. Lancet 1998; 352:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/5\">",
"      Gerber MA, Shapiro ED, Burke GS, et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 1996; 335:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/6\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/7\">",
"      Tugwell P, Dennis DT, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997; 127:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/8\">",
"      Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of lyme borreliosis. Clin Microbiol Rev 2005; 18:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/9\">",
"      Nowakowski J, Schwartz I, Liveris D, et al. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin Infect Dis 2001; 33:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/10\">",
"      Feder HM Jr. Lyme disease in children. Infect Dis Clin North Am 2008; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/11\">",
"      Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/12\">",
"      Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/13\">",
"      Goldberg NS, Forseter G, Nadelman RB, et al. Vesicular erythema migrans. Arch Dermatol 1992; 128:1495.",
"     </a>",
"    </li>",
"    <li>",
"     Cutaneous tumors and tumor syndromes. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd ed, Paller AS, Mancini AJ (Eds), WB Saunders, Philadelphia 2006. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/15\">",
"      Belman AL, Iyer M, Coyle PK, Dattwyler R. Neurologic manifestations in children with North American Lyme disease. Neurology 1993; 43:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/16\">",
"      Wormser GP, McKenna D, Carlin J, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/17\">",
"      Christen HJ, Hanefeld F, Eiffert H, Thomssen R. Epidemiology and clinical manifestations of Lyme borreliosis in childhood. A prospective multicentre study with special regard to neuroborreliosis. Acta Paediatr Suppl 1993; 386:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/18\">",
"      Christen HJ, Bartlau N, Hanefeld F, et al. Peripheral facial palsy in childhood--Lyme borreliosis to be suspected unless proven otherwise. Acta Paediatr Scand 1990; 79:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/19\">",
"      Nigrovic LE, Thompson AD, Fine AM, Kimia A. Clinical predictors of Lyme disease among children with a peripheral facial palsy at an emergency department in a Lyme disease-endemic area. Pediatrics 2008; 122:e1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/20\">",
"      Clark JR, Carlson RD, Sasaki CT, et al. Facial paralysis in Lyme disease. Laryngoscope 1985; 95:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/21\">",
"      Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med 1991; 114:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/22\">",
"      Shapiro ED, Gerber MA. Lyme disease and facial nerve palsy. Arch Pediatr Adolesc Med 1997; 151:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/23\">",
"      Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/24\">",
"      Belman AL, Reynolds L, Preston T, et al. Cerebrospinal fluid findings in children with Lyme disease-associated facial nerve palsy. Arch Pediatr Adolesc Med 1997; 151:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/25\">",
"      Kuiper H, de Jongh BM, van Dam AP, et al. Evaluation of central nervous system involvement in Lyme borreliosis patients with a solitary erythema migrans lesion. Eur J Clin Microbiol Infect Dis 1994; 13:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/26\">",
"      V&aacute;zquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics 2003; 112:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/27\">",
"      Adams WV, Rose CD, Eppes SC, Klein JD. Cognitive effects of Lyme disease in children. Pediatrics 1994; 94:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/28\">",
"      Bingham PM, Galetta SL, Athreya B, Sladky J. Neurologic manifestations in children with Lyme disease. Pediatrics 1995; 96:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/29\">",
"      Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. Infection 1996; 24:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/30\">",
"      Thorstrand C, Belfrage E, Bennet R, et al. Successful treatment of neuroborreliosis with ten day regimens. Pediatr Infect Dis J 2002; 21:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/31\">",
"      Skogman BH, Croner S, Nordwall M, et al. Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome. Pediatr Infect Dis J 2008; 27:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/32\">",
"      Skogman BH, Glim&aring;ker K, Nordwall M, et al. Long-term clinical outcome after Lyme neuroborreliosis in childhood. Pediatrics 2012; 130:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/33\">",
"      Treatment of Lyme disease. Med Lett Drugs Ther 1997; 39:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/34\">",
"      Avery RA, Frank G, Glutting JJ, Eppes SC. Prediction of Lyme meningitis in children from a Lyme disease-endemic region: a logistic-regression model using history, physical, and laboratory findings. Pediatrics 2006; 117:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/35\">",
"      Shah SS, Zaoutis TE, Turnquist J, et al. Early differentiation of Lyme from enteroviral meningitis. Pediatr Infect Dis J 2005; 24:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/36\">",
"      Eppes SC, Nelson DK, Lewis LL, Klein JD. Characterization of Lyme meningitis and comparison with viral meningitis in children. Pediatrics 1999; 103:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/37\">",
"      Tuerlinckx D, Bodart E, Jamart J, Glupczynski Y. Prediction of Lyme meningitis based on a logistic regression model using clinical and cerebrospinal fluid analysis: a European study. Pediatr Infect Dis J 2009; 28:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/38\">",
"      Tveitnes D, Nat&aring;s OB, Skadberg &Oslash;, &Oslash;ymar K. Lyme meningitis, the major cause of childhood meningitis in an endemic area: a population based study. Arch Dis Child 2012; 97:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/39\">",
"      Rothermel H, Hedges TR 3rd, Steere AC. Optic neuropathy in children with Lyme disease. Pediatrics 2001; 108:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/40\">",
"      Nord JA, Karter D. Lyme disease complicated with pseudotumor cerebri. Clin Infect Dis 2003; 37:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/41\">",
"      Feder HM Jr, Gerber MA, Krause PJ, et al. Early Lyme disease: a flu-like illness without erythema migrans. Pediatrics 1993; 91:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/42\">",
"      Steere AC, Sikand VK, Schoen RT, Nowakowski J. Asymptomatic infection with Borrelia burgdorferi. Clin Infect Dis 2003; 37:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/43\">",
"      Seltzer EG, Shapiro ED. Misdiagnosis of Lyme disease: when not to order serologic tests. Pediatr Infect Dis J 1996; 15:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/44\">",
"      Bachman DT, Srivastava G. Emergency department presentations of Lyme disease in children. Pediatr Emerg Care 1998; 14:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/45\">",
"      Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics 1998; 102:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/46\">",
"      Culp RW, Eichenfield AH, Davidson RS, et al. Lyme arthritis in children. An orthopaedic perspective. J Bone Joint Surg Am 1987; 69:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/47\">",
"      Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum 1977; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/48\">",
"      Thompson A, Mannix R, Bachur R. Acute pediatric monoarticular arthritis: distinguishing lyme arthritis from other etiologies. Pediatrics 2009; 123:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/49\">",
"      Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/50\">",
"      Szer IS, Taylor E, Steere AC. The long-term course of Lyme arthritis in children. N Engl J Med 1991; 325:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/51\">",
"      Shapiro ED. Long-term outcomes of persons with Lyme disease. Vector Borne Zoonotic Dis 2002; 2:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/52\">",
"      Feder HM Jr, Johnson BJ, O'Connell S, et al. A critical appraisal of \"chronic Lyme disease\". N Engl J Med 2007; 357:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/53\">",
"      Baker PJ. Chronic Lyme disease: in defense of the scientific enterprise. FASEB J 2010; 24:4175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7225/abstract/54\">",
"      Hatcher S, Arroll B. Assessment and management of medically unexplained symptoms. BMJ 2008; 336:1124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6038 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7225=[""].join("\n");
var outline_f7_3_7225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Associated findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - History of tick bite",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EARLY DISSEMINATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiple erythema migrans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cranial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonspecific symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LATE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CONGENITAL LYME DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5896392\">",
"      \"CHRONIC LYME DISEASE\" IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6038|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/0/25614\" title=\"figure 1\">",
"      Prevalence and pred value",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6038|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/16/19712\" title=\"picture 1\">",
"      Erythema migrans bulls eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/35/575\" title=\"picture 2\">",
"      Erythema migrans uniform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/20/35140\" title=\"picture 3\">",
"      EM vesicular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22751\" title=\"picture 4\">",
"      Tinea corporis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 5\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26883\" title=\"picture 6\">",
"      Erythema migrans multiple",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/16/24839?source=related_link\">",
"      Approach to the patient with a suspected spider bite: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26263?source=related_link\">",
"      Evaluation of a tick bite for possible Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22922?source=related_link\">",
"      Granuloma annulare",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3960?source=related_link\">",
"      Prevention of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26533?source=related_link\">",
"      Southern tick-associated rash illness (STARI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22809?source=related_link\">",
"      Viral meningitis: Epidemiology, pathogenesis, and etiology in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7226="Malignancy-associated gastroparesis: Pathophysiology and management";
var content_f7_3_7226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy-associated gastroparesis: Pathophysiology and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Mehnaz A Shafi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Eiad Nasser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Milind Javle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Eduardo Bruera, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/3/7226/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/3/7226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of nausea and vomiting in cancer patients is a challenging task. Gastroparesis is one of the most underdiagnosed problems in cancer patients, and often overlooked as a potential etiology of chronic nausea and vomiting.",
"   </p>",
"   <p>",
"    While the exact prevalence is not known, gastroparesis is common among patients with upper gastrointestinal tract tumors (gastric, pancreatic, esophageal, and biliary) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As many as 60 percent of patients treated for pancreatic cancer have symptoms of delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, these patients may also have a more generalized disorder of gastrointestinal motility, with components of dysphagia and abnormal small bowel motility (intestinal pseudo-obstruction, \"functional ileus\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastroparesis is important to recognize for many reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The consequences of malignancy-associated gastroparesis can be serious, particularly in the context of other common problems that affect nutrition and fluid-electrolyte balance in cancer patients. If unrecognized and untreated, malignancy-associated gastroparesis can compound the anorexia and cachexia that often accompanies advanced cancer and the gastrointestinal side effects of specific anticancer treatments such as radiation or chemotherapy. The potential consequences include electrolyte disturbances, dehydration, hospitalization, and significant impairment of quality of life.",
"     </li>",
"     <li>",
"      Misdiagnosis of malignancy-associated gastroparesis as chemotherapy-induced emesis can lead to delays in administration of potentially efficacious anticancer therapy.",
"     </li>",
"     <li>",
"      Patients with malignancy-associated gastroparesis have difficulty with gastric emptying of solids, particularly those that are fiber-rich. This may result in the formation of a bezoar, which can cause a mechanical gastric outlet obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will cover malignancy-associated gastroparesis. A general discussion of the pathogenesis, etiology (including benign causes) and differential diagnosis, and treatment of delayed gastric emptying is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link\">",
"     \"Pathogenesis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF GASTRIC EMPTYING",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of delayed gastric emptying\", section on 'Anatomy and physiology of gastric motor function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of malignancy-associated gastroparesis is typically multifactorial, and the contributing factors vary depending on the type of underlying cancer (",
"    <a class=\"graphic graphic_table graphicRef70134 \" href=\"UTD.htm?40/32/41483\">",
"     table 1",
"    </a>",
"    ). Among the most important etiologic factors are paraneoplastic phenomena, direct tumor infiltration of the celiac plexus or vagus nerve, past gastrointestinal surgery, viral infection, and the toxic effects of chemotherapy and radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, comorbidities, including poorly controlled diabetes, hypothyroidism, other neuromuscular disorders (",
"    <a class=\"graphic graphic_figure graphicRef52708 \" href=\"UTD.htm?17/3/17459\">",
"     figure 1",
"    </a>",
"    ) or use of medications that affect gastric emptying (particularly narcotics), may also contribute to the development of gastroparesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Paraneoplastic gastrointestinal dysmotility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patients have been described with small cell lung cancer (rarely other tumors such as breast, ovarian and pancreatic cancer, carcinoid, retroperitoneal sarcoma, Hodgkin lymphoma, and cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]) in association with a paraneoplastic gastrointestinal motility disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. These patients often have antineuronal nuclear (ANNA-1, anti-Hu) antibodies which can be detected by an immunofluorescence-based assay [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The autoantibody is postulated to be directed toward an epitope that is shared between the neuronal elements within the enteric nervous system and the underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/17\">",
"     17",
"    </a>",
"    ]. In a series of 162 patients with neurologic manifestations associated with small cell lung cancer (SCLC) and antineuronal nuclear antibodies, 12 percent had solely a gastrointestinal motility disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/18\">",
"     18",
"    </a>",
"    ]. The condition presented as achalasia, gastroparesis, or chronic intestinal pseudo-obstruction.",
"   </p>",
"   <p>",
"    Besides ANNA-1, other circulating autoantibodies that are associated with paraneoplastic gastrointestinal dysmotility include antineuronal antibodies type 2 (ANNA-2 or anti-Ri), amphiphysin antibody, type 1 Purkinje cell cytoplasmic antibody (PCA-1, also called anti-Yo), PCA-2, PCA-Tr, collapsing response modifier protein (CRMP) antibodies and antineuronal calcium channel antibodies of the",
"    <span class=\"nowrap\">",
"     P/Q",
"    </span>",
"    and N-type (",
"    <a class=\"graphic graphic_table graphicRef72670 \" href=\"UTD.htm?17/3/17467\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/19\">",
"     19",
"    </a>",
"    ]. The two most common are ANNA-1 and N-type voltage-gated calcium channel antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism whereby a cross-reacting immune response results in disordered gastrointestinal motility has not been elucidated. Studies conducted in patients with SCLC and gastrointestinal dysmotility have demonstrated immune-mediated destruction of the interstitial cells of Cajal (the so-called intestinal pacemaker cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/11\">",
"     11",
"    </a>",
"    ]. However, others have suggested that dysmotility results from a visceral neuropathy of the myenteric plexus, caused by infiltration with lymphocytes and plasma cells, and subsequent axonal degeneration within the plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Postsurgical dysmotility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Described extensively in the literature, postsurgical gastroparesis often follows abdominal surgery involving the stomach or the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/21\">",
"     21",
"    </a>",
"    ]. The mechanisms contributing to postsurgical gastroparesis are multiple. Vagotomy (or invasion of the vagal nerve from a tumor such as a cholangiocarcinoma), resection of the duodenum and parts of the stomach, the extent of lymphatic dissection, and the type of reconstruction can all influence the degree of postoperative gastroparesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of the duodenum results in reduced plasma concentrations of the hormone motilin which appears to be important for the antral contractions that clear nondigestible solid residues from the stomach during fasting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis of delayed gastric emptying\", section on 'Motor functions of the stomach regions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Both standard pancreaticoduodenectomy (Whipple procedure) and pylorus-preserving pancreaticoduodenectomy are associated with gastroparesis. Gastroparesis after a pylorus-preserving pancreaticoduodenectomy occurs either in the immediate postoperative period, a condition called early gastric stasis, or later as delayed postprandial gastric emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/22\">",
"       22",
"      </a>",
"      ].Loss of phase III activity of the migrating motor complex normally seen in the fasting state has been suggested as the mechanism responsible for early gastric stasis. Recovery may be prolonged.",
"      <br/>",
"      <br/>",
"      Postprandial delayed gastric emptying occurs after the initiation of oral intake in patients who have undergone either a pylorus-preserving or standard Whipple surgery and ranges in incidence from 5 to 46 percent. Whether a pylorus-preserving procedure results in a higher frequency of delayed postprandial gastric emptying is unclear, as the available data are conflicting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H15#H15\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Pylorus-preserving pancreaticoduodenectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The stomach's accommodation response and contractility in response to distention are abolished following vagotomy and partial gastric resection. The vagus nerve carries the parasympathetic impulses to the stomach, and therefore vagotomy leads to hypo-peristalsis. While immediate early transfer of the liquid phase of the meal to the distal stomach and beyond is retained, emptying of solids is delayed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis of delayed gastric emptying\", section on 'Postvagotomy gastric motor dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extensive upper abdominal lymph node dissection is also associated with gastroparesis, possibly as a result of damage to the extrinsic nerves,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intra-abdominal inflammation caused by the dissection. Recovery from postprandial gastroparesis in these cases may take six months or longer.",
"     </li>",
"     <li>",
"      Gastroparesis after surgery for gastric cancer is also influenced by the type of reconstruction. In one case series, the incidence of gastroparesis was significantly lower after a Billroth I gastrectomy than after Roux-en-Y reconstruction (4.3 versus 15.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the Roux stasis syndrome, which can occur after a Roux-en-Y anastomosis, stasis results from incoordination of contractions in the efferent Roux limb. This causes stasis in either the gastric remnant or in the Roux limb itself. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H8#H8\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Iatrogenic disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Celiac plexus injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical damage to the celiac plexus, resulting from either cancer infiltration or a celiac plexus nerve block, can also lead to gastroparesis, although this appears to be a rare complication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/24\">",
"     24",
"    </a>",
"    ]. Injury to the celiac plexus affects parasympathetic input to the stomach, resulting in loss of myenteric coordination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link&amp;anchor=H17#H17\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=see_link&amp;anchor=H380437852#H380437852\">",
"     \"Cancer pain management: Interventional therapies\", section on 'Sympathetic blocks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     High-dose chemotherapy and stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with gastric motor function are reported in up to one-half of patients undergoing hematopoietic stem cell transplantation (HSCT), both autologous and allogeneic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Viral infection (cytomegalovirus, herpes simplex virus) has been implicated in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/25\">",
"     25",
"    </a>",
"    ]. However, gastric dysmotility with abnormalities in gastric myoelectric activity has been documented in the absence of viral infection among patients undergoing high-dose chemotherapy with autologous HSCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an upper gastrointestinal form of acute graft versus host disease (GVHD) has been described that is characterized by anorexia, dyspepsia, food intolerance, nausea, and vomiting. This is more common following allogeneic than autologous HSCT, largely because of the higher rate of graft versus host disease in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\", section on 'Upper gastrointestinal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroparesis is rarely reported as a complication of abdominal radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. This is presumably the result of damage to the enteric nervous system. There is no information as to incidence or risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting symptoms of cancer-associated gastroparesis include nausea, abdominal pain, early satiety, emesis, bloating, and weight loss. In one study, nausea was the major complaint in 93 percent of patients with gastroparesis, 89 percent had abdominal pain, 86 percent experienced early satiety, and vomiting occurred in 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, nonspecific symptoms such as these are not uncommon among patients who have cancer, and may be attributed to the malignancy itself or various treatment modalities, including surgery, chemotherapy, or radiation therapy. Thus, in order to avoid misdiagnosis, clinicians must maintain a high index of suspicion for the diagnosis of gastroparesis.",
"   </p>",
"   <p>",
"    Malignant gastroparesis should always be included in the differential diagnosis of patients who present the aforementioned constellation of symptoms, especially if the symptoms become more pronounced after ingestion of solid meals and if there is vomiting of food eaten several hours earlier. Malignancy-associated gastroparesis should particularly be suspected in cancer patients experiencing refractory, otherwise-unexplained nausea and vomiting.",
"   </p>",
"   <p>",
"    Physical examination may be unrevealing or there may be epigastric distention or tenderness, but not guarding or rigidity. A succussion splash may be heard on auscultation of the epigastric area; this physical finding is due to stasis of the gastric contents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnostic workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial steps of the diagnostic workup are to exclude mechanical obstruction and side effects from narcotics, and to assess nutritional status. Upper gastrointestinal endoscopy should be obtained in most cases. The endoscopic appearance of a dilated distended stomach with decreased peristalsis is strongly indicative of gastroparesis. If there are signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms to suggest small bowel pathology (such as a partial small bowel obstruction or generalized gastrointestinal dysmotility), an oral contrast upper GI tract series with small bowel follow-through is indicated.",
"   </p>",
"   <p>",
"    Routine laboratory testing is not useful for the diagnosis of gastric stasis itself, although it may help to identify diseases that are associated with delayed gastric emptying, to rule out other disorders, and assess nutritional status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gastric emptying scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard test for establishing the diagnosis of gastroparesis is gastric scintigraphy following a standardized solid meal. Consensus standards for performing and reporting gastric emptying scintigraphy are available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/31\">",
"     31",
"    </a>",
"    ]. The suggested protocol involves a low fat meal (bread, jam, and scrambled egg substitute with technetium-99m pertechnetate) with imaging at zero, one, two, and four hours after meal ingestion. Normal values for the percent remaining in the stomach at the key time points are 37 to 90 percent at one hour, 30 to 60 percent at two hours, and 0 to 10 percent at four hours. In clinical practice, the most useful parameters to define gastroparesis are gastric retention of &gt;10 percent at four hours, and &gt;70 percent at two hours. [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology and diagnosis of delayed gastric emptying\", section on 'Scintigraphic gastric emptying'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric emptying scintigraphy can be utilized both for diagnosis and to monitor the effectiveness of prokinetic therapy, although the repeated exposure to radiation may limit the utility of frequent testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Alternatives to scintigraphy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Liquid-phase gastric emptying (with the radioactive technetium-99m pertechnetate mixed in orange juice) can be performed if the patient cannot tolerate solids or when mechanical obstruction cannot be excluded. Delayed gastric emptying is defined as greater than 50 percent retention of gastric contents at 30 minutes.",
"   </p>",
"   <p>",
"    The gastric emptying study was developed for use in patients with normal gastric anatomy. It may be difficult to interpret the study in postsurgical patients as there are no standardized controls for patients, with a subtotal or total gastrectomy. The study also does not quantify intestinal dysmotility, which also occurs in this patient population. Finally, scintigraphy bears some radiation hazard and may therefore not be suitable for repeated investigations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Alternatives to scintigraphy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smart Pill &ndash; A new, ambulatory method for assessing gastrointestinal motility involves ingesting a radiotelemetry wireless capsule (\"Smart Pill\"), which is swallowed and simultaneously measures pressure and pH as it traverses different segments of the gastrointestinal tract. Acceptance of this new technology (particularly for initial diagnosis of gastroparesis) has been slow. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"       \"Etiology and diagnosis of delayed gastric emptying\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Breath tests &ndash; After ingestion in a labeled meal, carbon-13-labeled substrate (octanoate, acetate) is metabolized to 13-CO2, which is rapidly absorbed through the small intestine and excreted through the lungs. It can be measured in expired air by mass spectrometry or infrared spectroscopy. The rate of gastric emptying is directly proportional to the rate of excretion of 13-CO2.",
"      <br/>",
"      <br/>",
"      The accuracy of these breath tests in normal and pathologic conditions is comparable to that of scintigraphic measurements of gastric emptying, as long as small bowel absorption and pulmonary function are normal. Breath tests are considered the test of choice in some areas and are likely to become available as office-based tests of gastric emptying. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H18#H18\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Alternatives to scintigraphy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Manometry &ndash; Antroduodenal manometry measures gastric motility by using an intraluminal catheter to monitor pressure patterns. Motility is recorded during fasting and after solid meals. Gastroparesis is characterized by loss of normal fasting migrating motor complexes and reduced fed antral contractions. Measurements can be performed for four to five hours. Continuous, 24-hour ambulatory recordings may be useful for monitoring the efficacy of prokinetic agents. Manometry may be indicated for excluding small intestinal dysmotility (which often accompanies gastroparesis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H19#H19\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Manometry'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other tests &ndash; Other tests for gastric motility, such cutaneous electrogastrogram (EGG) and MRI, are considered investigational and are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link&amp;anchor=H23#H23\">",
"       \"Etiology and diagnosis of delayed gastric emptying\", section on 'Research tests in patients with gastric stasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Quantifying symptom severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tools are available to quantify the severity of symptoms of gastroparesis.",
"   </p>",
"   <p>",
"    The patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM SF-36) is a self-reported instrument that assesses the severity of symptoms related to gastroparesis, gastroesophageal reflux, and dyspepsia. It has been validated and can be used to measure the efficacy of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Gastroparesis Cardinal Symptom Index (GCSI) was developed to assess the severity of symptoms associated with gastroparesis. It evaluates nine symptoms using a scale from 1 to 9 with a maximal score of 45. This validated symptom score measures three subscales: post prandial",
"    <span class=\"nowrap\">",
"     fullness/early",
"    </span>",
"    satiety,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    and bloating. Good correlation has been seen between the SF-36 and GCSI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quality of life instruments for gastric or pancreatic cancer such as the Functional Assessment of Cancer Therapy (FACT-G) or the European Organization for Research and Treatment of Cancer (EORTC) PAN26 do not include a formal assessment for cancer-associated gastroparesis, although the symptoms of this disorder are recorded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longstanding untreated malignancy-associated gastroparesis has serious nutritional and metabolic consequences. All patients should be assessed at baseline for dehydration, electrolyte abnormalities, malnutrition, and weight loss. Comorbidities such as poorly controlled diabetes and hypothyroidism need to be corrected, and medications that contribute to delayed gastric emptying should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild nutritional impairment can be managed with dietary and behavioral modification, as well as oral prokinetic and antiemetic medications. When a patient has evidence of malnourishment (hypoalbuminemia and a &ge;10 percent weight loss), enteral nutrition should be considered in addition to prokinetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antiemetic medications. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Nutrition issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with severe fluid and electrolyte disturbances or hypotension, hospitalization may be needed. Initial management includes correction of the fluid and electrolyte disturbances, intravenous administration of prokinetic and antiemetic agents, nasogastric or gastrostomy tube placement to decompress the stomach, and consideration for surgical, radiological, or endoscopic jejunostomy tube placement for longer-term decompression and feeding, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dietary and behavioral modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for dietary and behavioral modification are focused on measures that contribute to enhanced gastric emptying. For the most part, these recommendations have been derived empirically rather than from controlled studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of delayed gastric emptying\", section on 'Dietary modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be encouraged to eat while upright and stand or walk afterwards as gravity and body movement help in gastric emptying.",
"     </li>",
"     <li>",
"      Increasing the liquid nutrient component of the ingested meal is helpful, as liquids transit more rapidly than solids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small, frequent, low-fat, low-residue meals are appropriate for patients with gastroparesis in order to avoid gastric distension and symptoms of bloating, early satiety, and nausea. Lipids and indigestible fiber delay gastric emptying.",
"     </li>",
"     <li>",
"      Alcohol and tobacco smoking should be avoided because both decrease antral contractility and slow gastric emptying.",
"     </li>",
"     <li>",
"      Patients should avoid dehydration by ensuring an adequate daily fluid intake.",
"     </li>",
"     <li>",
"      Nutritional and vitamin supplementation are often required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic agents used for cancer-associated gastroparesis closely parallel those used for non-cancer associated gastroparesis (",
"    <a class=\"graphic graphic_table graphicRef72735 \" href=\"UTD.htm?14/5/14429\">",
"     table 3",
"    </a>",
"    ). There are no randomized trials that specifically address the efficacy of any agent for the treatment of malignancy-associated gastroparesis. Prokinetic and antiemetic agents are the mainstay of therapy; specific goals are to accelerate gastric emptying, improve symptoms, and prevent nausea or emesis.",
"   </p>",
"   <p>",
"    The benefit of oral prokinetics for improving gastric emptying was addressed in a systematic review included 36 clinical studies involving 514 patients who were treated with prokinetics for gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/37\">",
"     37",
"    </a>",
"    ]. They concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    had the strongest effect on gastric emptying as compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    , cisapride or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    . However, these investigators and others have shown that objective improvement in gastric emptying does not necessarily correlate with symptomatic improvement. Very little information is available regarding symptom relief with prokinetic agents. In a systematic review of the benefits of oral erythromycin for gastroparesis, only five of 35 published studies included any form of symptom assessment as a study endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/38\">",
"     38",
"    </a>",
"    ]. Symptom improvement was reported in 26 of 60 patients (43 percent).",
"   </p>",
"   <p>",
"    The only two prokinetic agents that remain available in the US are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"     Tegaserod",
"    </a>",
"    is no longer approved by the US Food and Drug Administration (FDA). Cisapride and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    are not readily available in the US and require an Investigational New Drug Application (IND).",
"   </p>",
"   <p>",
"    What follows is a general discussion of the data that are available regarding benefit of prokinetics and antiemetics in malignancy-associated gastroparesis. The data in patients with non-malignant causes of delayed gastric emptying are summarized elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of delayed gastric emptying\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metoclopramide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    (Reglan) is a combined serotonin-4 (5-HT4) receptor agonist and dopamine D(2) receptor antagonist. It promotes gastric emptying and intestinal transit by facilitating gastrointestinal cholinergic and nitrergic (nitric oxide mediated) activity. It also has antiemetic properties that are related to central and peripheral inhibition of dopamine receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link&amp;anchor=H7#H7\">",
"     \"Characteristics of antiemetic drugs\", section on 'Benzamides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective reports support the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (5 to 10 mg taken orally before meals and at bedtime, or 5 mg subcutaneously two to four times daily) for cancer patients with gastroparesis and chronic nausea from a variety of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Benefits include improvement in symptoms of nausea, vomiting, abdominal pain, postprandial fullness, nausea, weight loss, and early satiety.",
"   </p>",
"   <p>",
"    One problem is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    readily crosses the blood-brain barrier, where D(2) receptor antagonism can cause akathisia, tardive dyskinesia, and other extrapyramidal symptoms. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of metoclopramide because of the risk of developing tardive dyskinesia, which is not reversible. While the risk of tardive kinesia with long-term administration has been estimated to be between 1 and 10 percent, a 2010 literature review noted that evidence from large, national prescription databases in the United Kingdom and Sweden recorded a far lower incidence of tardive dyskinesia (less than one percent) than was suggested from case series that were typically collected at tertiary referral clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of adverse effects from metoclopramide can be reduced if the dose is kept at or below 40 mg per day. However, physicians should document the discussion of potential adverse effects of metoclopramide in the medical record when they prescribe metoclopramide for long-term use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    is a bacteriostatic macrolide antibiotic with prokinetic properties that is widely used for diabetic gastroparesis. It is a potent motilin agonist that improves gastric emptying by inducing gastric peristalsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of delayed gastric emptying\", section on 'Anatomy and physiology of gastric motor function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IV administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (erythromycin lactobionate, 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours) may be used to \"restart\" or \"kick-start\" the stomach during acute episodes of gastric stasis in which oral intake is not tolerated. Infusion should be performed over 45 minutes to avoid pain on injection and damage to peripheral veins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of delayed gastric emptying\", section on 'Macrolide antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with diabetic gastroparesis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    is generally less effective when taken orally as compared to IV. Tachyphylaxis may limit long-term efficacy, although this is not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Lack of efficacy after one month should alert the clinician to this possibility.",
"   </p>",
"   <p>",
"    Evidence of the effectiveness of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    in patients with malignancy-associated gastroparesis is limited. In retrospective reports, improvement in symptoms has been seen in patients who developed gastroparesis after radiation therapy and bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/26,37,46,47\">",
"     26,37,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    are a concern, especially with long-term use. These include gastrointestinal toxicity, ototoxicity, pseudomembranous colitis, the induction of resistant bacterial strains, and the risk of sudden death due to long QT syndrome, which is further increased when the drug is used in conjunction with other medications that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cisapride",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cisapride (Propulsid&reg;) is a gastrointestinal prokinetic agent that stimulates serotonin receptors and releases acetylcholine from the myenteric plexus, inducing intestinal peristalsis.",
"   </p>",
"   <p>",
"    Cisapride accelerates gastric emptying of solids and liquids in a variety of gastric stasis syndromes; this effect has been maintained during long-term (one year) open trials. Although it is available in several other countries, cisapride is only available in the US through a special IND program since it has been associated with cardiac dysrhythmias when administered with medications that are inhibitors of the CYP3A4 metabolizing isoenzyme (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of delayed gastric emptying\", section on 'Cisapride'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Tegaserod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"     Tegaserod",
"    </a>",
"    (Zelnorm) is a partial 5-HT4 receptor agonist that stimulates intestinal secretions, increasing peristalsis. It was approved in the US for constipation-predominant irritable bowel syndrome and chronic idiopathic constipation but removed from the market in 2007 because of serious cardiovascular adverse events (eg, angina, heart attacks, and strokes).",
"   </p>",
"   <p>",
"    There are only a few published reports on the benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"     tegaserod",
"    </a>",
"    (which is generally given at a dose of 6 mg prior to meals) in patients with gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Nevertheless, this medication is available for use in countries outside of the US.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"     Tegaserod",
"    </a>",
"    is only available for refractory gastroparesis in the US under an emergency IND process only. Emergency use is defined as immediately life-threatening or requiring hospitalization. Physicians with patients who may qualify can contact the FDA's Division of Drug Information via email (",
"    <a class=\"external\" href=\"mailto:druginfo@fda.hhs.gov\">",
"     druginfo@fda.hhs.gov",
"    </a>",
"    ). The FDA may either deny the request or authorize shipment of Zelnorm&reg; by Novartis. Additional information can be found at",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm\">",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Domperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    (Motilium&reg;) is a dopamine antagonist that stimulates gastrointestinal motility by blocking dopamine D1 receptors and by inhibiting release of acetylcholine through a blockade of D2 receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of delayed gastric emptying\", section on 'Domperidone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    is not approved for use by the US FDA but is available in Canada and other countries. However, the FDA has encouraged \"physicians who would like to prescribe domperidone for their patients with severe gastrointestinal disorders that are refractory to standard therapy to open an IND Application\". The contact person at the FDA is",
"    <a class=\"external\" href=\"mailto:daughertys@cder.fda.gov\">",
"     daughertys@cder.fda.gov",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Antiemetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phenothiazines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    are commonly used to control nausea in patients with gastroparesis. Prochlorperazine acts centrally by inhibiting the dopamine receptors in the chemoreceptor trigger zone in the medulla and peripherally by blocking the vagus nerve. It can be administered orally, parenterally, or rectally.",
"   </p>",
"   <p>",
"    The 5-HT3 antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , or tropisetron are used for treatment and prevention of chemotherapy induced nausea and vomiting. Drugs of this class selectively bind to 5-HT3 receptors on the vagus nerve, blocking signals to the vomiting center; they also act centrally in the chemoreceptor trigger zone in the area postrema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of 5-HT3 antagonists in the management of gastroparesis is controversial. Drugs of this class are expensive, and they confer no advantage over other antiemetics in patients with gastric stasis syndromes. However, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    or a related agent is reasonable for patients who fail to respond to a prokinetic agent, or a phenothiazine antiemetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment considerations for paraneoplastic dysmotility",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with paraneoplastic gastrointestinal dysmotility, antitumor therapy may improve symptoms. Although symptoms often do not improve in cases such as this with paraneoplastic autonomic dysfunction, occasional patients have substantive and sustained clinical improvement with antitumor or nonspecific immune therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link&amp;anchor=H9#H9\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management options for refractory cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the 2 to 5 percent of patients with severe gastroparesis who have minimal or no improvement of symptoms with dietary and behavioral modification and pharmacotherapy, more invasive methods for symptom control include placement of a venting gastrostomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jejunostomy tube, or surgery. In addition, referral to gastroenterology specialty clinic is recommended. Another option that may be tried at experienced centers is placement of a gastric electrical stimulator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneously or laparoscopically placed gastrostomy or jejunostomy tubes can decompress a dilated upper gut. In patients with more generalized motility disorders, this is an effective method to eliminate frequent emesis and reduce the need of hospitalization for acute exacerbations of dysmotility. However, decompression is only rarely necessary. In patients without permanent enterostomy tubes, IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    usually relieves acute gastric stasis rapidly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of delayed gastric emptying\", section on 'Decompression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although helpful for decompression, a gastrostomy tube alone is of questionable value for nutritional support without a jejunal tube placement. A radiologically- or endoscopically-placed double-lumen enteric tube with separate gastric and jejunal ports is not ideal because of the risk of migration of the jejunal tube into the stomach. The advantages and disadvantages of several nonpharmacologic interventions for refractory gastroparesis are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef76547 \" href=\"UTD.htm?39/53/40797\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Feeding jejunostomy tubes are discussed below. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Enteral nutrition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Other operative interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Completion gastrectomy with preservation of only a small cuff of gastric tissue provides long-term symptom relief in 43 to 67 percent of patients with postsurgical gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/50\">",
"     50",
"    </a>",
"    ]. However, this is a major surgical procedure, and cancer patients with a limited life span may not be appropriate candidates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of delayed gastric emptying\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Roux-en-Y stasis syndrome can be particularly difficult to manage medically and may benefit from surgical intervention. Patients with Roux-en-Y stasis are treated the same way as chronic intestinal pseudo-obstruction, with emphasis on hydration, antiemetics and prokinetic agents. However, some patients who have retained food predominantly in the gastric remnant improve after subtotal gastrectomy, retaining only a cuff of proximal stomach anastomosed to the Roux limb. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of delayed gastric emptying\", section on 'Roux-en-Y stasis syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical placement of a feeding jejunostomy is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Gastric pacing or electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing investigation has suggested a role for gastric pacing with an implantable device in refractory gastroparesis. One such device is already available in the US as an option for patients with severe gastroparesis unresponsive to other measures.",
"   </p>",
"   <p>",
"    Data on the efficacy of the gastric neurostimulator are evolving. In the US, the technology has been given a human device exemption for diabetic and idiopathic gastroparesis, which has been documented by objective measures of gastric emptying of solids. Use of this technology in patients with gastroparesis secondary to other conditions has not been addressed by the FDA. Prospective studies of electrical stimulation in cancer-associated gastroparesis are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=see_link\">",
"     \"Electrical stimulation for gastroparesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Botulinum treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin reduces the tone and phasic contractions of the pylorus by preventing cholinergic contractile activity. Although small case series reported improved symptoms and gastric emptying after botulinum toxin injection into the pylorus, at least two randomized controlled trials have failed to demonstrate any benefit. Until further trials are available, routine use of botulinum toxin in malignancy-associated gastroparesis cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of delayed gastric emptying\", section on 'Botulinum toxin injection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nutrition issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;For gastroparetic patients who are unable to eat because of severe nausea and vomiting, every attempt should be made to provide enteral nutrition, which is less expensive, associated with fewer complications, and may enhance gastrointestinal motility. Parenteral nutrition should only be considered if attempts at small bowel feeding have not been successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition is preferably delivered via an endoscopic or surgically placed jejunostomy tube (",
"    <a class=\"graphic graphic_table graphicRef76547 \" href=\"UTD.htm?39/53/40797\">",
"     table 5",
"    </a>",
"    ). Gastrostomy tubes should be avoided, if possible, as they may lead to partial pyloric obstruction, impair recovery of gastric emptying and they can interfere with placement of electrodes for neurostimulation, if indicated (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before placing a permanent jejunal tube, it is appropriate to perform a 48- to 72-hour trial of nasojejunal feeding to confirm that the patient will be able to handle infusion of nutrient at a rate that delivers an adequate caloric and protein level [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/51\">",
"     51",
"    </a>",
"    ]. For patients requiring long-term enteral nutrition, surgically placed jejunostomy tubes are preferable. Endoscopically placed jejunal tubes often migrate back into stomach, particularly in patients with recurrent vomiting.",
"   </p>",
"   <p>",
"    Enteral feeding is effective in the long-term care of patients with gastroparesis, although there are few data in patients with malignancy-associated gastroparesis. In a study of 26 patients with diabetic gastroparesis, surgically placed jejunostomy improved quality of life and decreased the frequency of hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, one-half of the patients were able to resume full oral intake and have the jejunostomy tube removed. Complications of jejunal tube placement include infection, tube dysfunction, and tube dislodgement.",
"   </p>",
"   <p>",
"    The choice of enteral formula in patients with gastroparesis is based on practical experience rather than controlled studies. The main principle is to use an iso-osmolar, non-elemental liquid supplement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Indications for parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral nutrition is seldom necessary in patients with gastric stasis unless it is part of a generalized motility disorder. For patients with malignancy-associated gastroparesis, parenteral nutrition is indicated if they have failed previous attempts of enteral nutrition due to intolerance or complications related to enteral feeding. The morbidity of parenteral nutrition is considerable and includes vein thrombosis, sepsis, and hepatic cholestasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSTIC IMPACT OF GASTROPARESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on the impact of malignant gastroparesis on prognosis. In a single-institution review of 95 patients diagnosed with gastroparesis, 59 postsurgical and 36 with cancer and nonsurgical gastroparesis, median survival was significantly better for surgical versus non-surgical patients (21 versus 6.5 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/3/7226/abstract/53\">",
"     53",
"    </a>",
"    ]. Current palliative options for patients with malignancy-associated, nonsurgical gastroparesis are suboptimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroparesis is one of the most underdiagnosed problems in cancer patients and often overlooked as a potential etiology of nausea and vomiting. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology is often multifactorial, and the contributing factors vary depending on the type of underlying cancer. Among the most important are paraneoplastic phenomena, direct tumor infiltration, past gastrointestinal surgery, and the toxic effects of chemotherapy and radiotherapy. Poorly controlled diabetes, hypothyroidism, other neuromuscular disorders, and use of medications that affect gastric emptying (particularly opioids) may also contribute. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presenting symptoms include nausea, abdominal pain, early satiety, vomiting, bloating, and weight loss (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The initial steps of the diagnostic workup are to exclude mechanical bowel obstruction, and side effects from narcotics as a cause of symptoms. Patients should be assessed for dehydration, electrolyte abnormalities, malnutrition, and weight loss. Upper gastrointestinal endoscopy should be obtained in most cases. The standard test for establishing the diagnosis of gastroparesis is gastric scintigraphy following a standardized solid meal. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic workup'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild nutritional impairment can be managed with dietary and behavioral modification, and oral prokinetic and antiemetic medications. When a patient has evidence of malnourishment (hypoalbuminemia and a &ge;10 percent weight loss), enteral nutrition should be considered in addition to prokinetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antiemetic medications. For patients with severe fluid and electrolyte disturbances or hypotension, hospitalization may be needed. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dietary modifications include small, frequent, low-fat, low-residue meals, eating while upright and walking or standing after meals, avoidance of alcohol and tobacco, and carbonated drinks, and increased intake of liquid as compared to solid nutrition. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Dietary and behavioral modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only two prokinetic agents that are commercially available in the US are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ; neither agent is ideal. In countries in which it remains available, we suggest cisapride rather than metoclopramide or erythromycin for subacute or chronic delayed gastric emptying (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Several precautions must be taken (avoidance of concurrent drugs that are inhibitors of CYP3A4, (",
"      <a class=\"graphic graphic_table graphicRef72735 \" href=\"UTD.htm?14/5/14429\">",
"       table 3",
"      </a>",
"      )) and the maximum dose should be kept below 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 60 mg per day in adults. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In settings where cisapride is not available, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    (40 to 80 mg orally per day in four divided doses) in countries where it is approved, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (either subcutaneous or orally, 5 to 10 mg three to four times daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (125 to 250 mg orally three times daily) (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    remain a concern, especially the risk of sudden death due to long QT syndrome when used in patients taking medications that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef72735 \" href=\"UTD.htm?14/5/14429\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Erythromycin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of adverse effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    can be reduced if the dose is kept at or below 40 mg per day but the risk of potentially permanent extrapyramidal side effects with long-term use beyond three months must be discussed with patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Metoclopramide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All these prokinetics should be administered 10 to 15 minutes before meals; an additional dose before bedtime might be useful.",
"   </p>",
"   <p>",
"    During acute episodes of gastric stasis in which oral intake is not tolerated, we suggest IV administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (erythromycin lactobionate, 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours) to \"restart\" or \"kick-start\" the stomach (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). An alternative is to use subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (5 to 10 mg three times daily) after a test dose to exclude extrapyramidal adverse effects (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiemetics may help with nausea and vomiting. We recommend a drug of the phenothiazine class rather than a serotonin receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Antiemetic agents'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      or a related agent is reasonable for patients who fail to respond to a prokinetic agent or a phenothiazine antiemetic.",
"     </li>",
"     <li>",
"      Patients who have persistent symptoms despite maximal dietary modification and pharmacologic therapy should be considered for more invasive means of palliation. Nonpharmacologic interventions such as a drainage gastrostomy and feeding jejunostomy tubes provide symptom palliation and nutritional support. In addition, another option that may be tried at experienced centers is placement of a gastric electrical stimulator. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Management options for refractory cases'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the US, other options are to pursue an emergency IND for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"       Tegaserod",
"      </a>",
"      or approval for use of cisapride or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      from the FDA. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Tegaserod'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Cisapride'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Domperidone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/1\">",
"      Schraml FV, Krueger WH. Presentation of gastric carcinoma on a radionuclide gastric-emptying study. Clin Nucl Med 2005; 30:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/2\">",
"      Leung VK, Kan PS, Lai MS. Cholangiocarcinoma presenting as pseudoachalasia and gastroparesis. Hong Kong Med J 2003; 9:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/3\">",
"      Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci 1986; 31:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/4\">",
"      Emerson AP. Foods high in fiber and phytobezoar formation. J Am Diet Assoc 1987; 87:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/5\">",
"      Donthireddy KR, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/6\">",
"      Ghoshal UC, Sachdeva S, Sharma A, et al. Cholangiocarcinoma presenting with severe gastroparesis and pseudoachalasia. Indian J Gastroenterol 2005; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/7\">",
"      Caras S, Laurie S, Cronk W, et al. Case report: pancreatic cancer presenting with paraneoplastic gastroparesis. Am J Med Sci 1996; 312:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/8\">",
"      Lautenbach E, Lichtenstein GR. Retroperitoneal leiomyosarcoma and gastroparesis: a new association and review of tumor-associated intestinal pseudo-obstruction. Am J Gastroenterol 1995; 90:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/9\">",
"      Gerl A, Storck M, Schalhorn A, et al. Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid. Gut 1992; 33:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/10\">",
"      Moskovitz DN, Robb KV. Small cell lung cancer with positive anti-Hu antibodies presenting as gastroparesis. Can J Gastroenterol 2002; 16:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/11\">",
"      Pardi DS, Miller SM, Miller DL, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002; 97:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/12\">",
"      Hejazi RA, Zhang D, McCallum RW. Gastroparesis, pseudoachalasia and impaired intestinal motility as paraneoplastic manifestations of small cell lung cancer. Am J Med Sci 2009; 338:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/13\">",
"      Nguyen-tat M, Pohl J, G&uuml;nter E, et al. Severe paraneoplastic gastroparesis associated with anti-Hu antibodies preceding the manifestation of small-cell lung cancer. Z Gastroenterol 2008; 46:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/14\">",
"      Sodhi N, Camilleri M, Camoriano JK, et al. Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. Dig Dis Sci 1989; 34:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/15\">",
"      Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/16\">",
"      Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/17\">",
"      Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/18\">",
"      Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/19\">",
"      Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/20\">",
"      Chinn JS, Schuffler MD. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 1988; 95:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/21\">",
"      Shafi MA, Pasricha PJ. Post-surgical and obstructive gastroparesis. Curr Gastroenterol Rep 2007; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/22\">",
"      Tanaka M. Gastroparesis after a pylorus-preserving pancreatoduodenectomy. Surg Today 2005; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/23\">",
"      Hirao M, Fujitani K, Tsujinaka T. Delayed gastric emptying after distal gastrectomy for gastric cancer. Hepatogastroenterology 2005; 52:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/24\">",
"      Iftikhar S, Loftus EV Jr. Gastroparesis after celiac plexus block. Am J Gastroenterol 1998; 93:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/25\">",
"      Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes. Am J Gastroenterol 1997; 92:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/26\">",
"      Brand RE, DiBaise JK, Quigley EM, et al. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet 1998; 352:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/27\">",
"      DiBaise JK, Brand RE, Lyden E, et al. Gastric myoelectrical activity and its relationship to the development of nausea and vomiting after intensive chemotherapy and autologous stem cell transplantation. Am J Gastroenterol 2001; 96:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/28\">",
"      Baert D, Burvenich P, Lagae J, et al. Radiotherapy-induced gastroparesis: an unusual complication. J Clin Gastroenterol 2002; 34:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/29\">",
"      Layer P, Demol P, Hotz J, Goebell H. Gastroparesis after radiation. Successful treatment with carbachol. Dig Dis Sci 1986; 31:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/30\">",
"      Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/31\">",
"      Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/32\">",
"      Linke R, Meier M, Muenzing W, et al. Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl Med Commun 2005; 26:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/33\">",
"      Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004; 13:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/34\">",
"      Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003; 18:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/35\">",
"      Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/36\">",
"      Bouras EP. Gastroparesis and electrical stimulation: can we afford the power bill? Neurogastroenterol Motil 2005; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/37\">",
"      Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/38\">",
"      Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003; 98:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/39\">",
"      Shivshanker K, Bennett RW Jr, Haynie TP. Tumor-associated gastroparesis: correction with metoclopramide. Am J Surg 1983; 145:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/40\">",
"      Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care 1993; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/41\">",
"      Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage 1996; 11:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/42\">",
"      Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010; 31:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/43\">",
"      Desautels SG, Hutson WR, Christian PE, et al. Gastric emptying response to variable oral erythromycin dosing in diabetic gastroparesis. Dig Dis Sci 1995; 40:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/44\">",
"      Dhir R, Richter JE. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol 2004; 38:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/45\">",
"      Ramirez B, Eaker EY, Drane WE, et al. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci 1994; 39:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/46\">",
"      Eagle DA, Gian V, Lauwers GY, et al. Gastroparesis following bone marrow transplantation. Bone Marrow Transplant 2001; 28:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/47\">",
"      Sturm A, von der Ohe M, Rosien U, et al. [Treatment of radiotherapy-induced gastroparesis with erythromycin]. Dtsch Med Wochenschr 1996; 121:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/48\">",
"      Banh HL, MacLean C, Topp T, Hall R. The use of tegaserod in critically ill patients with impaired gastric motility. Clin Pharmacol Ther 2005; 77:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/49\">",
"      Tougas G, Earnest DL, Chen Y, et al. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther 2005; 22:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/50\">",
"      Eckhauser FE, Conrad M, Knol JA, et al. Safety and long-term durability of completion gastrectomy in 81 patients with postsurgical gastroparesis syndrome. Am Surg 1998; 64:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/51\">",
"      Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003; 98:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/3/7226/abstract/52\">",
"      Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996; 91:2174.",
"     </a>",
"    </li>",
"    <li>",
"     Donthireddy, ER, Nasser, E, Tan, W, et al. Malignant gastroparesis: indicator of poor prognosis (abstract #27). Data presented at the 2007 ASCO Gastrointestinal Cancers Symposium, January 19-21, Orlando, Fl.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2809 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7226=[""].join("\n");
var outline_f7_3_7226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF GASTRIC EMPTYING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Paraneoplastic gastrointestinal dysmotility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Postsurgical dysmotility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Celiac plexus injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      High-dose chemotherapy and stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnostic workup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gastric emptying scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Alternatives to scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Quantifying symptom severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dietary and behavioral modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metoclopramide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Erythromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cisapride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Tegaserod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Domperidone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Antiemetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment considerations for paraneoplastic dysmotility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management options for refractory cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Other operative interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Gastric pacing or electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Botulinum treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nutrition issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Indications for parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSTIC IMPACT OF GASTROPARESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2809|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/3/17459\" title=\"figure 1\">",
"      Neuromuscular disorders impairing gastric motor function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/32/41483\" title=\"table 1\">",
"      Pathogen malignancy-related gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/3/17467\" title=\"table 2\">",
"      Paraneoplastic GI motor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/5/14429\" title=\"table 3\">",
"      Med mgmt gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/53/40797\" title=\"table 5\">",
"      Nonpharm intervent refract gastroparesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31574?source=related_link\">",
"      Electrical stimulation for gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14312?source=related_link\">",
"      Pathogenesis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_3_7227="Limitations of provocative testing for GH deficiency";
var content_f7_3_7227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Limitations of provocative testing for growth hormone deficiency in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pharmacological testing is not physiologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normality is arbitrarily defined, if defined at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reproducibility in both normal and abnormal children is poor, even when the same test is performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age and sex steroid hormone status affect the response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutritional adequacy and body composition, particularly, adiposity, can affect response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no standard serum growth hormone assay, and there are large&nbsp;interassay variations among the assays&nbsp;in use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All the tests are costly",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7227=[""].join("\n");
var outline_f7_3_7227=null;
var title_f7_3_7228="Birth outcome data New Jersey";
var content_f7_3_7228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neonatal morbidity and mortality data by delivery type, New Jersey 1989-1993, rate per 10,000 deliveries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unassisted delivery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Forceps delivery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vacuum delivery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vacuum plus forceps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalohematoma",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        635",
"       </td>",
"       <td>",
"        1117",
"       </td>",
"       <td>",
"        1361",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial nerve injury",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        37.0",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        52.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        17.0",
"       </td>",
"       <td>",
"        16.2",
"       </td>",
"       <td>",
"        26.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical ventilation",
"       </td>",
"       <td>",
"        23.5",
"       </td>",
"       <td>",
"        31.3",
"       </td>",
"       <td>",
"        40.3",
"       </td>",
"       <td>",
"        74.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinal hemorrhage",
"       </td>",
"       <td>",
"        18.2",
"       </td>",
"       <td>",
"        19.3",
"       </td>",
"       <td>",
"        15.7",
"       </td>",
"       <td>",
"        31.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"space\" colspan=\"5\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third degree perineal tear",
"       </td>",
"       <td>",
"        378",
"       </td>",
"       <td>",
"        1252",
"       </td>",
"       <td>",
"        962",
"       </td>",
"       <td>",
"        1562",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fourth degree perineal tear",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        975",
"       </td>",
"       <td>",
"        627",
"       </td>",
"       <td>",
"        1329",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Demissie K, Rhoads GG, Smulian JC, et al. BMJ 2004; 329:24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7228=[""].join("\n");
var outline_f7_3_7228=null;
var title_f7_3_7229="Effect of neck flexion";
var content_f7_3_7229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Effect of neck movement with variable thoracic inlet obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 366px; background-image: url(data:image/gif;base64,R0lGODlhSgJuAcQAAP///39/fwAAAD8/P7+/v+/v7x8fHy8vLw8PD5+fn6+vr19fX9/f38/Pz29vb09PT4+PjwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABKAm4BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX2Nna29zd3t/g4eLj5OXm5+jp6uvs7e7v8PHy8/T19vf4+fr78QQB/wABEuBH0JS/gAAHBCjIcNW/hhBPPYxIUdTEihg7XcxoTICAAtY2chyWwOOBkAtH/xYz4FFAgmoiVQLzWNIAzJQyhXkEwPLltJg5e+2sCVIa0KC6GghAIIIlTmhHsTRYIABpHwgCHohQ4JGB0acjCDQw4WAAgAYDfCZxwNIqnwcCIIwYIMBsNJENAtQ1QRcAgwAD+w4hQFiEXrd7EAgYK4KBRwV3wdLdW6LvX8JOBzJYMGDB2AQBGEDwOkLBg86aOXsWkeC0gwIDYhuuijjPThJ6ETB2FpMAZRJ9fQdIoDgtAwQHAiBgSlfxQNZZAzwIjVw5U73TDTwfcbj2Hd8nSRQ44FEub7AAfNsFXlU4AMFYFwSgS4Bu0RFYk7+MP18AAQQ2AVDAfe+1tJ13cqhnQv8BcGVFYDK9/TZXewIsJJhe8v3DgGAl9CeAAxgC5Nh6CPoRHwpYCWCAWhCC1UB+BBAYXIUFKtCAUgcoQIADaNFGAgQOEFDSAzjqyCNcEBDwwIEl4qEXeiM0wJKKLBoj0mQeHTjjQgooJpcC5AlwwIY+ljblAyCBaRIDBSygmAGkNZkHVealkMCULS21AGTCRCVnK/S1cGeehBZaKAKxTRdAkmI5BOWfrpDHpAsKuGnopZh6hGhsAOlIQJyb+AmpKrcN0QBhEPxz2gCKZZrnpgr94ymojYg6KioePbgEA4QpkFBsrbqqaaL/MLqbILbeaoqkXfBKgK//xMaqsEsppAD/rXokqywpdPGJxqkEpCodsJkisKeTj26LigM00sGAr9MWqp0d2qobil4O+FFpq6/RUa+9n3BFIh8FsEvlHP8C3Al4ghAwZYBwJKwwGwchZPHFGGecscEad+zxxyCHLHLGU45s8skoY6zQxHxUnPLLygmQIcw012yzRwbYrPPOgLG8CpKE+Oafz/xgpRUh7EJMND5KIaCrHwX0tLQ+LOVLSE1T5yP0pH5gnTU+ST/Nh9Rf3xN1VoOUWrY9SsUliNpr15PisX3AHTc9cBkgNh523y3PeGLubUffRxTWg+F+mwL4AYLTQbgRErMQeeKVLN64HI8XMbkKm1M+ieV8ZE5E/+cokO55JKDrIfoQppvQ+umPpM53mUq8jlu6sH8C+Iq20Z6E7dzhnrsngB88uO9IzMez8sOnMqjxc6wuhMs7c938KM8bQLcb0l/vzqAIePtG9963U3ydbRRA/vTbl3VWWuX3QpXMbyjoRF4SimBZzxzGf0uKjGvDkJ4wmYEVyC+AcViFUtOZz4RmNP5jRZegl4YnQcF+7ElPhYhTlwQcJznLKZBzIsgKKXlkANYTA1yqtAQMTkiDFqINf+hjHxK6ogAxkxm2xBCoJ7hQfxSK4WxmRiYbwmIzmgrA5bSQqye8SEwxyqB7unUjMRmpR0aMRX1wJj4wNA0KWBraC90zwf8vhWlM/cuiK573gB1uAUNqbEjBNIW+LpCHhXHcRwPOuD0sqO8jeYwIBPi1xCeUJDyBhAgDGmSALlqBKsJLZD4UcCY3RkExfZQkQea4lDpKwWuarMgeTZLJJpAtlBgZpEf6FQVQohIji8QZHpVwyldmhJInTGERXGnLjOCwVQuwpBDONsteUgSJS1FiEsijNGOqZIsUHAJVdONMqzwPhURIkSOrqZJfeiSYQeCK27iJGGQiQJk9aIBiFkBOBEGzkTxQp5ja2aRrCvMFHAwgPUuEw5agkwYGG0Ah96kSMkXTBbBZJUFvhcuDqgCXCCjmQhGUPYk2ZjLam6i9sme9fnr/5J8aVdfzWPmu+bRqAPcM6Z84eSl4qpRoChxWAK710pra9KY4zalOd8rTnvr0p0AN6k+fJ0uh/mlflzLXNo0qk5hSkKj6ZKpMOKlUFCA1qlL1ZZhYqQLZZZUiu9NlCc52tK9GxKstaJsnzcoP8mD1BXNjK0OIUoO8DVSu7qilDM5mQLzWg5czkKfV/GoPYuagJC4hrD300kwbsIuaipWHYwSwVBrQRW+RjQdd+mqDsyEys+wQZ0plIE92gpYdTgGCONd62nFwxWlB0GZr0UEV0wZhmqWcbTcUU9kdMPOuup3Ga4tA1uCKo7ZGEJpFjVsN3h4hN6NlLjT+uMx5Sncb/wxDwnHadV1sCEwJiBVrd5uBryXYdbzWYFckf1Bc9FKjW0xQrnunwSwmQHe+0WhiE9yKX2is7wfbXW9/gZFdJ4R3wMv4IRPOi2BknAgKZxtsg4thwShsbcLGoNMUwoZhYvQwChHu8DDqK4ULi3gmyHsCh0/si/8St2os7kWBqWDiGOdCwVJYsY3/R78rhHjHt6jwFWoM5FloOAs6LnIsPuxjGCtZFiTGApGf3AoXLyHJVF6FlZXQ3iyzYstKkK+XVaGUxmbhvmNGBY6zwN80n2LNWAiwmw2SPy4ceM6jgHMWGIxnUJQ3DF3usyeEDAYxC1oj3A0Dmg8dqkSHoc2M1v+Eessg50hngsliuLOlLYFpFaoIuJsuRKcBzRLbhloSow6D0Hp76kSwJLdfeCyoW/0HMFuBPGWldSNsXQW16toRvK7Con+diGBXYbPEXoSxqVBpQFAvIOKd87KpEFdnq0zAaZ42FeDyWUMAT8TankIBFCPhQny7w+GegjijvYdzYzjdU6AKZr2N7THDWwqePYS7J3xvKZSW3rTutxRWa+56e1ngUpDtIPbdYIRLAbcLN3iWHS6F3yJL4lSmOIhZwtlsYfzJGo+CYAPBcASHvJU0AUTJ00kVoZ48Co+Ftb/Q06gSuA8ty/0BW1Ks05dH4bKzXsNG8GfA/QWG5zsgzHP/ugNUn0PYrUGv4FMKyJeqXEaBPdtMAwEAGtGAyjSo8YtqGNOaAbxGWrNxOdLjgNY7iETBW+KgcaoTwuaIkevRmc4HrQMA7ARgXrhZ+02dDmKotxsscA/iAQEwQ//U8EdiGg7jZdaf/wRoQOzJUtMFz3bD5+Htdd7S4kOkoTQaZjIgoryG6vxVwuObmTJvw9BhJCPFU7FIO8JiCYAkpKzg/khxURK7d+r615cHXZnX/BhpVEYAqElMRSxBQ9Hk/DOyyVJwYmvx8d0g6tdh5f3V7x8AGHUwgB+/UfaDCd/6hvPPF76CaLvsP67kSQ8irHJwv3v/fP+tll8L+ode31UI/5zUbUJHf0U2Y0GjGDknBgE4XtSFCIjFeYqGgEH1bMuTMR+VgRzYgRq4gR4YghezMsGFgSL4D6V2giqYgSC4gic4fGm2QoqwfcnmA4RmCDRYgzwwQMVGgTrYBXr2B47BFD+YBhF4CANYhGggfubmaEpIBqkGCPD3hGYgg4egGNFFhWfmhG/jg1qIBTyIg174hVYQhHUzhmRIBUdYCDmYhjTgXGLYBIiTdDCIZ8gVh/ZlgSfwgPg1XHi4BOfGh/gFh/fneoGoh1R2h4OggMmDiB3iiErmh4OQhLUDicHzg4RIch/SBIf4g4oYCPYHiLGyMyRYg5IYCFMYZhxYh4KWif9/kH5uKAafWGuAFItlcIpQ04a2WAN61TLW5UPtYxY4t4snAFh7QIlLQHRVh0BHR4wk0IvZsolOQHWVYXUJlBlit3VdB0FKaIx5EIpyGHpBJHceRHfMsRR3V4TQiAepGF/iCEOL13hb9H995o13AIth9o5TRBukFxqmp4TreDz0eANPdABRtHwxZCO/p3tfaI90sIZMEEZaonjN93xohIanFpBzwIjOOAYOKQfI2JFkoJFxwH8iWQZ09Y1ceJJhwBK5ZgftyJJi0DYNuAb4KJPmtxSxtwZMiJNjQBcGyHa66JM0MG7SSAccSZRgIE6spgYhqZRhIGv+cpRQSQbk0XH/awCOVTmTimGJVxCTWwkGiLWTVpmOYelp8zY+tXiWY8BXcACRbBkGI+cGZhiXWoBYNfkFYWiXYxBzsreSfOkFQMcGVhiYbel5aRCFhskF8jcGPbmYYNCYS7kUkGkGkukFs1iZgIaYY+CKmrmZgUMGuPiZYrA7ZEkFmUmaoDlOPVBSrMI7O+CZqglo3TeQrIEnecJ+MzBZs5kGKQKbNvA8iDJTDDAouhkDddmbXGBCDsUCSHVQl9kCcKScaVBRlGIpRYUC0bkCkESda0BUAzAdCRAjBSAk4/Iq57ICi2MDiumdmYab5ZKeCCWbLtAV7pk+5nkaJySeBykDqdkCXGFm2veJCK81a3DhlQMqB6kVA5OVhQn6B6IVA9jxoI+AbDDAEk1JoYIwWRnaGJSpoY7AWC/wlCB6CGfToTdYookwoS0AlipqCA3KAkbpoC/aBwfKAklTo40QoIIzZTqKCE6GAkH6o4rgo1uxFLZJpHPwWFzzn0pKgP5HAhzUoU/6B5y0Is8poFV6CE6VnVv6CHdSVV86pmRapmZ6pmiapmq6pmzapm76pnAap3I6p3Rap3Z6p3iap3q6p3zap376p4AaqII6qIRaqIZ6qIiaqIq6qIzaqI76qJAKBCEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow-volume loops in variable thoracic inlet obstruction with the neck flexed (top) and with the neck extended (bottom). The loops show an intrathoracic and then an extrathoracic location, as the lesion moves within the chest with neck flexion and outside the thoracic inlet with neck extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7229=[""].join("\n");
var outline_f7_3_7229=null;
var title_f7_3_7230="Type2 DM weight and exercise";
var content_f7_3_7230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Importance of body weight and exercise on development of type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 247px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adjusted incidence of type 2 diabetes mellitus in 5990 men in relation to body mass index (BMI, in kg/m2) and the level of physical activity (in kcal/wk). The risk of type 2 diabetes was directly related to BMI, while regular exercise was protective except for men with a BMI below 24.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr.&nbsp;Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7230=[""].join("\n");
var outline_f7_3_7230=null;
var title_f7_3_7231="Patterns of glycemic control";
var content_f7_3_7231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Patterns of blood glucose control",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 195px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood glucose excursions in three hypothetical patients who have the same mean blood glucose concentration of about 200 mg/dL (11.1 mmol/L, equivalent to a hemoglobin A1c value of about 8.2 percent), but who have different overall blood glucose control. Patient B (blue curve) has relatively small variations during the day and on different days; this patient should have little difficulty in lowering daily mean blood glucose concentrations without inducing hypoglycemia. In comparison, patient A (purple curve) has marked blood glucose variations on the same day and patient C (green curve) has marked blood glucose variations on different days. These aspects of blood glucose control must be improved before the mean blood glucose concentration can be safely lowered. Increasing the intensity of insulin therapy can precipitate hypoglycemia in patients A and C, since many of their blood glucose values are already in the low-normal range.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_3_7231=[""].join("\n");
var outline_f7_3_7231=null;
